

CITATION REPORT

List of articles citing

Tumor angiogenesis: therapeutic implications

DOI: 10.1056/nejm197111182852108

New England Journal of Medicine, 1971, 285, 1182-6.

Source: <https://exaly.com/paper-pdf/10655652/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2196	Vascular endothelial growth factor expression and inhibition in uveal melanoma cell lines. 2013 , 7, 336		14
2195	Cell culture on artificial capillaries: an approach to tissue growth in vitro. 1972 , 178, 65-6		386
2194	Models for the Growth of a Solid Tumor by Diffusion. 1972 , 51, 317-340		338
2193	Tumor dormancy in vivo by prevention of neovascularization. 1972 , 136, 261-76		728
2192	Microvascular abnormalities in virally-induced canine brain tumors. Structural bases for altered blood-brain barrier function. 1972 , 17, 29-39		91
2191	Angiogenesis in psoriasis: therapeutic implications. 1972 , 59, 40-3		69
2190	The production of a bone resorbing factor by dental cysts in vitro. 1973 , 10, 334-8		31
2189	Self-regulation of growth in three dimensions. 1973 , 138, 745-53		658
2188	Tumor angiogenesis: iris neovascularization at a distance from experimental intraocular tumors. 1973 , 50, 219-28		137
2187	A Review of Recent Experimental Work on the Dental Cyst. 1974 , 67, 1259-1263		
2186	Studio Autoradiografico Sulla Relazione Tra Accrescimento Tumorale E Proliferazione Endoteliale. 1974 , 60, 257-259		
2185	Tumor growth and neovascularization: an experimental model using the rabbit cornea. 1974 , 52, 413-27		667
2184	Hemangiopericytoma of the orbit. 1974 , 78, 816-34		58
2183	Inhibition of tumor angiogenesis mediated by cartilage. 1975 , 141, 427-39		320
2182	In vitro demonstration of an endothelial proliferative factor produced by neural cell lines. 1975 , 190, 682-4		55
2181	Immunological surveillance against cancer: critique of an established hypothesis. 1975 , 1, 43-50		6
2180	Optic disk neovascularization associated with chronic uveitis. 1976 , 82, 175-8		43

2179	Letter: Cancer to cancer metastasis. 1976 , 7, 357	5
2178	Endothelial growth factor present in tissue culture of CNS tumors. 1976 , 44, 342-6	44
2177	Vasoformative properties of normal and hypoxic retinal tissue. 1977 , 61, 394-8	15
2176	The inhibition of corneal vascularization in rabbits. 1977 , 84, 305-9	12
2175	Inhibition of neovascularization by an extract derived from vitreous. 1977 , 84, 323-8	120
2174	The spread of cancer in the organism. Facts and problems. 1977 , 64, 403-9	5
2173	Experimental rubeosis of the iris in rabbits. 1978 , 209, 11-8	4
2172	A new approach to the problem of retinal neovascularization. 1978 , 85, 626-37	18
2171	Coagulation factors in renal adenocarcinoma. 1978 , 119, 727-30	18
2170	The influence of implantation site on tumor growth and blood flow. 1979 , 15, 771-7	13
2169	Partial purification and characterization of a factor which stimulates an increase in ornithine decarboxylase activity in the liver from tumor cell-free ascites fluid. 1979 , 582, 221-33	5
2168	Angiogenesis and Antiangiogenesis ²³ . 1980 ,	
2167	Experimental ocular angiogenesis. 1980 , 89, 231-7	48
2166	The stimulation of capillary endothelial cell migration by aqueous humor. 1981 , 30, 262-8	5
2165	The vasculature of experimental brain tumours. Part 1. A sequential light and electron microscope study of angiogenesis. 1981 , 49, 55-66	76
2164	The vasculature of experimental brain tumours. Part 2. A quantitative assessment of morphological abnormalities. 1981 , 49, 67-77	60
2163	Inhibition of tumor growth, vascularization, and collagenolysis in the rabbit cornea by medroxyprogesterone. 1981 , 78, 1176-80	111
2162	The significance of atypical vessels and neovascularization in cervical neoplasia. 1981 , 139, 154-9	106

2161	Angiogenesis induced by "normal" human breast tissue: a probable marker for precancer. 1982 , 218, 293-5	121
2160	Glycosaminoglycan synthesis by mammary tumor spheroids. 1982 , 107, 1130-7	16
2159	Clinical pharmacokinetics of cerebrospinal fluid. 1982 , 7, 312-35	53
2158	[Experiments concerning tumor angiogenesis]. 1982 , 219, 20-3	0
2157	The role of proteinases in cellular invasiveness. 1983 , 695, 177-214	100
2156	Inhibition of tumor-induced angiogenesis and of tumor growth by activated lymphocytes. 1983 , 39, 542-4	
2155	[Microangiographic examinations of different human tumors after transplantation to thymus aplastic nude mice]. 1983 , 182, 63-70	6
2154	Microcirculatory flow changes during tissue growth. 1983 , 25, 1-21	39
2153	Age Related Changes in Tumor Vascularity: Angiography and Vascular Casts of the VX2 Tumor in the Rabbit Hind Leg. 1984 , 25, 529-533	5
2152	Functional characterization of the microcirculation in tumors. 1984 , 3, 115-26	50
2151	Tierexperimentelle untersuchungen zur rolle von entzündungsmediatoren bei der hornhautneovaskularisation. 1984 , 57, 215-262	25
2150	Revascularization of skin transplanted into the brain: source of the graft endothelium. 1984 , 28, 113-24	20
2149	Effect of Medroxyprogesterone and an Aorta-Derived Cell Growth Inhibitor on B16 Melanoma in Mice2. 1984 ,	
2148	Angiogenic activity of the corneal epithelium. 1985 , 41, 721-32	13
2147	CELL BIOLOGY AND BIOCHEMISTRY OF ENDOTHELIAL CELLS AND THE PHENOMENON OF INTRAOCULAR NEOVASCULARIZATION. 1986 , 215-243	4
2146	Internal pressure and oxygen tension of bone tumors and tumorous conditions. 1986 , 105, 326-31	3
2145	Neocortical transplants in the mammalian brain lack a blood-brain barrier to macromolecules. 1987 , 235, 772-4	125
2144	Angiogenic factors. 1987 , 235, 442-7	4067

2143	Abdominal SPECT imaging. 1987 , 17, 230-46	7
2142	Retinal pigment epithelial cells release inhibitors of neovascularization. 1987 , 94, 780-4	67
2141	Multicellular spheroids. A review on cellular aggregates in cancer research. 1987 , 113, 101-22	338
2140	Tumor cord and growth in human brain tumors based on mathematical morphology. 1988 , 6, 119-28	4
2139	A study on the vascular proliferation in tissues around the tumor in breast cancer. 1988 , 18, 235-42	22
2138	Dissecting multistep tumorigenesis in transgenic mice. 1988 , 22, 479-519	198
2137	Renin in glioblastoma multiforme and its role in neovascularization. 1988 , 90, 437-41	39
2136	Blood flow distribution within transplantable tumours in the mouse. 1989 , 25, 1683-8	4
2135	Inhibition of tumor angiogenesis by a synthetic cell-adhesive polypeptide containing the Arg-Gly-Asp (RGD) sequence of fibronectin, poly(RGD). 1990 , 81, 668-75	34
2134	Tumor interactions with the vasculature: angiogenesis and tumor metastasis. 1990 , 1032, 89-118	188
2133	Cell kinetic studies of endothelial cells in the adenocarcinoma EO 771 and the effect of cyclophosphamide. 1990 , 59, 251-6	8
2132	Cortisone inhibition of tumor angiogenesis measured by a quantitative colorimetric assay in mice. 1990 , 26, 461-3	20
2131	Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction. 1990 , 9, 171-4	115
2130	Gangliosides, copper ions and angiogenic capacity of adult tissues. 1990 , 9, 239-51	33
2129	Systemic amiloride inhibits experimentally induced neovascularization. 1990 , 108, 1474-6	36
2128	Angiogenesis: modulation with opioids. 1991 , 22, 1077-9	39
2127	Macrophages secrete a heparin-binding inhibitor of endothelial cell growth. 1991 , 42, 187-97	22
2126	Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. 1991 , 64, 327-36	2428

2125	Transvaginal color Doppler imaging for hemodynamic assessment of reproductive tract tumors. 1991 , 36, 301-8	30
2124	The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. 1991 , 5, 1806-14	1150
2123	Morpho-Functional Study of Vascular Fluorochrome Delivery to Lung and Liver Metastases of Lewis Lung Carcinoma (3LL). 1991 , 77, 206-211	1
2122	Immunolocation of TNF-alpha/cachectin in human melanoma cells: studies on co-cultivated malignant melanoma. 1991 , 96, 238-42	8
2121	The identification of proliferation and tumour-induced proteins in human endothelial cells: a possible target for tumour therapy. 1991 , 12, 500-8	20
2120	The premature retina: a model for the in vivo study of molecular genetics?. 1992 , 6 (Pt 2), 161-5	27
2119	Systemic antiangiogenic therapy for choroidal neovascularization. What is the role of interferon alfa?. 1992 , 110, 1383-4	16
2118	1992 Mack Forster Award Lecture. Review. Regulation of angiogenesis in vitro. 1992 , 22, 504-15	87
2117	Adhesion molecules and their role in cancer metastasis. 1993 , 23, 3-89	38
2116	Physeal and epiphyseal extent of primary malignant bone tumors in childhood. Correlation of preoperative MRI and the pathologic examination. 1993 , 23, 421-4	50
2115	Analysis of experimental antiangiogenic therapy. 1993 , 28, 445-50; discussion 450-1	73
2114	The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. 1993 , 28, 1253-7	96
2113	Longitudinal quantitation of middle cerebral artery blood flow in normal human fetuses. 1993 , 169, 1393-8	30
2112	Inhibition of tumor cell-induced angiogenesis by retinoids, 1,25-dihydroxyvitamin D3 and their combination. 1993 , 75, 35-9	74
2111	Choroidal neovascularisation in age-related macular disease. 1993 , 77, 614-5	12
2110	Functional-characterization of developing tumor vascular system and drug delivery (review). 1993 , 2, 289-96	2
2109	Inhibition of angiogenesis and growth of human nerve-sheath tumors by AGM-1470. 1993 , 78, 470-6	70
2108	Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma. 1993 , 85, 1585-92	54

2107	Effects of modulation of basic fibroblast growth factor on tumor growth in vivo. 1993 , 85, 121-31	87
2106	TAN-1120, a new anthracycline with potent angiostatic activity. 1993 , 46, 569-79	17
2105	Phenotype Changes in Tumor Vessels Associated with the Progression of Hepatocellular Carcinoma. 1993 ,	
2104	Angiogenesis and Breast Cancer. 1994 , 8, 51-71	28
2103	Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. 1994 , 93, 662-70	822
2102	Angiogenesis and breast cancer. 1994 , 12, 441-3	201
2101	Telmisartan is a potent target for prevention and treatment in human prostate cancer. 1994 , 20, 295	4
2100	Quantitative immunohistological analysis of the microvasculature in untreated human glioblastoma multiforme. Computer-assisted image analysis of whole-tumor sections. 1994 , 81, 902-9	89
2099	Inhibition of angiogenesis as a strategy for tumor growth control. 1994 , 21, 329-36	4
2098	The observation of angiogenin and basic fibroblast growth factor gene expression in human colonic adenocarcinomas, gastric adenocarcinomas, and hepatocellular carcinomas. 1994 , 172, 171-5	86
2097	Detection of biological activity in the cerebrospinal fluid of patients with central nervous system tumors. 1994 , 19, 17-23	
2096	Use of human tissue specimens obtained by directional atherectomy to study restenosis. 1994 , 4, 213-21	21
2095	Angiogenesis inhibition: a review. 1994 , 63, 265-311	256
2094	Inhibition of induced angiogenesis in a human microvascular endothelial cell line by ET-18-OCH ₃ . 1994 , 34, 175-8	22
2093	Does improved control of tumour growth require an anti-cancer therapy targeting both neoplastic and intratumoral endothelial cells?. 1994 , 30A, 201-6	26
2092	Current approaches to targeting cancer using antiangiogenesis therapies. 1994 , 20, 393-412	46
2091	Interferon-alpha-2a for the treatment of complex hemangiomas of infancy and childhood. 1994 , 219, 605-12; discussion 612-4	76
2090	Vascular Endothelial Growth Factor in Angiogenesis. 1995 , vmr-6, 311-322	

2089	The role of growth factors in vascular cell development and differentiation. 1995 , 161, 1-48	35
2088	Serum basic fibroblast growth factor in men with and without prostate carcinoma. 1995 , 76, 2304-11	66
2087	Tumor angiogenesis and prognosis in squamous cell carcinoma of the head and neck. 1995 , 17, 312-8	88
2086	Inhibition of angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470. 1995 , 23, 23-9	41
2085	The influence of angiogenesis research on management of patients with breast cancer. 1995 , 36, 109-18	70
2084	A quantitative in vivo method of analyzing human tumor-induced angiogenesis in mice using agarose microencapsulation and hemoglobin enzyme-linked immunosorbent assay. 1995 , 86, 1182-8	9
2083	The use of colour-coded and spectral Doppler ultrasound in the differentiation of benign and malignant breast lesions. 1995 , 71, 137-9	45
2082	Angiogenesis and cancer metastases: therapeutic approaches. 1995 , 20, 9-39	30
2081	Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. 1995 , 2, 683-95	235
2080	Hepatic artery dexamethasone infusion inhibits colorectal hepatic metastases: a regional antiangiogenic therapy. 1995 , 2, 114-20	17
2079	Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. 1995 , 13, 765-82	362
2078	Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies. 1995 , 6, 817-25	68
2077	New Delivery Systems for Brain Tumor Therapy. 1995 , 13, 813-825	24
2076	Novel Biologic Therapies for Malignant Gliomas. 1995 , 13, 827-846	24
2075	Angiogenesis Inhibitors Generated by Tumors. 1995 , 1, 120-122	170
2074	Nutraceuticals and Angiogenesis. 1995 , 1, 243-247	4
2073	Angiogenesis as a prognostic marker in early head and neck cancer. 1995 , 104, 724-9	65
2072	Exuberant granulation tissue mimicking vascular tumours associated with burns. 1995 , 21, 383-6	1

2071	Assessment of angiogenesis in breast carcinoma: an important factor in prognosis?. 1995 , 26, 1196-200	119
2070	Intratumoral peak systolic velocity as a new possible predictor for detection of adnexal malignancy. 1995 , 172, 1496-500	51
2069	Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. <i>New England Journal of Medicine</i> , 1995 , 333, 1757-63	59.2 1931
2068	Thrombosis and hemorrhage in oncology patients. 1996 , 10, 875-907	38
2067	Peritumoral angiogenesis in carcinomas of the head and neck. 1996 , 23, 57-62	6
2066	Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. 1996 , 348, 370-4	834
2065	TNP-470 (AGM-1470): mechanisms of action and early clinical development. 1996 , 32A, 2520-7	98
2064	Expression of angiogenic factors and structural proteins in central nervous system vascular malformations. 1996 , 38, 915-24; discussion 924-5	202
2063	Therapeutic angiogenesis: a new frontier for vascular therapy. 1996 , 1, 79-87	45
2062	Quantitative immunohistochemistry of factor VIII-related antigen in breast carcinoma: a comparison of computer-assisted image analysis with established counting methods. 1996 , 105, 705-10	58
2061	Clinical studies with angiogenesis inhibitors: biological rationale and challenges for their evaluation. 1996 , 7, 441-4	24
2060	Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. 1996 , 93, 13791-6	197
2059	Monitoring tumour response. 1996 , 6, 775-85	17
2058	Enhanced CD34 expression of sinusoid-like vascular endothelial cells in hepatocellular carcinoma. 1996 , 46, 751-6	77
2057	Angiogenesis factor in endometrial carcinoma: a new prognostic indicator?. 1996 , 174, 1879-82; discussion 1882-4	64
2056	Antiangiogenesis restricted tumor dormancy. 1996 , 15, 241-5	29
2055	A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction). 1996 , 15, 247-72	107
2054	Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in vivo. 1996 , 106, 1114-8	48

2053	Arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease. 1996 , 7, 959-88	141
2052	Antineoplastic effect of 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in transgenic mice with retinoblastoma. 1996 , 114, 1396-401	17
2051	Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. 1996 , 271, 3154-62	229
2050	Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. 1996 , 271, 29461-7	279
2049	Search for genes that suppress cancer metastasis. 1996 , 88, 1700-3	39
2048	Observations on the vascular structure of malignant tumours of the mandible using specimen arteriography. 1996 , 25, 169-72	
2047	Assessment of response following treatment for malignant disease. 1997 , 70 Spec No, S41-9	5
2046	Regulation of Angiogenesis. 1997 ,	3
2045	VLA(3)/integrin expression in breast carcinomas evaluated by automated and quantitative immunohistochemistry. 1997 , 11, 849-56	
2044	Mathematical modelling of avascular-tumour growth. 1997 , 14, 39-69	221
2043	Bronchial vascular congestion and angiogenesis. 1997 , 10, 1173-80	82
2042	Factors controlling ocular angiogenesis. 1997 , 124, 521-9	119
2041	Advances in angiogenesis research: relevance to urological oncology. 1997 , 158, 1663-74	77
2040	Vascular Endothelial Growth Factor (VEGF) Expression in Prostate Cancer and Benign Prostatic Hyperplasia. 1997 , 157, 2323-2328	144
2039	Vascular Endothelial Growth Factor (VEGF) Expression in Human Prostate Cancer: In Situ and in Vitro Expression of VEGF by Human Prostate Cancer Cells. 1997 , 157, 2329-2333	213
2038	Molecular aspects of neuro-oncology. 1997 , 99, 184-95	11
2037	Angiogenesis in vulvar intraepithelial neoplasia. 1997 , 64, 496-500	39
2036	Angiostatic treatment of neuroblastoma. 1997 , 33, 2020-3	12

2035	Central nervous system hemangiomas in early childhood. 1997 , 17, 365-70	3
2034	Cell adhesion and angiogenesis. 1997 , 99, 373-6	88
2033	Inhibition of malignant angiogenesis. 1997 , 23, 263-86	15
2032	Pathologic Prognostic Factors for Patients with Breast Carcinoma. 1997 , 6, 415-462	20
2031	Structure and Function of Angiogenin. 1997 , 445-489	18
2030	Tumor growth in a defined microcirculation. 1997 , 105, 487-96	1
2029	Prognostic significance of angiogenesis in clinically localized prostate cancer (staining for Factor VIII-related antigen and CD34 Antigen). 1997 , 1, 32-38	28
2028	Vascular density in melanoma xenografts correlates with vascular permeability factor expression but not with metastatic potential. 1997 , 76, 561-70	54
2027	Nachweis des angiogenen Zytokins Vascular Endothelial Growth Factor (VEGF) durch nicht radioaktive In-situ-Hybridisierung. 1997 , 179, 559-562	
2026	Anti-angiogenic drug AGM1470 suppresses smooth muscle cell migration induced by endothelial PDGF. 1997 , 14, 290-8	5
2025	Growth factors in angiogenesis: current interest and therapeutic potential. 1997 , 3, 14-23	68
2024	Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. 1997 , 74, 64-8	201
2023	Angiogenesis in brain tumors; pathobiological and clinical aspects. 1997 , 32, 253-65	186
2022	The preclinical evaluation of angiogenesis inhibitors. 1997 , 15, 5-13	27
2021	Organogenesis and angiogenin. 1997 , 53, 803-15	45
2020	Antiangiogenic drugs as a novel anticancer therapeutic strategy. Which are the more promising agents? What are the clinical developments and indications?. 1997 , 26, 147-62	16
2019	Evaluation of the anticancer action of a permanently charged tamoxifen derivative, tamoxifen methiodide: an MRI study. 1997 , 153, 147-157	4
2018	An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. 1997 , 37, 1107-13	101

2017	Integrin Antagonists and Other Low Molecular Weight Compounds as Inhibitors of Angiogenesis: New Drugs in Cancer Therapy. 1997 , 36, 588-590	46
2016	Angiogenic factors expressed by human prostatic cell lines: effect on endothelial cell growth in vitro. 1997 , 33, 123-32	13
2015	General mechanisms of metastasis. 1997 , 80, 1529-1537	503
2014	Effect of angiogenesis inhibitor TNP-470 on the progression of human gastric cancer xenotransplanted into nude mice. 1997 , 71, 838-41	31
2013	Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival. 1997 , 74, 455-8	111
2012	Angiostatin and endostatin: endothelial cell-specific endogenous inhibitors of angiogenesis and tumor growth. 1998 , 2, 37-48	34
2011	Inhibition of angiogenesis in liver metastases by carboxyamidotriazole (CAI). 1998 , 2, 373-9	25
2010	Therapeutic angiogenesis in the heart using peptide growth factors: angiogenesis research entering clinical trials. 1998 , 2, 115-117	5
2009	Color-coded and spectral Doppler flow in breast carcinomas--relationship with the tumor microvasculature. 1998 , 47, 83-9	60
2008	An old paradigm for treating cancer and other diseases in the 21st century. 1998 , 17, 149-54	
2007	Orthotopic models are necessary to predict therapy of transplantable tumors in mice. 1998 , 17, 279-84	310
2006	Angiogenesis: possibilities for therapeutic interventions. 1998 , 20, 225-35	4
2005	A multivariate logistic regression analysis in predicting malignancy for patients with ovarian tumors. 1998 , 68, 256-62	20
2004	VLA2 integrin expression in breast carcinomas evaluated by automated and quantitative immunohistochemistry. 1998 , 77, 2274-80	6
2003	Immunohistochemical determination of tumor angiogenesis measured by the maximal microvessel density in human prostate cancer. 1998 , 106, 463-9	32
2002	Arterial gene transfer of naked DNA for therapeutic angiogenesis: early clinical results. 1998 , 30, 185-197	57
2001	Angiogenesis, a target for tumor therapy. 1998 , 132, 363-8	16
2000	Preliminary clinical experience with laser-induced interstitial thermotherapy in patients with hepatocellular carcinoma. 1998 , 8, 235-9	26

1999	The effect of antibody against vascular endothelial growth factor on tumor growth and metastasis. 1998 , 124, 615-20	23
1998	Temporal sampling requirements for the tracer kinetics modeling of breast disease. 1998 , 16, 1057-73	220
1997	Expression of vascular endothelial growth factor in cerebellar hemangioblastomas does not correlate with tumor angiogenesis. 1998 , 132, 213-7	11
1996	Involvement of platelets in tumour angiogenesis?. 1998 , 352, 1775-7	314
1995	Quantitative analysis of microvascular changes in diffuse astrocytic neoplasms with increasing grade of malignancy. 1998 , 29, 352-8	86
1994	Nodal metastases: predictive factors. 1998 , 31, 621-37	90
1993	INHIBITION OF TUMOR GROWTH AND ANGIOGENESIS BY VITAMIN D3 AGENTS IN MURINE RENAL CELL CARCINOMA. 1998 , 160, 247-251	65
1992	Basic fibroblast growth factor and the complexity of tumour angiogenesis. 1998 , 7, 797-801	3
1991	Emerging therapeutic targets in angiogenesis. 1998 , 2, 213-229	1
1990	Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis. 1998 , 247, 414-9	82
1989	Zinc-binding of endostatin is essential for its antiangiogenic activity. 1998 , 252, 190-4	101
1988	Solution structure of acidic fibroblast growth factor bound to 1,3, 6-naphthalenetrisulfonate: a minimal model for the anti-tumoral action of suramins and suradistas. 1998 , 281, 899-915	47
1987	Angiogenic Growth Factors: A Review for Tissue Engineering. 1998 , 4, 117-130	63
1986	Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence. 1998 , 55, 575-81	120
1985	Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. 1998 , 51, 161-7	192
1984	Nature of interaction between basic fibroblast growth factor and the antiangiogenic drug 7,7-(Carbonyl-bis[imino-N-methyl-4, 2-pyrrolicarbonylimino[N-methyl-4,2-pyrrole]-carbonylimino]bis-(1, 3-naphthalene disulfonate). 1998 , 75, 672-82	14
1983	Angiogenesis and tumor metastasis. 1998 , 49, 407-24	761
1982	CD34 IMMUNOHISTOCHEMICAL ASSESSMENT OF ANGIOGENESIS AS A PROGNOSTIC MARKER FOR PROSTATE CANCER RECURRENCE AFTER RADICAL PROSTATECTOMY. 1998 , 160, 459-465	142

1981	Angiogenic therapy of the human heart. 1998 , 97, 628-9	66
1980	Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. 1998 , 88, 513-20	175
1979	The use of suicide gene systems in vascular cells in vitro. 1998 , 8, 73-8	1
1978	Neomycin inhibits angiogenin-induced angiogenesis. 1998 , 95, 9791-5	104
1977	Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta. 1998 , 273, 26277-80	137
1976	Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. 1998 , 97, 1114-23	962
1975	ELAM selectin expression in breast carcinomas detected by automated and quantitative immunohistochemical assays. 1998 , 12, 1041-8	5
1974	Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer. 1998 , 12, 541-4	24
1973	Tumor microvasculature has no independent prognostic significance for breast cancer. 1998 , 30, 105-10	9
1972	Regulating angiogenesis: a new therapeutic strategy. 1998 , 38, 898-903	17
1971	UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response. 1998 , 18, 209-18	25
1970	Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. 1998 , 95, 3609-14	215
1969	Angiostatin-mediated suppression of cancer metastases by primary neoplasms engineered to produce granulocyte/macrophage colony-stimulating factor. 1998 , 188, 755-63	73
1968	Establishing a Link between Oncogenes and Tumor Angiogenesis. 1998 , 4, 286-295	109
1967	Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. 1998 , 12, 1731-8	110
1966	Power Doppler findings of adenoma malignum of uterine cervix. 1998 , 45, 213-6	8
1965	Tissue Factor Expression and Metastatic Potential of Colorectal Cancer. 1998 , 80, 894-898	102
1964	Applied vascular biology: can angiogenesis inhibitors help control malignant growth?. 1998 , 129, 841-3	5

1963 Autopsy: a tool for diagnosis and for education. **1998**, 129, 844

1962 Assessment of Tumor Vascularization: Immunohistochemical and Non-Invasive Methods. **1999**, 14, 218-231 26

1961 Student Report - The Fight against Cancer and Angiogenesis Inhibitors: Are we Entering a New Era?. **1999**, 14, 272-274

1960 Interleukin-18 acts as an angiogenesis and tumor suppressor. **1999**, 13, 2195-202 170

1959 Review of Three New Agents that Target Angiogenesis, Matrix Metalloproteinases, and Cyclin-Dependent Kinases. **1999**, 6, 1-5 6

1958 Signal relays in the VEGF system. **1999**, 4, D141-52 23

1957 Angiogenesis Inhibition: Drugs in Clinical Trials. **1999**, 22, 282-290 3

1956 New Treatment Strategies for Malignant Gliomas. **1999**, 4, 209-224 121

1955 Cellular Vascular Endothelial Growth Factor Is a Predictor of Outcome in Patients With Acute Myeloid Leukemia. **1999**, 94, 3717-3721 328

1954 Vascular Endothelial Growth Factor in Cervical Carcinoma. **1999**, 93, 761-765 1

1953 National cancer institute leases new supercomputer. **1999**, 91, 1191A-191

1952 Why angiogenesis inhibition? Commentary. **1999**, 4, 413-7 3

1951 Embryo implantation and tumor metastasis: common pathways of invasion and angiogenesis. **1999**, 17, 275-90 175

1950 Antiangiogenic Agents in Cancer Therapy. **1999**, 4

1949 Science, medicine, and the future. Antivascular therapy: a new approach to cancer treatment. **1999**, 318, 853-6 41

1948 Angiostatic treatment of neuroblastoma. **1999**, 104, 1-24 24

1947 Molecular advances in cardiac and cardiovascular disease. **1999**, 14, 89-99 1

1946 Angiogenesis and anti-angiogenesis: Perspectives for the treatment of solid tumors. **1999**, 10, S60-S63 21

1945	Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. 1999 , 91, 512-23	201
1944	Fully automated microvessel counting and hot spot selection by image processing of whole tumour sections in invasive breast cancer. 1999 , 52, 184-92	56
1943	VEGF and therapeutic opportunities in cardiovascular diseases. 1999 , 10, 541-3	24
1942	Stochastic simulation of benign avascular tumour growth using the Potts model. 1999 , 30, 183-198	67
1941	New strategies in anti-vascular cancer therapy. 1999 , 29, 802-9	34
1940	The tumour microcirculation as a target in cancer therapy: a clearer perspective. 1999 , 29, 733-6	39
1939	Role of vascular endothelial growth factor in the regulation of angiogenesis. 1999 , 56, 794-814	547
1938	Pharmacokinetics of thalidomide in an elderly prostate cancer population. 1999 , 88, 121-5	87
1937	Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. 1999 , 878, 236-70	221
1936	Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma. 1999 , 90, 874-9	58
1935	Clinical applications of angiogenic growth factors and their inhibitors. 1999 , 5, 1359-64	878
1934	New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. 1999 , 18, 5356-62	642
1933	Effects of radiotherapy and estramustine on the microvasculature in malignant glioma. 1999 , 80, 142-8	31
1932	Reproducibility of microvessel counts in breast cancer specimens. 1999 , 81, 1088-93	12
1931	Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. 1999 , 79, 1828-35	258
1930	Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma. 1999 , 109, 810-4	71
1929	Angiogenesis in malignancies of the female genital tract. 1999 , 72, 220-31	83
1928	Tumor angiogenesis in vulvar squamous cell carcinoma. 1999 , 72, 65-70	4

1927	[Therapeutic neoangiogenesis]. 1999 , 88, 241-4	2
1926	Angiogenesis as a target for breast cancer therapy. 1999 , 4, 415-23	8
1925	Role of endothelial cell survival and death signals in angiogenesis. 1999 , 3, 101-16	45
1924	Zinc ligand-disrupted recombinant human Endostatin: potent inhibition of tumor growth, safety and pharmacokinetic profile. 1999 , 3, 41-51	48
1923	Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits angiogenesis. 1999 , 3, 259-69	47
1922	Changes in microvessel endothelial cell gene expression in an in vitro human breast tumour endothelial cell model. 1999 , 3, 221-9	9
1921	Inhibition of PKCalpha decreases the gelatinase activity and the angiogenic and metastatic ability of the highly metastatic B16 murine melanoma cells. 1999 , 3, 241-7	3
1920	Tumor flow in malignant breast tumors measured by Doppler ultrasound: an independent predictor of survival. 1999 , 54, 65-71	21
1919	A new xenograft model of primary central nervous system lymphoma. 1999 , 43, 153-60	14
1918	Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. 1999 , 17, 195-212	73
1917	Molecular and biological properties of vascular endothelial growth factor. 1999 , 77, 527-43	880
1916	[Vascular endothelial factor (VEGF): therapeutic angiogenesis and vasculogenesis in the treatment of cardiovascular disease]. 1999 , 94, 193-201	10
1915	[Anti-angiogenesis: a new approach to tumor therapy?]. 1999 , 94, 570-9	1
1914	Vascular endothelial growth factor in ovarian cancer. 1999 , 1, 59-63	30
1913	Geometric control of switching between growth, apoptosis, and differentiation during angiogenesis using micropatterned substrates. 1999 , 35, 441-8	350
1912	Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors. 1999 , 82, 169-93	60
1911	Role of carbohydrate on angiostatin in the treatment of cancer. 1999 , 134, 553-60	9
1910	Intra-tumor injection of an angiogenesis inhibitor, TNP-470, in rabbits bearing VX2 carcinoma of the tongue. 1999 , 28, 118-124	7

1909	Cytokines: From the laboratory to the clinic. 1999 , 46, 197-205	4
1908	Increased tumor cell proliferation in murine tumors with decreasing dosage of wild-type p53. 1999 , 24, 197-208	14
1907	Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake. 1999 , 26, 213-25	156
1906	New approaches to cancer therapies. 1999 , 187, 138-46	16
1905	Perspective: cancer care and the new biology. 1999 , 187, 4-7	
1904	Relationships between vascularization and proliferation in invasive breast cancer. 1999 , 189, 309-18	40
1903	Disruption of the KEX1 gene in <i>Pichia pastoris</i> allows expression of full-length murine and human endostatin. 1999 , 15, 563-72	49
1902	Molecular markers as prognostic factors for local recurrence and radioresistance in head and neck squamous cell carcinoma. 1999 , 7, 125-44	58
1901	Inhibierung der Angiogenese in vivo durch ets-1-Antisense-Oligonucleotide [Hemmung der Expression des Ets-1-Transkriptionsfaktors durch das Antibiotikum Fumagillin. 1999 , 111, 3432-3435	6
1900	Archimedische Synthese und magische Zahlen: Größenvariation von Molybdän-Sauerstoff-Riesenkugeln vom Keplerattyp. 1999 , 111, 3435-3439	68
1899	Inhibition of Angiogenesis In Vivo by ets-1 Antisense Oligonucleotides-Inhibition of Ets-1 Transcription Factor Expression by the Antibiotic Fumagillin. 1999 , 38, 3228-3231	52
1898	The role of the vascular phase in solid tumor growth: a historical review. 1999 , 1, 293-302	112
1897	Angiogenesis and the atherosclerotic carotid plaque: an association between symptomatology and plaque morphology. 1999 , 30, 261-8	316
1896	New approaches to coronary heart disease: induction of neovascularisation by growth factors. 1999 , 11, 301-8	10
1895	Factors promoting tumor angiogenesis. 1999 , 17, 594-623	90
1894	Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. 1999 , 85, 221-8	2784
1893	Inhibition of angiogenic factor- and tumour-induced angiogenesis by gamma linolenic acid. 1999 , 60, 21-9	20
1892	Does breast cancer exist in a state of chaos?. 1999 , 35, 886-91	71

1891	Dissecting glioma invasion: interrelation of adhesion, migration and intercellular contacts determine the invasive phenotype. 1999 , 17, 625-41	42
1890	Intra-tumor injection of an angiogenesis inhibitor, TNP-470, in rabbits bearing VX2 carcinoma of the tongue. 1999 , 28, 118-124	7
1889	Prognostic significance of tumor angiogenesis in epithelial ovarian cancer. 1999 , 138, 175-82	39
1888	Prognostic significance of tumor angiogenesis in primary fallopian tube cancer. 1999 , 141, 179-86	2
1887	Prognostic and predictive value of intratumoral microvessels density in operable non-small-cell lung cancer. 1999 , 24, 81-8	40
1886	Prognostic significance of tumor angiogenesis in endometrial cancer. 1999 , 93, 367-71	16
1885	Vascular endothelial growth factor in cervical carcinoma. 1999 , 93, 761-5	32
1884	Expression of vascular endothelial growth factor receptors in human prostate cancer. 1999 , 54, 567-72	162
1883	Prognostic factors in multiple myeloma. 1999 , 13, 1295-314, xi	81
1882	The rationale and future potential of angiogenesis inhibitors in neoplasia. 1999 , 58, 17-38	127
1881	Vascular Endothelial Growth Factor Molecular and Biological Aspects. 1999 , 7, 25-57	6
1880	Gene therapy for myocardial angiogenesis. 1999 , 138, S132-41	69
1879	Inhibition of angiogenesis induces chromaffin differentiation and apoptosis in neuroblastoma. 1999 , 154, 395-403	46
1878	VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. 1999 , 247, 495-504	322
1877	The tumor-suppressing activity of angiostatin protein resides within kringle 1 to 3. 1999 , 264, 469-77	44
1876	Angiogenesis and Cancer Control: From Concept to Therapeutic Trial. 1999 , 6, 1-18	74
1875	Chapter 7 Angiogenesis in prostate cancer. 1999 , 3, 139-154	
1874	Prognostic Significance of Tumor Angiogenesis in Endometrial Cancer. 1999 , 93, 367-371	7

1873	Angiogenesis, angiogenic growth factors, and cell adhesion molecules are upregulated in chronic pancreatic diseases: angiogenesis in chronic pancreatitis and in pancreatic cancer. 1999 , 18, 96-103	63
1872	Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. 1999 , 35, 399-407	69
1871	Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. 2000 , 18, 2046-52	210
1870	Cancer chemotherapeutics - angiogenesis agents: October 1999 - March 2000. 2000 , 10, 767-786	7
1869	Entwicklungen in der Chemotherapie maligner Neoplasien. 2000 , 23, 286-291	
1868	Endothelial monocyte-activating polypeptide II, a tumor-derived cytokine that plays an important role in inflammation, apoptosis, and angiogenesis. 2000 , 23, 519-27	40
1867	Implications of human macrophage metalloelastase and vascular endothelial growth factor gene expression in angiogenesis of hepatocellular carcinoma. 2000 , 231, 67-73	40
1866	A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients. 2000 , 58, 324-33	17
1865	Angiostatin generation by human tumor cell lines: involvement of plasminogen activators. 2000 , 86, 760-7	42
1864	Anti-angiogenic treatment of human cancer: pitfalls and promises. 2000 , 86, 870-3	7
1863	Role of surgery in the management of postmastectomy extremity angiosarcoma (Stewart-Treves syndrome). 2000 , 73, 182-8	50
1862	Retroviral vector-producer cell mediated angiogenesis inhibition restricts neuroblastoma growth in vivo. 2000 , 35, 638-40	13
1861	Progress in antiangiogenic gene therapy of cancer. 2000 , 89, 1181-1194	89
1860	Novel strategies and therapeutics for the treatment of prostate carcinoma. 2000 , 89, 1329-48	45
1859	Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. 2000 , 89, 475-83	120
1858	The growth inhibition of hepatoma by gene transfer of antisense vascular endothelial growth factor. 2000 , 2, 289-96	32
1857	Monomethyl selenium--specific inhibition of MMP-2 and VEGF expression: implications for angiogenic switch regulation. 2000 , 29, 236-50	102
1856	Target molecules for anti-angiogenic therapy: from basic research to clinical trials. 2000 , 34, 89-110	87

1855	Expression of angiogenic growth factors in paragangliomas. 2000 , 110, 161-7	48
1854	The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension of nasopharyngeal carcinoma. 2000 , 110, 2066-9	81
1853	Chemotherapeutic drugs--more really is not better. 2000 , 6, 500-2	82
1852	A novel strategy for the tumor angiogenesis-targeted gene therapy: generation of angiostatin from endogenous plasminogen by protease gene transfer. 2000 , 7, 589-96	27
1851	The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts. 2000 , 7, 1537-42	61
1850	New agents for acute myelogenous leukemia. 2000 , 14, 488-90	15
1849	Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. 2000 , 14, 1414-8	176
1848	Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. 2000 , 130, 641-9	146
1847	Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. 2000 , 80, 837-49	232
1846	Vascular-specific growth factors and blood vessel formation. 2000 , 407, 242-8	3120
1845	Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. 2000 , 2, 737-44	2191
1844	Effect of angiostatin on liver metastasis of pancreatic cancer in hamsters. 2000 , 91, 723-30	24
1843	TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. 2000 , 91, 837-44	63
1842	Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors. 2000 , 5, 344-353	51
1841	Commentary on Pilot and Safety Trial of Carboplatin, Paclitaxel, and Thalidomide in Advanced Non-Small-Cell Lung Cancer 2000 , 2, 53-54	
1840	New molecular mediators in tumor angiogenesis. 2000 , 4, 262-269	33
1839	Eriochrome Black T inhibits endothelial cell growth through S-phase blockade. 2000 , 399, 85-90	7
1838	Genes that regulate metastasis and angiogenesis. 2000 , 50, 71-87	66

1837	Antiangiogenesis -- therapeutic strategies and clinical implications for brain tumors. 2000 , 50, 189-200	67
1836	Local anti-angiogenic brain tumor therapies. 2000 , 50, 181-8	24
1835	Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and remodeling. 2000 , 50, 1-15	267
1834	Descriptive analysis and quantification of angiogenesis in human brain tumors. 2000 , 50, 165-72	50
1833	Endothelial cell survival and apoptosis in the tumor vasculature. 2000 , 5, 323-8	97
1832	Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). 2000 , 10, 359-66	128
1831	Expression and function of angiopoietin-1 in breast cancer. 2000 , 83, 1154-60	104
1830	Angiogenesis and surgery: from mice to man. 2000 , 166, 435-46	7
1829	Cells on the move: a dialogue between polarization and motility. 2000 , 49, 89-96	37
1828	Antiangiogenic chemotherapeutic agents. 2000 , 19, 67-73	29
1827	Shark cartilage extracts as antiangiogenic agents: smart drinks or bitter pills?. 2000 , 19, 83-6	17
1826	Angiostatin and angiostatin-related proteins. 2000 , 19, 97-107	83
1825	Social isolation stress augments angiogenesis induced by colon 26-L5 carcinoma cells in mice. 2000 , 18, 1-10	26
1824	The contributions of cyclooxygenase-2 to tumor angiogenesis. 2000 , 19, 19-27	271
1823	Application of advances in molecular biology to the treatment of brain tumors. 2000 , 2, 425-33	7
1822	Multi-agent cytostatic treatment of 'low-grade' gliomas. 2000 , 2, 454-62	
1821	[Functional magnetic resonance tomography in the diagnosis and therapy monitoring in multiple myeloma]. 2000 , 40, 723-30	6
1820	Autologous tissue-fragmented extracardiac conduit with rapid, stable endothelialization due to angiogenesis. 2000 , 48, 153-60	1

1819	[Therapeutic neoangiogenesis of peripheral arteries]. 2000 , 25, 600-10	
1818	[Angiogenesis and vasculogenesis. Therapeutic strategies for stimulation of postnatal neovascularization]. 2000 , 25, 611-22	26
1817	The role of circulating cytokines in colorectal carcinoma. 2000 , 5, 217-228	2
1816	Tumor sinuses- vascular channels. 2000 , 6, 83-6	23
1815	A cure for cancer? Dealing with minimal residual disease. 2000 , 169, 13-6	
1814	Tumorangiogenese [Therapiekonzepte]. 2000 , 6, 443-449	
1813	Immunohistochemical tenascin-C expression in paediatric supratentorial glioblastoma multiforme. 2000 , 16, 357-62	2
1812	Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. 2000 , 96, 1900-1905	74
1811	Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. 2000 , 96, 2240-2245	583
1810	Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. 2000 , 7, 725-9	71
1809	Fiber type-specific differential expression of angiogenic factors in response to chronic hindlimb ischemia. 2000 , 279, H932-8	47
1808	Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. 2000 , 18, 708-15	377
1807	Angiogenesis in neuroblastoma: relationship to survival and other prognostic factors in a cohort of neuroblastoma patients. 2000 , 18, 27-34	48
1806	Phase II evaluation of thalidomide in patients with metastatic breast cancer. 2000 , 18, 2710-7	99
1805	Angiogenesis: A Common Denominator of Disease?. 2000 , 40, 564-565	
1804	Incipient angiogenesis. 2000 , 92, 94-5	87
1803	Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. 2000 , 97, 3884-9	332
1802	Expression of antisense to integrin subunit beta 3 inhibits microvascular endothelial cell capillary tube formation in fibrin. 2000 , 275, 32281-8	30

1801	Prognostic value of vascular endothelial growth factor in breast cancer. 2000 , 5 Suppl 1, 37-44	256
1800	Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. 2000 , 14, 2477-85	88
1799	Expression of the adrenomedullin gene in epithelial ovarian cancer. 2000 , 6, 867-72	45
1798	Elevated levels of urine angiostatin and plasminogen/plasmin in cancer patients. 2000 , 5, 547-51	17
1797	Autocrine motility factor receptor expression associates with tumor progression in thymoma. 2000 , 17, 259-64	8
1796	Neuropilin-2 expression affects the increased vascularization and is a prognostic factor in osteosarcoma. 2000 , 17, 291-5	41
1795	Hammerhead ribozyme specifically inhibits vascular endothelial growth factor gene expression in a human hepatocellular carcinoma cell line. 2000 , 17, 495-9	3
1794	Prostate vascular flow: the effect of ejaculation as revealed on transrectal power Doppler sonography. 2000 , 175, 1169-72	42
1793	[Influence of histopathological factors on dynamic MR mammography]. 2000 , 172, 894-900	6
1792	Cartilaginous tumors: fast contrast-enhanced MR imaging. 2000 , 214, 539-46	175
1791	Boron neutron capture therapy of the rat 9L gliosarcoma: evaluation of the effects of shark cartilage. 2000 , 73, 429-34	3
1790	New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. 2000 , 79, 1-38	131
1789	VEGF receptor signaling in tumor angiogenesis. 2000 , 5 Suppl 1, 3-10	394
1788	Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secreted endostatin. 2000 , 11, 1983-96	76
1787	Angiogenesis in the thyroid gland. 2000 , 166, 475-80	112
1786	Bone sialoprotein and the paradox of angiogenesis versus atherosclerosis. 2000 , 86, 827-8	5
1785	Chymase as a proangiogenic factor. A possible involvement of chymase-angiotensin-dependent pathway in the hamster sponge angiogenesis model. 2000 , 275, 5545-52	87
1784	Gene Therapy for Cardiovascular Disease. 2000 , 4, 289-300	

1783	Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. 2000 , 97, 6427-32	146
1782	Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. 2000 , 268, 183-91	77
1781	Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells. 2000 , 276, 371-8	96
1780	Vascular endothelial growth factor (VEGF) and melanoma. N-acetylcysteine downregulates VEGF production in vitro. 2000 , 12, 374-8	52
1779	Inhibitory effect of TNP-470 on hepatic metastasis of mouse neuroblastoma. 2000 , 93, 82-7	13
1778	Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis. 2000 , 60, 70-80	81
1777	Vasculogenic mimicry and tumor angiogenesis. 2000 , 156, 361-81	563
1776	Modulation of human colon tumor-stromal interactions by the endothelin system. 2000 , 157, 1863-74	66
1775	Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. 2000 , 153, 7-12	87
1774	Anti-angiogenesis therapy: concepts and importance of dosing schedules in clinical trials. 2000 , 3, 223-235	18
1773	Angiogenèse: de la physiologie à la thérapeutique. 2000 , 9, 534-544	2
1772	Anti-angiogenic agents: clinical trial design and therapies in development. 2000 , 36, 1713-24	89
1771	Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. 2000 , 36, 1833-43	60
1770	Use of Doppler ultrasound in the evaluation of breast carcinoma. 2000 , 21, 297-307	34
1769	VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease. 2000 , 70, 829-34	242
1768	Pharmacology of thalidomide. 2000 , 37, 5-14	33
1767	Pilot studies of thalidomide in acute myelogenous leukemia, myelodysplastic syndromes, and myeloproliferative disorders. 2000 , 37, 26-34	9
1766	Efficacy of antiangiogenic therapy with TNP-470 in superficial and invasive bladder cancer models in mice. 2000 , 56, 521-6	18

1765	Canine Hemangiosarcoma Treated with Standard Chemotherapy and Minocycline. 2000 , 14, 395-398	52
1764	Inhibici3n farmacol3gica del Factor de Crecimiento Fibrobl3stico b3sico (FCFb) en un modelo experimental de tumor neuroectod3rmico. 2000 , 11, 373-376	2
1763	Angiogenesis inhibitors. New agents in cancer therapy. 2000 , 17, 249-55	26
1762	EXPRESSION OF THE VEGF-RECEPTOR Flt-1 IN BENIGN, PREMALIGNANT AND MALIGNANT PROSTATE TISSUES. 2000 , 164, 506-510	41
1761	Role of radionuclide imaging in trials of antiangiogenic therapy. 2000 , 7, 851-67	31
1760	Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. 2000 , 35, 71-103	482
1759	Tumor angiogenesis: past, present and the near future. 2000 , 21, 505-15	773
1758	Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. 2000 , 92, 143-7	292
1757	Vascular endothelial growth factor and its correlation with superficial bladder cancer recurrence rates and stage progression. 2000 , 27, 191-7	17
1756	Tumor angiogenesis: molecular pathology, therapeutic targeting, and imaging. 2000 , 7, 800-11	84
1755	Intravital fluorescence videomicroscopy to study tumor angiogenesis and microcirculation. 2000 , 2, 53-61	85
1754	VEGF-induction of angiogenesis. 2000 , 31, 1252-1255	1
1753	Angiogenesis imaging. 2000 , 7, 783-5	40
1752	The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors. 2000 , 1 Suppl 1, S80-4	59
1751	Pilot and safety trial of carboplatin, paclitaxel, and thalidomide in advanced non small-cell lung cancer. 2000 , 2, 48-52; discussion 53-4	22
1750	Phytoestrogens and cardiovascular health. 2000 , 35, 1403-10	223
1749	Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. 2001 , 24, 87-117	58
1748	Somatostatin analogs for cancer treatment and diagnosis: an overview. 2001 , 47 Suppl 2, 1-29	63

1747	The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. 2001 , 41, 189-207	1871
1746	Combretastatin A-4 and hyperthermia;a potent combination for the treatment of solid tumors. 2001 , 60, 147-54	39
1745	Endothelial cells contain a glycine-gated chloride channel. 2001 , 40, 197-204	42
1744	The hemostatic system and angiogenesis in malignancy. 2001 , 3, 371-84	91
1743	Nutrition and Cancer Prevention. 2001 ,	3
1742	Procoagulants in fetus rejection: the role of the OX-2 (CD200) tolerance signal. 2001 , 13, 255-63	34
1741	Ganglioside GD1a enhances VEGF-induced endothelial cell proliferation and migration. 2001 , 282, 1031-7	45
1740	Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. 2001 , 230, 151-60	317
1739	Therapeutic angiogenesis for ischemic cardiovascular disease. 2001 , 33, 379-93	158
1738	Controlling tumor-derived and vascular endothelial cell growth: role of the 4Ff2 cell surface antigen. 2001 , 159, 165-78	9
1737	Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: a new world of angiogenesis research. 2001 , 158, 789-96	109
1736	Angiogenesis inhibitors in the treatment of lung cancer. 2001 , 34 Suppl 3, S81-9	26
1735	New molecular targets and biological therapies in sarcomas. 2001 , 27, 317-26	19
1734	Wound-induced angiogenesis and its pharmacologic inhibition in a murine model. 2001 , 130, 497-501	11
1733	[Thalidomide: the revival]. 2001 , 22, 5-7	4
1732	[The mechanisms of angiogenesis. Medical and therapeutic applications]. 2001 , 22, 1064-82	8
1731	Feature extraction and classification of breast cancer on dynamic magnetic resonance imaging using artificial neural network. 2001 , 171, 183-91	47
1730	Different features of angiogenesis between ovarian and breast carcinoma. 2001 , 170, 161-7	18

1729	Metronomic scheduling: the future of chemotherapy?. 2001 , 2, 733-40	221
1728	Targeting of vasculature in cancer and other angiogenic diseases. 2001 , 22, 129	25
1727	Ribonucleases and their antitumor activity. 2001 , 129, 175-91	55
1726	Angiogenesis: the role of the microenvironment in flipping the switch. 2001 , 11, 35-40	112
1725	Clinical significance of urinary vascular endothelial growth factor and microvessel density in patients with renal cell carcinoma. 2001 , 58, 904-8	16
1724	Technology update. 2001 , 39, 385-97	24
1723	Antiangiogenesis therapy. Current and future agents. 2001 , 15, 835-51, viii	18
1722	Liver cancer. 2001 , 5, 479-507	28
1721	Imaging the results of antiangiogenesis therapy. 2001 , 8, 119-20	1
1720	Nonsurgical treatment of hepatocellular carcinoma. 2001 , 5, 175-89	8
1719	ANGIOGENESIS AND ANGIOGENIC GROWTH FACTORS IN WILMS TUMOR. 2001 , 165, 2274-2279	41
1718	[Growth factors for therapeutic angiogenesis in cardiovascular diseases]. 2001 , 54, 1210-24	11
1717	Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. 2001 , 98, 6656-61	270
1716	Somministrazione Settimanale del Paclitaxel: Peculiarit� Presupposti Biologici. 2001 , 87, 1-7	1
1715	Color Doppler imaging of untreated and irradiated choroidal melanomas. 2001 , 11, 150-5	15
1714	Angiogenesis Research: Guidelines for Translation to Clinical Application. 2001 , 86, 23-33	203
1713	Intracellular Ca(2+) signaling in endothelial cells by the angiogenesis inhibitors endostatin and angiostatin. 2001 , 280, C1140-50	41
1712	Redefining the target: chemotherapeutics as antiangiogenics. 2001 , 19, 1195-206	365

1711	Adenylate cyclase/protein kinase A signaling pathway enhances angiogenesis through induction of vascular endothelial growth factor in vivo. 2001 , 87, 181-8	51
1710	Clinical implications of circulating angiogenic factors in cancer patients. 2001 , 19, 1207-25	491
1709	A novel snake venom disintegrin that inhibits human ovarian cancer dissemination and angiogenesis in an orthotopic nude mouse model. 2001 , 31, 183-91	23
1708	Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb?. 2001 , 7, 79-94	20
1707	Angiogenesis. 2001 , 66-73	12
1706	Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. 2001 , 226, 665-73	134
1705	Angiogenesis in hematologic malignancies. 2001 , 80, 695-705	47
1704	Mechanistic insights on the inhibition of tumor angiogenesis. 2001 , 78, 663-72	49
1703	[Imaging of angiogenesis]. 2001 , 41, 138-45	4
1702	Angiozyme: a novel angiogenesis inhibitor. 2001 , 3, 141-6	93
1701	Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. 2001 , 8, 72-9	189
1700	A preliminary study of angiogenesis in paediatric glioblastoma multiforme and its correlation with survival. 2001 , 17, 577-83	5
1699	Expression of angiopoietin-2 gene and its receptor Tie2 in hepatocellular carcinoma. 2001 , 21, 228-30, 235	17
1698	The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. 2001 , 7, 14-23	456
1697	The inverse relationship between microvessel counts and tumor volume in breast cancer. 2001 , 7, 184-8	27
1696	The use of microvessel density in assessing human urological tumours. 2001 , 87, 866-75	10
1695	Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. 2001 , 39, 409-15	150
1694	Angiogenesis in B-chronic lymphocytic leukemia. 2001 , 25, 485-6	3

1693	Antiangiogenic agents and their promising potential in combined therapy. 2001 , 39, 155-71	45
1692	Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. 2001 , 49, 293-305	114
1691	MR-derived cerebral blood volume maps: issues regarding histological validation and assessment of tumor angiogenesis. 2001 , 46, 735-47	105
1690	Serum endostatin levels are elevated in patients with soft tissue sarcoma. 2001 , 91, 1525-9	78
1689	Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas. 2001 , 92, 240-8	36
1688	Vascular remodelling during the normal and malignant life cycle of the mammary gland. 2001 , 52, 182-9	143
1687	Bone marrow microcirculation analysis in multiple myeloma by contrast-enhanced dynamic magnetic resonance imaging. 2001 , 93, 862-8	62
1686	Microencapsulation of an anti-VE-cadherin antibody secreting 1B5 hybridoma cells. 2001 , 76, 285-94	35
1685	Tissue engineering in plastic reconstructive surgery. 2001 , 263, 372-8	23
1684	Engineering of Blood Vessel Patterns by Angio-Morphogens [Angiotropins]:. Non-Mitogenic Copper-Ribonucleoprotein Cytokines [CuRNP Ribokines] with their Metalloregulated Constituents of RAGE-binding S100-EF-Hand Proteins and extracellular RNA Bioaptamers in Vascular Remodeling of Tissue and Angiogenesis in vitro. 2001 , 32, 984-1008	4
1683	Quantitative analysis of angiogenesis using confocal laser scanning microscopy. 2001 , 4, 187-91	14
1682	Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. 2001 , 16, 1077-91	107
1681	The relationship between genetic aberrations as detected by comparative genomic hybridization and vascularization in glioblastoma xenografts. 2001 , 51, 121-7	7
1680	Effects of genotypically different strains of Helicobacter pylori on human microvascular endothelial cells in vitro. 2001 , 46, 54-61	14
1679	The treatment of advanced renal cell cancer with high-dose oral thalidomide. 2001 , 85, 953-8	89
1678	Bone marrow as a source of endothelial cells for natural and iatrogenic vascular repair. 2001 , 953, 75-84	64
1677	Therapeutic angiogenesis in critical limb and myocardial ischemia. 2001 , 14, 511-28	57
1676	Reduced growth in response to ganciclovir treatment of subcutaneous xenografts expressing HSV-tk in the vascular compartment. 2001 , 8, 913-20	17

1675	Angiogenesis and G-protein-coupled receptors: signals that bridge the gap. 2001 , 20, 1556-62	82
1674	The metastasis-associated Mts1(S100A4) protein could act as an angiogenic factor. 2001 , 20, 4685-95	200
1673	Angiogenesis in B-chronic lymphocytic leukemia. 2001 , 25, 709-10	8
1672	Corneal vascularisation: the superficial and the deep. 2001 , 24, 3-8	4
1671	Genetic mechanisms in squamous cell carcinoma of the head and neck. 2001 , 37, 115-26	53
1670	Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. 2001 , 69, 135-44	240
1669	RNA damage and inhibition of neoplastic endothelial cell growth: effects of human and amphibian ribonucleases. 2001 , 155, 171-174	6
1668	Can mosaic tumor vessels facilitate molecular diagnosis of cancer?. 2001 , 98, 398-400	86
1667	Life and death of a cardiac myocyte: principles of cellular biology. 2001 , 16, 229-41	1
1666	The role of vascular endothelial growth factor in angiogenesis. 2001 , 106, 148-56	332
1665	Antiangiogenic therapy in leukemia. 2001 , 106, 190-207	25
1664	Neuroendocrine lung tumors: grade correlates with proliferation but not angiogenesis. 2001 , 14, 1195-9	40
1663	Angiogenesis and the ischaemic heart. 2001 , 22, 903-18	35
1662	Effect of TNP-470 (AGM-1470) on the growth of rat rhabdomyosarcoma tumors of different sizes. 2001 , 19, 35-40	10
1661	From therapeutic angiogenesis to myocardium regeneration. 2001 , 1, 287-295	1
1660	Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review). 2001 , 19, 257-62	38
1659	Association between host tissue vascularity and the prognostically relevant tumor vascularity in human cervical cancer. 2001 , 19, 827	
1658	Therapeutic potential of bone marrow-derived endothelial progenitor cells for cardiovascular ischemic diseases. 2001 , 1, 361-374	

1657	Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia. 2001 , 58, 761-8	107
1656	Angiogenesis Protocols. 2001 ,	8
1655	Measuring changes in human tumour vasculature in response to therapy using functional imaging techniques. 2001 , 85, 1085-93	52
1654	Endostatin binds tropomyosin. A potential modulator of the antitumor activity of endostatin. 2001 , 276, 25190-6	92
1653	Angiopoietin-1, unlike angiopoietin-2, is incorporated into the extracellular matrix via its linker peptide region. 2001 , 276, 34990-8	80
1652	Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively. 2001 , 276, 32714-9	127
1651	PTEN controls tumor-induced angiogenesis. 2001 , 98, 4622-7	205
1650	Apoptosis and angiogenesis in cancer prevention by selenium. 2001 , 492, 131-45	28
1649	TNP-470 Suppresses the Tumorigenicity of HT1080 Fibrosarcoma Tumor Through the Inhibition of VEGF Secretion From the Tumor Cells. 2001 , 5, 197-202	8
1648	Particle-mediated intravascular delivery of oligonucleotides to tumors: associated biology and lessons from gene therapy. 2001 , 8, 191-213	31
1647	Molecular markers in head and neck squamous cell carcinoma: their biological function and prognostic significance. 2001 , 110, 221-8	20
1646	Assessment of risks associated with cardiovascular gene therapy in human subjects. 2001 , 89, 389-400	119
1645	Hold that line. Angiomotin regulates endothelial cell motility. 2001 , 152, F35-6	8
1644	Role of protein kinase C ζ in Ras-mediated transcriptional activation of vascular permeability factor/vascular endothelial growth factor expression. 2001 , 276, 2395-403	60
1643	Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice. 2001 , 93, 382-7	79
1642	Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) receptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. 2001 , 276, 26969-79	240
1641	High microvessel density in primitive neuroectodermal brain tumors of childhood. 2001 , 32, 75-9	29
1640	Growth Factors and their Receptors in Cancer Metastasis. 2001 ,	

1639	Therapeutic inhibition of angiogenesis. 2001 , 46, 3-26	1
1638	Tumor transport physiology: implications for imaging and imaging-guided therapy. 2001 , 177, 747-53	73
1637	Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. 2001 , 86, 656-8	173
1636	[Therapeutic neoangiogenesis. Alternative or adjuvant option in the treatment of advanced coronary and peripheral ischemic vascular disease]. 2001 , 126, 1053-7	1
1635	Thymidine phosphorylase: a two-face Janus in anticancer chemotherapy. 2001 , 1, 141-53	54
1634	Evidence for telomerase involvement in the angiogenesis of astrocytic tumors: expression of human telomerase reverse transcriptase messenger RNA by vascular endothelial cells. 2001 , 94, 961-71	29
1633	Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. 2002 , 12, 953-61	62
1632	The 93rd Annual Meeting of the American Association for Cancer Research. 6-10 April 2002, San Francisco, California, USA. 2002 , 3, 629-32	
1631	Lung Cancer. 2002 ,	
1630	An Angiogenic, Endothelial-Cell-Targeted Polymeric Gene Carrier. 2002 , 6, 664-672	
1629	Overexpression of the p53-inducible brain-specific angiogenesis inhibitor 1 suppresses efficiently tumour angiogenesis. 2002 , 86, 490-6	35
1628	Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. 2002 , 86, 244-9	104
1627	A model for co-expression pattern analysis of genes implicated in angiogenesis and tumour cell invasion in cervical cancer. 2002 , 87, 537-44	66
1626	Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. 2002 , 86, 864-9	63
1625	Blood pressure control and diabetic retinopathy. 2002 , 86, 365-7	36
1624	Molecular approaches to sarcoma therapy. 2002 , 6, 27-42	7
1623	Antiangiogenic activity of aeroplysinin-1, a brominated compound isolated from a marine sponge. 2002 , 16, 261-3	76
1622	Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. 2002 , 20, 3804-14	172

1621	Angioarchitecture of primary oral malignant melanomas. 2002 , 50, 1555-62	14
1620	Reality Testing in Cancer Treatment: The Phase I Trial of Endostatin. 2002 , 7, 58-65	2
1619	Tumor cell specific expression of MMP-2 correlates with tumor vascularisation in breast cancer. 2002 , 21, 25	6
1618	An evaluation of the prognostic significance of vascular endothelial growth factor in node positive primary breast carcinoma. 2002 , 20, 717	3
1617	Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. 2002 , 20, 1227	8
1616	Clinicopathologic study of neovascularization and VEGF expression in superficial esophageal carcinoma. 2002 , 21, 1181	
1615	Tumor vascularity: evaluation in a murine model with contrast-enhanced color Doppler US effect of angiogenesis inhibitors. 2002 , 222, 460-7	54
1614	Four Birds with One Stone: RAPA as Potential Anticancer. 2002 , 1, 358-360	8
1613	Gene therapy of prostate cancer with the soluble vascular endothelial growth factor receptor Flk1. 2002 , 1, 548-53	35
1612	From the war on cancer to translational oncology. 2002 , 1, 711-4	1
1611	Effect of reproductive hormones on ovarian epithelial tumors: II. Effect on angiogenic activity. 2002 , 1, 307-12	3
1610	Ablation of microvessels in vivo upon dimerization of iCaspase-9. 2002 , 9, 444-51	42
1609	ETS proteins and MMPs: partners in invasion and metastasis. 2002 , 3, 359-67	35
1608	Dynamische MRT der Lendenwirbelsäule zur Beurteilung der Mikrozirkulation unter anti-angiogenetischer Therapie bei Patienten mit Myelodysplastischen Syndromen. 2002 , 174, 58-64	0
1607	B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. 2002 , 16, 911-9	109
1606	The significance of immunohistochemistry in the diagnosis and therapy of neoplasms. 2002 , 2, 371-93	11
1605	Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. 2002 , 87, 1737-42	81
1604	Continuous intravascular secretion of endostatin in mice from transduced hematopoietic stem cells. 2002 , 5, 345-51	50

1603	[Antivascular strategies--a new concept for diagnosis and therapy of head and neck cancer. A review]. 2002 , 81, 509-15	1
1602	Antiangiogenic and antitumor effects of endostatin on follicular thyroid carcinoma. 2002 , 143, 3522-8	31
1601	Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships. 2002 , 2, 973-1000	83
1600	Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. 2002 , 20, 3772-84	222
1599	Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. 2002 , 13, 1259-63	68
1598	Treatment options in hormone resistant prostate cancer. 2002 , 13 Suppl 4, 95-102	3
1597	Interrelationships among angiogenesis, proliferation, and apoptosis in the tumor microenvironment during N-methyl-N-nitrosourea androgen-induced prostate carcinogenesis in rats. 2002 , 23, 1701-11	28
1596	Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target?. 2002 , 9, 151-60	50
1595	Second symposium of novel molecular targets for cancer therapy. 2002 , 7 Suppl 3, 1-3	4
1594	Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review. 2002 , 1, 327-37	36
1593	Analysis of mural cell recruitment to tumor vessels. 2002 , 105, 112-7	153
1592	Semi-automated method of quantifying vasculature of 1-methyl-1-nitrosourea-induced rat mammary carcinomas using immunohistochemical detection. 2002 , 50, 213-22	19
1591	Vascular density profile of rat mammary carcinomas induced by 1-methyl-1-nitrosourea: implications for the investigation of angiogenesis. 2002 , 23, 847-54	11
1590	Anti-angiogenic therapy for uveal melanoma--more haste, less speed. 2002 , 86, 368-9	9
1589	. 2002 , 10, 121-127	5
1588	Therapeutic angiogenesis for coronary artery disease. 2002 , 136, 54-71	181
1587	Direct myocardial revascularization and therapeutic angiogenesis. 2002 , 23, 1492-502	1
1586	Pathologic neovascularization in cartilage tumors. 2002 , 76-82	28

1585	Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor. 2002 , 25, 111-21	62
1584	Comparative evaluation of angiogenesis in gastric adenocarcinoma by nestin and CD34. 2002 , 10, 121-7	21
1583	Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. 2002 , 9, 24-36	73
1582	Perindopril: possible use in cancer therapy. 2002 , 13, 221-8	27
1581	Human T-cell lymphotropic virus type 1-transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells. 2002 , 99, 3383-9	53
1580	Involvement of hypoxia-inducible factor 1 in human cancer. 2002 , 41, 79-83	168
1579	Image analysis of Transwell assays in the assessment of invasion by malignant cell lines. 2002 , 59, 11-4	9
1578	Angiogenesis in epithelial ovarian cancer. 2002 , 55, 348-59	116
1577	Gut cancers differentiate without CDX2. 2002 , 55, 359-359	4
1576	14 Role of immunohistochemical expression and in situ hybridization expression of endothelin in colon carcinoma. 2002 , 245-253	
1575	An Angiogenic, Endothelial-Cell-Targeted Polymeric Gene Carrier. 2002 , 6, 664-672	117
1574	Celecoxib: a specific COX-2 inhibitor with anticancer properties. 2002 , 9, 28-35	181
1573	Thromboembolic disease and cancer: possible new treatments. 2002 , 25, 67-73	4
1572	Treatment of colon and rectal cancer. 2002 , 34, 15-26	25
1571	Antiangiogenesis agents. 2002 , 15, 453-8	15
1570	Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. 2002 , 20, 4368-80	1287
1569	Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer. 2002 , 19, 557-70	25
1568	Vascular endothelial growth factor: regulation in the mouse skin carcinogenesis model and use in antiangiogenesis cancer therapy. 2002 , 7 Suppl 3, 4-11	49

1567	New paradigm for vessel intravasation by tumor cells. 2002 , 160, 1937-9	27
1566	The ribonucleolytic activity of angiogenin. 2002 , 41, 1343-50	50
1565	Comparison of methods of microvascular staining and quantification in prostate carcinoma: relevance to prognosis. 2002 , 110, 177-85	25
1564	Novel clinical trials in androgen-independent prostate cancer. 2002 , 1, 51-7	10
1563	Endothelial progenitor cells for vascular regeneration. 2002 , 11, 171-8	97
1562	Angiogenesis in non-small cell lung cancer. A new target for therapy. 2002 , 1, 325-38	4
1561	Is diabetic retinopathy an inflammatory disease?. 2002 , 86, 363-5	249
1560	New vessel formation and aberrant VEGF/VEGFR signaling in acute leukemia: does it matter?. 2002 , 43, 1901-9	9
1559	Reactive oxygen generated by Nox1 triggers the angiogenic switch. 2002 , 99, 715-20	392
1558	In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. 2002 , 100, 4622-8	122
1557	G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells. 2002 , 297, 1058-61	168
1556	Mechanisms for 2-methoxyestradiol-induced apoptosis of prostate cancer cells. 2002 , 531, 141-51	58
1555	Nature of Interaction between basic fibroblast growth factor and the antiangiogenic drug 7,7-(carbonyl-bis[imino-N-methyl-4,2-pyrrolicarbonylimino[N-methyl-4,2-pyrrole]-carbonylimino])-bis-(1,3-naphthalene disulfonate). II. Removal of polar interactions affects protein folding. 2002 , 82, 2652-64	19
1554	Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. 2002 , 37, 22-30	78
1553	Angiogenesis: an expanding universe. 2002 , 33, 1061-3	13
1552	Topotecan is anti-angiogenic in experimental hepatoblastoma. 2002 , 37, 857-61	23
1551	The role of arachidonic acid in normal and malignant hematopoiesis. 2002 , 66, 57-69	17
1550	Thalidomide, an antiangiogenic agent with clinical activity in cancer. 2002 , 56, 194-9	23

1549	Looking for a good endothelial address. 2002 , 1, 113-5	59
1548	Angiogenesis and anti-angiogenesis in neuroblastoma. 2002 , 38, 750-7	41
1547	Hypoxia as a target for combined modality treatments. 2002 , 38, 240-57	159
1546	PET for in vivo pharmacokinetic and pharmacodynamic measurements. 2002 , 38, 2094-107	90
1545	Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches. 2002 , 197, 239-50	87
1544	Recombinant arginine deiminase as a potential anti-angiogenic agent. 2002 , 183, 155-62	55
1543	Tea catechins inhibit angiogenesis in vitro, measured by human endothelial cell growth, migration and tube formation, through inhibition of VEGF receptor binding. 2002 , 180, 139-44	136
1542	Costunolide, a sesquiterpene lactone from <i>Saussurea lappa</i> , inhibits the VEGFR KDR/Flk-1 signaling pathway. 2002 , 187, 129-33	75
1541	Cancer gene therapy: scientific basis. 2002 , 53, 437-52	56
1540	Assessing perfusion and capillary permeability changes induced by a VEGF inhibitor in human tumor xenografts using macromolecular MR imaging contrast media. 2002 , 9 Suppl 2, S328-9	8
1539	Dynamic susceptibility contrast MRI of gliomas. 2002 , 12, 501-23	89
1538	Adenovirus-mediated delivery of a soluble form of the VEGF receptor Flk1 delays the growth of murine and human pancreatic adenocarcinoma in mice. 2002 , 132, 857-65	42
1537	Anti-angiogenic agents for the treatment of brain tumors. 2002 , 12, 477-99	11
1536	Angiogenesis as a target for cancer therapy. 2002 , 16, 1125-71	20
1535	Gene therapy for pancreatic cancer. 2002 , 11, 537-69	9
1534	Modeling and simulation of the formation of vascular networks. 2002 , 12, 108-114	1
1533	Angiogenesis in Health and Disease: Insights into Basic Mechanisms and Therapeutic Opportunities. 2002 , 66, 962-975	55
1532	A Mathematical Model of an In Vitro Experiment to Investigate Endothelial Cell Migration. 2002 , 4, 251-270	5

1531	Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases. 2002 , 109, E37	65
1530	Angiogenesis in advanced colorectal adenocarcinoma with special reference to tumoral invasion. 2002 , 39, 32-8	11
1529	Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. 2002 , 9, 36-44	206
1528	Unusual "to-and-fro" Doppler spectral waveform in lymph node metastasis. 2002 , 21, 663-7	
1527	Expression of target molecules in lung cancer: challenge for a new treatment paradigm. 2002 , 29, 2-8	7
1526	Local drug delivery to the brain. 2002 , 54, 987-1013	129
1525	Thalidomide as an anti-cancer agent. 2002 , 6, 160-74	51
1524	Gestational sac diameter in very early pregnancy as a predictor of fetal outcome. 2002 , 20, 267-9	26
1523	Three-dimensional angioarchitecture in transplantable rat fibrosarcomas. 2002 , 126, 66-70	2
1522	VEGF gene delivery for treatment of ischemic cardiovascular disease. 2002 , 12, 108-14	54
1521	Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies. 2002 , 11, 13-23	14
1520	Angiogenesis in bladder cancer--prognostic marker and target for future therapy. 2002 , 11, 85-100	44
1519	Synthesis and biological investigation of novel tricyclic benzodiazepinedione-based RGD analogues. 2002 , 3, 1078-88	20
1518	Nuclear medicine applications in molecular imaging. 2002 , 16, 352-61	70
1517	Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. 2002 , 24, 280-3	113
1516	Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. 2002 , 98, 682-9	121
1515	Melphalan availability in hypoxia-inducible factor-1alpha+/+ and factor-1alpha-/- tumors is independent of tumor vessel density and correlates with melphalan erythrocyte transport. 2002 , 99, 514-9	15
1514	Differential production of angiostatin by concomitant antitumoral resistance-inducing cancer cells. 2002 , 100, 14-21	8

1513	Strategies for vascular targeting in tumors. 2002 , 100, 123-30	48
1512	VEGF isoforms and mutations in human colorectal cancer. 2002 , 101, 32-6	36
1511	Hypoxia upregulates Bcl-2 expression and suppresses interferon-gamma induced antiangiogenic activity in human tumor derived endothelial cells. 2002 , 94, 2745-55	32
1510	Neuropilin 1 and neuropilin 2 co-expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma. 2002 , 95, 2196-201	130
1509	Serum endostatin predicts tumor vascularity in hepatocellular carcinoma. 2002 , 95, 2188-95	50
1508	Engineering vascular networks in porous polymer matrices. 2002 , 60, 668-78	180
1507	Inhibition of angiogenesis and promotion of melanoma dormancy by vitamin E succinate. 2002 , 9, 1023-32	54
1506	Angiogenesis in ovarian cancer: molecular pathology and therapeutic strategies. 2002 , 4, 165-74	13
1505	New molecular targets of breast cancer therapy. 2002 , 178, 123-33	17
1504	[Leflunomide reduces the angiogenesis score and tumor growth of subcutaneously implanted colon carcinoma cells in the mouse model]. 2002 , 73, 716-20	14
1503	[Dynamic contrast-enhanced MRI for evaluating bone marrow microcirculation in malignant hematological diseases before and after thalidomide therapy]. 2002 , 42, 222-30	7
1502	Sharks: a potential source of antiangiogenic factors and tumor treatments. 2002 , 4, 521-5	30
1501	Chemical pregnancies: immunologic and ultrasonographic studies. 2002 , 48, 323-8	14
1500	Association between vascular endothelial growth factor (VEGF) expression and tumor angiogenesis in ameloblastomas. 2002 , 31, 28-34	48
1499	Antiangiogenic mechanisms of diet-derived polyphenols. 2002 , 13, 380-390	134
1498	Therapeutic potential of the anti-angiogenesis drug TNP-470. 1998 , 79, 359-62	17
1497	Disseminated lobular capillary haemangioma. 2002 , 43, 297-300	14
1496	A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. 2002 , 9, 1207-13	64

1495	The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target. 2002 , 21, 1309-15	41
1494	Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression. 2002 , 21, 2805-14	69
1493	Tumor angiogenesis as a predictive marker for organ preservation in patients with advanced laryngeal carcinoma. 2002 , 112, 844-51	25
1492	Suppressed angiogenesis in kininogen-deficiencies. 2002 , 82, 871-80	48
1491	Analysis of intrapulmonary vessels and epithelial-endothelial interactions in the human developing lung. 2002 , 82, 293-301	48
1490	Myocardial gene therapy. 2002 , 415, 234-9	310
1489	VEGF and the quest for tumour angiogenesis factors. 2002 , 2, 795-803	1204
1488	Angiogenesis modulation in cancer research: novel clinical approaches. 2002 , 1, 415-26	144
1487	A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. 2002 , 86, 1604-14	64
1486	Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor. 2002 , 87, 119-26	36
1485	Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. 2002 , 87, 1166-72	251
1484	Suppression of basic fibroblast growth factor-induced angiogenesis by a specific chymase inhibitor, BCEAB, through the chymase-angiotensin-dependent pathway in hamster sponge granulomas. 2002 , 137, 554-60	21
1483	Therapeutic angiogenesis: a fantastic new adventure. 2002 , 15, 223-9	10
1482	Vascular growth factors for coronary angiogenesis. 2002 , 15, 511-8	13
1481	Cyclooxygenase-2 and adenylate cyclase/protein kinase A signaling pathway enhances angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. 2002 , 15, 13-24	20
1480	Tissue factor expression and angiogenesis in human glioma. 2002 , 35, 321-5	81
1479	Comparison between pediatric acute myeloid leukemia (AML) and adult AML in VEGF and KDR (VEGF-R2) protein levels. 2002 , 26, 399-402	22
1478	Antitumor effects induced by the combination of TNP-470 as an angiogenesis inhibitor and lentinan as a biological response modifier in a rabbit spontaneous liver metastasis model. 2002 , 32, 503-9	17

1477	[Tumor angiogenesis--value and significance in squamous epithelial carcinoma of the mouth cavity]. 2002 , 6, 217-30	
1476	Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. 2002 , 20, 183-94	75
1475	Antitumor effect of TNP-470 is not associated to decrease of angiogenesis in an experimental malignant neuroectodermic tumor. 2002 , 58, 131-6	4
1474	Issues and challenges for antiangiogenic therapies. 2002 , 75 Suppl 1, S45-50; discussion S57-8	8
1473	The thin prep rat aortic ring assay: a modified method for the characterization of angiogenesis in whole mounts. 2002 , 5, 81-6	60
1472	Comparative study of isoflavone, quinoxaline and oxindole families of anti-angiogenic agents. 2002 , 5, 45-51	39
1471	A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. 2002 , 5, 35-44	89
1470	Recombinant human prothrombin kringle have potent anti-angiogenic activities and inhibit Lewis lung carcinoma tumor growth and metastases. 2002 , 5, 191-201	15
1469	A computer algorithm describing the process of vessel formation and maturation, and its use for predicting the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth. 2002 , 5, 203-14	85
1468	Pancreatic tumor growth is regulated by the balance between positive and negative modulators of angiogenesis. 2002 , 5, 181-90	22
1467	Anti-angiogenic therapy: rationale, challenges and clinical studies. 2002 , 5, 237-56	108
1466	Importance of vascular endothelial growth factor A in the progression of experimental neuroblastoma. 2002 , 5, 267-74	19
1465	NG2 precursor cells in neoplasia: functional, histogenesis and therapeutic implications for malignant brain tumours. 2002 , 31, 507-21	40
1464	Use of a spontaneous adverse drug events database for identification of unanticipated drug benefits. 2002 , 71, 99-102	14
1463	Smad4 transcriptional pathways and angiogenesis. 2002 , 31, 47-59	35
1462	Targeting tumor vasculature: reality or a dream?. 2002 , 10, 529-33	29
1461	Angiogenesis and antiangiogenic strategies in pancreatic cancer. 2003 , 33, 79-88	22
1460	Therapeutic inhibition of angiogenesis. 2003 , 25, 185-200	3

1459	Proliferative activity of microvascular cells in glioblastomas does not correlate with time to recurrence. 2003 , 63, 9-13	4
1458	Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer. 2003 , 21, 359-66	17
1457	Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma. 2003 , 64, 203-9	30
1456	Discovery and development of anti-angiogenic peptides: A structural link. 2003 , 6, 83-91	18
1455	Inhibition of angiogenic initiation and disruption of newly established human vascular networks by juice from <i>Morinda citrifolia</i> (noni). 2003 , 6, 143-9	50
1454	Angiogenesis and the ET-1/ETA receptor system: immunohistochemical expression analysis in bone metastases from patients with different primary tumors. 2003 , 6, 225-31	10
1453	Anti-angiogenic activity of contortrostatin, a disintegrin from <i>Agkistrodon contortrix contortrix</i> snake venom. 2003 , 6, 213-24	38
1452	Effect of human Angiostatin protein on human angiogenesis in vitro. 2003 , 6, 233-40	9
1451	Novel function of ascorbic acid as an angiostatic factor. 2003 , 6, 259-69	51
1450	Increased expression of VEGF-receptors (FLT-1, KDR, NRP-1) and thrombospondin-1 is associated with glomeruloid microvascular proliferation, an aggressive angiogenic phenotype, in malignant melanoma. 2003 , 6, 295-301	40
1449	Angiostatin and hepatocellular carcinoma. 2003 , 37, 505-6	3
1448	The diagnostic and prognostic value of tumor angiogenesis. 1998 , 99-103	4
1447	Regulation of cancer metastasis by stress pathways. 2003 , 20, 31-43	66
1446	Dynamics of tumour angiogenesis: effect of razoxane-induced growth rate slowdown. 2003 , 20, 95-102	13
1445	Dynamic contrast-enhanced MR imaging in monitoring response to isolated limb perfusion in high-grade soft tissue sarcoma: initial results. 2003 , 13, 1849-58	50
1444	Microvascular structural entropy: a novel approach to assess angiogenesis in pituitary tumors. 2003 , 14, 239-47	24
1443	Color Doppler imaging and angiogenesis in ovarian tumors. 2003 , 36, 127-30	4
1442	Ets-1 and VEGF expression correlates with tumor angiogenesis, lymph node metastasis, and patient survival in esophageal squamous cell carcinoma. 2003 , 129, 430-6	35

1441	Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy. 2003 , 8, 200-6	46
1440	Effect of carbon dioxide pneumoperitoneum on tissue blood flow in the peritoneum, rectus abdominis, and diaphragm muscles. 2003 , 17, 1632-5	11
1439	Angiogenesis and apoptosis. 2003 , 13, 159-67	326
1438	Wiring the angiogenic switch: Ras, Myc, and Thrombospondin-1. 2003 , 3, 199-200	30
1437	Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors. 2003 , 4, 291-9	69
1436	Basic FGF and Ki-67 proteins useful for immunohistological diagnostic evaluations in malignant solitary fibrous tumor. 2003 , 53, 284-90	59
1435	A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. 2003 , 30, 117-24	400
1434	Evaluation of tumor proliferation using dynamic contrast enhanced-MRI of oral cavity and oropharyngeal squamous cell carcinoma. 2003 , 39, 290-5	27
1433	Antitumor activity of the angiogenesis inhibitor TNP-470 on murine lymphoma/leukemia cells in vivo and in vitro. 2003 , 31, 143-9	8
1432	Anti-angiogenesis and angioprevention: mechanisms, problems and perspectives. 2003 , 27, 229-38	56
1431	Angiogenesis in Waldenstrom's macroglobulinemia. 2003 , 30, 262-4	14
1430	Modulation of cell death in the tumor microenvironment. 2003 , 13, 31-41	83
1429	Nickel carcinogenesis. 2003 , 533, 67-97	512
1428	Novel systemic therapies for breast cancer. 2003 , 12, 277-87	7
1427	Suppression of tumor growth by a new glycosaminoglycan isolated from the African giant snail <i>Achatina fulica</i> . 2003 , 465, 191-8	34
1426	Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. 2003 , 30, 39-50	55
1425	Organ printing: computer-aided jet-based 3D tissue engineering. 2003 , 21, 157-61	960
1424	In vivo gene transfer of pigment epithelium-derived factor inhibits tumor growth in syngeneic murine models of thoracic malignancies. 2003 , 126, 28-38	50

1423	Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation. 2003 , 7, 11-20	65
1422	Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. 2003 , 98, 1377-85	94
1421	Efficacy of dendrimer-mediated angiostatin and TIMP-2 gene delivery on inhibition of tumor growth and angiogenesis: in vitro and in vivo studies. 2003 , 105, 419-29	79
1420	Baicalein and baicalin are potent inhibitors of angiogenesis: Inhibition of endothelial cell proliferation, migration and differentiation. 2003 , 106, 559-565	117
1419	Transfection of the genes for interleukin-12 into the K1735 melanoma and the EMT6 mammary sarcoma murine cell lines reveals distinct mechanisms of antitumor activity. 2003 , 106, 690-8	10
1418	Endothelial cell functions. 2003 , 196, 430-43	479
1417	Regulation of the pro-angiogenic microenvironment by carboxyamido-triazole. 2003 , 197, 139-48	16
1416	High-resolution three-dimensional MR angiography of rodent tumors: morphologic characterization of intratumoral vasculature. 2003 , 18, 59-65	52
1415	Angiogenesis of the heart. 2003 , 60, 138-58	38
1414	Integrin targeting using RGD-PEI conjugates for in vitro gene transfer. 2003 , 5, 588-99	185
1413	Differences in vasculature between pilocytic and anaplastic astrocytomas of childhood. 2003 , 41, 516-26	22
1412	Copper-lowering therapy with tetrathiomolybdate for cancer and diseases of fibrosis and inflammation. 2003 , 16, 191-199	12
1411	Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. 2003 , 220, 545-54	115
1410	Cyclo-oxygenase 2 inhibition in colorectal cancer therapy. 2003 , 90, 1055-67	40
1409	Does tumor growth follow a "universal law"?. 2003 , 225, 147-51	178
1408	Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. 2003 , 27, 661-9	33
1407	Optimal scheduling of radiotherapy and angiogenic inhibitors. 2003 , 65, 407-24	106
1406	In vitro and in vivo evaluations of THAM derived telomers bearing RGD and Ara-C for tumour neovasculature targeting. 2003 , 38, 825-36	15

1405	Multigated contrast-enhanced power Doppler to measure blood flow in mice tumors. 2003 , 29, 977-84	11
1404	Angiogenesis in hematologic malignancies. 2003 , 45, 227-44	95
1403	Angiogenesis inhibitors in genitourinary cancers. 2003 , 46 Suppl, S41-7	10
1402	Monoclonal gammopathies of undetermined significance: a review. 2003 , 194, 112-39	96
1401	Copper in medicine. 2003 , 7, 207-12	105
1400	The role of IFN-gamma in tumor transplantation immunity and inhibition of chemical carcinogenesis. 2003 , 15, 148-54	104
1399	Cutaneous breast cancer deposits show distinct growth patterns with different degrees of angiogenesis, hypoxia and fibrin deposition. 2003 , 42, 530-40	32
1398	Delivery of endostatin in experimental cancer therapy. 2002 , 83, 265-74	11
1397	Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model. 2003 , 120, 476-82	103
1396	Effect of SU5416 on the inhibition of growth and metastasis of human gastric cancer implanted in nude mice. 2003 , 4, 60-63	
1395	Transplantation of autologous endothelial cells induces angiogenesis. 2003 , 26, 496-9	47
1394	Neoadjuvant antiangiogenic therapy with tamoxifen does not impair gastrointestinal anastomotic repair in the rat. 2003 , 5, 335-41	7
1393	Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. 2003 , 17, 677-82	67
1392	Significance of angiogenesis in cancer therapy. 1998 , 85, 1044-55	36
1391	Cytomorphological variations, proliferation and angiogenesis in the prognosis of cutaneous melanoma. 2003 , 28, 310-4	9
1390	Inhibitory effects of Vietnamese medicinal plants on tube-like formation of human umbilical venous cells. 2003 , 17, 107-11	16
1389	The vascular network of tumours--what is it not for?. 2003 , 201, 173-80	51
1388	Significance of microvascular density (MVD) in cervical cancer recurrence. 2003 , 13, 856-62	21

1387	Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules. 2003 , 94, 479-85	31
1386	Induction of tube formation by angiopoietin-1 in endothelial cell/fibroblast co-culture is dependent on endogenous VEGF. 2003 , 94, 782-90	60
1385	An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. 2003 , 88, 822-7	84
1384	Less is more. 2003 , 4, 831-4	4
1383	Bone marrow-derived, endothelial progenitor-like cells as angiogenesis-selective gene-targeting vectors. 2003 , 10, 647-56	75
1382	Role and regulation of the thrombin receptor (PAR-1) in human melanoma. 2003 , 22, 3130-7	106
1381	Molecular basis of angiogenesis and cancer. 2003 , 22, 6549-56	237
1380	Inhibition of tumor-induced angiogenesis and matrix-metalloproteinase expression in confrontation cultures of embryoid bodies and tumor spheroids by plant ingredients used in traditional chinese medicine. 2003 , 83, 87-98	67
1379	COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo. 2003 , 83, 1385-94	70
1378	Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. 2003 , 9, 774-80	246
1377	Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. 2003 , 9, 1026-32	294
1376	Basement membranes: structure, assembly and role in tumour angiogenesis. 2003 , 3, 422-33	1290
1375	Translating angiogenesis research into the clinic: the challenges ahead. 2003 , 76 Spec No 1, S3-10	29
1374	The anti-angiogenic activity of human endostatin inhibits bladder cancer growth and its mechanism. 2003 , 170, 2000-3	20
1373	Functional response of tumor vasculature to PaCO ₂ : determination of total and microvascular blood volume by MRI. 2003 , 5, 330-8	23
1372	Experimental approaches to treatment of soft tissue sarcoma. 2003 , 12, 499-521	4
1371	The vasculopathy of Raynaud's phenomenon and scleroderma. 2003 , 29, 275-91, vi	67
1370	Probing the interactions of phosphosulfomannans with angiogenic growth factors by surface plasmon resonance. 2003 , 46, 4601-8	73

1369	Effects of angiogenesis inhibitor TNP-470 on the development of uterine adenomyosis in mice. 2003 , 80 Suppl 2, 788-94	15
1368	Nicotine promotes arteriogenesis. 2003 , 41, 489-96	98
1367	Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. 2003 , 2, 12	116
1366	Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. 2003 , 42, 1089-105	227
1365	The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer. 2003 , 2, 153-9	18
1364	Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. 2003 , 4, 231-6	50
1363	Current studies with PTK787, an oral inhibitor of vascular endothelial growth factor in colorectal cancer. 2003 , 3, 147-9	11
1362	Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. 2003 , 48, 231-6	155
1361	Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. 2003 , 108, 336-41	400
1360	Progress and challenges for cell encapsulation in brain tumour therapy. 2003 , 3, 551-61	25
1359	Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. 2003 , 162, 1431-9	108
1358	Lymphangiogenic growth factors, receptors and therapies. 2003 , 90, 167-84	107
1357	Cost of migration: invasion of malignant gliomas and implications for treatment. 2003 , 21, 1624-36	923
1356	Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer. 2003 , 42, 163-70	70
1355	Novel approaches in oncology at AstraZeneca. 2003 , 1, 3-8	7
1354	Anti-angiogenic effect of silymarin on colon cancer LoVo cell line. 2003 , 113, 133-8	70
1353	Vascular endothelial growth factor synthesis by human omental mesothelial cells is augmented by fibroblast growth factor-2: possible role of mesothelial cell on the development of peritoneal metastasis. 2003 , 115, 113-20	54
1352	Incorporation of adult organ-derived endothelial cells into tumor blood vessel. 2003 , 306, 219-24	17

1351	GH-RH antagonist (MZ-4-71) inhibits VEGF secretion and proliferation of murine endothelial cells. 2003 , 72, 2473-9	12
1350	Green tea extract inhibits angiogenesis of human umbilical vein endothelial cells through reduction of expression of VEGF receptors. 2003 , 73, 1299-313	50
1349	Fenretinide as an anti-angiogenic agent in neuroblastoma. 2003 , 197, 181-4	16
1348	Expression of angiogenesis factors in monolayer culture, multicellular spheroid and in vivo transplanted tumor by human ovarian cancer cell lines. 2003 , 196, 229-37	29
1347	Canine mammary gland tumors. 2003 , 33, 573-96	179
1346	Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. 2003 , 29, 297-307	417
1345	Docosapentaenoic acid (22:5, n-3) suppressed tube-forming activity in endothelial cells induced by vascular endothelial growth factor. 2003 , 68, 337-42	67
1344	What's new in the treatment of advanced prostate cancer?. 2003 , 39, 136-46	19
1343	Exploiting the hallmarks of cancer: the future conquest of breast cancer. 2003 , 39, 1668-75	102
1342	Anti-metastatic and anti-angiogenic activities of a new matrix metalloproteinase inhibitor, TN-6b. 2003 , 39, 1632-41	14
1341	Co-expression of vascular endothelial growth factor C (VEGF-C) and c-erbB2 in human breast carcinoma. 2003 , 39, 1698-703	28
1340	Angioarrestin mRNA expression in early-stage lung cancers. 2003 , 29, 649-53	10
1339	Breakthroughs in cancer gene therapy. 2003 , 19, 217-26	2
1338	Pro: anesthesiologists' role in treating refractory angina: spinal cord stimulators, thoracic epidurals, therapeutic angiogenesis, and other emerging options. 2003 , 17, 536-45	4
1337	Targeting excessive angiogenesis with functional foods and nutraceuticals. 2003 , 14, 455-468	32
1336	Copper lowering therapy with tetrathiomolybdate produces antiangiogenic, anticancer, antifibrotic, and antiinflammatory effects. 2003 , 1, 181-190	7
1335	Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy. 2003 , 5, 297-307	36
1334	Identification of Apoptotic and Antiangiogenic Activities of Terazosin in Human Prostate Cancer and Endothelial Cells. 2003 , 169, 724-729	22

1333	Basic and Clinical Aspects of Copper. 2003 , 40, 547-586	110
1332	Polymer Drugs in the Clinical Stage. 2003 ,	13
1331	Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syndromes. 2003 , 44, 213-22	36
1330	Recent insights into angiogenesis, apoptosis, invasion, and metastasis in colorectal carcinoma. 2003 , 10, 839-51	34
1329	Therapeutic angiogenesis: protein-based therapy for coronary artery disease. 2003 , 4, 219-26	6
1328	Angiogenesis: basic pathophysiology and implications for disease. 2003 , 24, 586-603	106
1327	Cell-based delivery systems for antiangiogenic therapy. 2003 , 20, 183-95	1
1326	Predicting treatment responses and disease progression in myeloma using serum vascular endothelial growth factor and hepatocyte growth factor levels. 2003 , 44, 1347-51	6
1325	A high cytosol value of urokinase-type plasminogen activator (uPA) may be predictive of early relapse in primary breast cancer. 2003 , 21, 208-16	12
1324	Head and Neck Cancer. 2003 ,	
1323	YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. 2003 , 95, 516-25	412
1322	Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. 2003 , 21, 2255-61	587
1321	Perlecan and tumor angiogenesis. 2003 , 51, 1393-410	110
1320	Leads for development of new naphthalenesulfonate derivatives with enhanced antiangiogenic activity: crystal structure of acidic fibroblast growth factor in complex with 5-amino-2-naphthalene sulfonate. 2003 , 278, 21774-81	36
1319	Clinician guide to angiogenesis. 2003 , 108, 2613-8	109
1318	CD105 is important for angiogenesis: evidence and potential applications. 2003 , 17, 984-92	404
1317	Immunotherapy of malignant diseases. Challenges and strategies. 2003 , 132, 294-309	29
1316	Antiangiogenesis: the fifth cancer treatment modality?. 2003 , 30, 934-44	9

1315	Optimizing the dosing schedule of TNP-470 [O-(chloroacetyl-carbamoyl) fumagillol] enhances its antitumor and antiangiogenic efficacies. 2003 , 304, 669-74	23
1314	Stem cell gene therapy: breakthrough culminating in combination of ex vivo protocols with transient topical gene therapy. 2003 , 2, 91-102	1
1313	585-nm pulsed dye laser treatment of glottal dysplasia. 2003 , 112, 751-8	67
1312	Tumour-Induced Angiogenesis: A Review. 2003 , 5, 137-153	26
1311	Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. 2003 , 197, 221-32	288
1310	Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation. 2003 , 17, 163-74	99
1309	The hepatitis C virus internal ribosome entry site facilitates efficient protein synthesis in blood vessel endothelium during tumour angiogenesis. 2003 , 31, e46	3
1308	A reinforced random walk model of tumour angiogenesis and anti-angiogenic strategies. 2003 , 20, 135-81	83
1307	Curcumin: Old Spice Is a New Medicine. 2003 , 9, 34-38	19
1306	Suppression of tumor growth by viral vector-mediated gene transfer of N-terminal truncated platelet factor 4. 2003 , 18, 829-40	17
1305	Local delivery of antineoplastic agents using biodegradable polymers for the treatment of malignant brain tumors. 2003 , 3, 533-46	7
1304	Potential inhibitors of angiogenesis. Part I: 3-(imidazol-4(5)-ylmethylene)indolin-2-ones. 2003 , 18, 243-52	9
1303	Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach. 2003 , 44, 937-48	11
1302	Predicting treatment responses and disease progression in myeloma using serum vascular endothelial growth factor and hepatocyte growth factor levels. 2003 , 44, 1275-9	3
1301	Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients. 2003 , 88, 102-8	28
1300	Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations. 2003 , 14, 1660-6	41
1299	Tumor Suppressor Genes. 2003 ,	
1298	The expression of P-glycoprotein does influence the distribution of novel fluorescent compounds in solid tumour models. 2003 , 89, 1581-9	43

1297	Hydrogen ion dynamics and the Na ⁺ /H ⁺ exchanger in cancer angiogenesis and antiangiogenesis. 2003 , 89, 1395-9	30
1296	Cancer gene therapy: lessons learned from experiences with chemotherapy. 2003 , 7, 717-9	4
1295	Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. 2003 , 21, 2299-304	154
1294	Loss of activator protein-2alpha results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. 2003 , 278, 46632-42	96
1293	Up-regulation of matrix metalloproteinase-9 in T lymphocytes of mammary tumor bearers: role of vascular endothelial growth factor. 2003 , 171, 4340-51	70
1292	Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a). 2003 , 278, 29000-8	62
1291	Kidney Cancer. 2003 ,	
1290	Novel Anticancer Agents in Clinical Development. 2003 , 2, 4-14	20
1289	The Complexity of Tumor Vascularity. 2003 , 2, 257-258	17
1288	Inhibition of metastatic brain tumor growth by intramuscular administration of the endostatin gene. 2003 , 23, 73	3
1287	All in the family: VEGF-B joins the ranks of proangiogenic cytokines. 2003 , 93, 87-90	12
1286	Angiogenesis Inhibitors: A New Class of Drugs. 2003 , 2, 126-132	61
1285	Tumor microenvironment and hemorheological abnormalities. 2003 , 29, 489-97	23
1284	Clinical Significance of Angiogenesis in Hepatocellular Carcinoma. 2003 , 01, 167-178	1
1283	Fundamental concepts of the angiogenic process. 2003 , 3, 643-51	544
1282	Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer. 2003 , 29, 291-300	39
1281	Therapeutic strategies using inhibitors of angiogenesis. 2003 , 223, 599-634	2
1280	Tumor angiogenesis: a potential target in cancer control by phytochemicals. 2003 , 3, 205-17	59

1279	Endoglin (CD105): a target for anti-angiogenetic cancer therapy. 2003 , 4, 291-6	46
1278	Gene therapy for cardiovascular angiogenesis. 2003 , 3, 599-616	18
1277	. 2003 , 238, 9-28	13
1276	Neovastat--a novel antiangiogenic drug for cancer therapy. 2003 , 14, 91-6	43
1275	Gene therapy with vascular endothelial growth factor reduces angina. 2003 , 18, 38-43	4
1274	Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches. 2003 , 238, 9-28	49
1273	Angiogenic factors in the central nervous system. 2003 , 53, 639-60; discussion 660-1	78
1272	Expression of angiogenic growth factors in acoustic neurinoma. 2003 , 123, 1040-5	31
1271	Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. 2003 , 37, 179-92	94
1270	Inhibition of the growth of squamous cell carcinoma by tetrathiomolybdate-induced copper suppression in a murine model. 2003 , 129, 781-5	35
1269	Prognostic value of angiogenesis in solitary bone plasmacytoma. 2003 , 101, 1715-7	86
1268	Synergy between tumor immunotherapy and antiangiogenic therapy. 2003 , 102, 964-71	147
1267	Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. 2003 , 102, 1340-6	720
1266	Exciting times for myeloma research. 2003 , 102, 3081-3081	
1265	. 2003 ,	4
1264	Gene Expression Profiling in Pulmonary and Systemic Vascular Cells Exposed to Biomechanical Stimuli. 153-171	
1263	What can digital transcript profiling reveal about human cancers?. 2003 , 36, 975-85	5
1262	Use of adenovirus vectors for functional gene analysis in the chicken chorioallantoic membrane. 2003 , 34, 178-83	5

1261	Mechanisms of tumor cell invasion and angiogenesis in the central nervous system. 2003 , 8, e289-304	31
1260	Antiangiogenic tumor therapy. 2003 , 34, 1048-50, 1052, 1054 passim	11
1259	Angiogenesis. 2004 , 227-233	2
1258	The difference of angiogenesis in human lung adenocarcinoma cell lines with different metastatic potency. 2004 , 71, 181-9	
1257	Angiogenesis: a target for cancer therapy. 2004 , 10, 11-26	61
1256	The role of growth factor signaling in malignancy. 2003 , 115, 19-72	13
1255	Molecular Cancer Therapeutics: Will the Promise be Fulfilled?. 2004 , 7-40	2
1254	Cardiovascular gene therapy: angiogenesis and beyond. 2004 , 327, 139-48	16
1253	Angiogenesis in leukemia and lymphoma. 2004 , 121, 221-38	4
1252	New therapies for locoregionally advanced and locoregionally recurrent head and neck cancer. 2003 , 114, 315-30	0
1251	Resistance to anti-VEGF agents. 2004 , 10, 51-64	20
1250	Prostate cancer prevention by silibinin. 2004 , 4, 1-11	100
1249	Vascular Endothelial Growth Factor (Vegf) and Other Common Tissue Prognostic Indicators in Breast Cancer: A Case-Control Study. 2004 , 19, 275-281	7
1248	Angiogenesis in Multiple Myeloma: Implications in Myeloma Therapy. 2004 , 02, 119-129	2
1247	Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4. 2004 , 92, 634-45	43
1246	Angiogenesis and its role in the behavior of astrocytic brain tumors. 2004 , 9, 3105-23	23
1245	[What is the role of endothelin system?]. 2004 , 20, 339-45	8
1244	Therapeutic Strategies to Improve the Efficacy of Oxaliplatin in Gastrointestinal Tumors. 2004 , 19, 183-189	1

1243	Antiangiogenic therapy in hematologic malignancies. 2004 , 10, 1221-34	27
1242	Gene transfer for therapeutic vascular growth in myocardial and peripheral ischemia. 2004 , 52, 117-64	24
1241	Endothelial cell development, vasculogenesis, angiogenesis, and tumor neovascularization: an update. 2004 , 30, 109-17	49
1240	Platelets and angiogenesis in malignancy. 2004 , 30, 95-108	228
1239	Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment. 2004 , 4, 129-40	13
1238	Expression of vascular endothelial growth factor in hepatocellular carcinoma and the surrounding liver: correlation with angiographically assisted CT. 2004 , 183, 1585-93	23
1237	Bone marrow microvessel density and its prognostic significance in AML. 2004 , 45, 1369-73	26
1236	Contribution of the hemostatic system to angiogenesis in cancer. 2004 , 30, 5-20	50
1235	Interfering with hemostatic system components: possible new approaches to antiangiogenic therapy. 2004 , 30, 145-56	3
1234	Analysis of FDA Approved Anticancer Drugs Reveals the Future of Cancer Therapy. 2004 , 3, 1033-1040	65
1233	Principles of Molecular Oncology. 2004 ,	6
1232	Office-based treatment of glottal dysplasia and papillomatosis with the 585-nm pulsed dye laser and local anesthesia. 2004 , 113, 265-76	112
1231	Matrix-mediated canal formation in primmorphs from the sponge <i>Suberites domuncula</i> involves the expression of a CD36 receptor-ligand system. 2004 , 117, 2579-90	33
1230	Targeted therapy of colorectal cancer: clinical experience with bevacizumab. 2004 , 9 Suppl 1, 11-8	82
1229	Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. 2004 , 64, 4601-10	44
1228	Inhibition of metastasis of tumor cells overexpressing thymidine phosphorylase by 2-deoxy-L-ribose. 2004 , 64, 1794-801	57
1227	Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials. 2004 , 10, 1206-11	45
1226	Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice. 2004 , 64, 6101-8	162

1225	The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. 2004 , 10, 4895-900	286
1224	Angiopoietin-3 inhibits pulmonary metastasis by inhibiting tumor angiogenesis. 2004 , 64, 6119-26	38
1223	Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: study of their antiangiogenic properties and physiological relevance. 2004 , 18, 2522-42	68
1222	HB-EGF is a potent inducer of tumor growth and angiogenesis. 2004 , 64, 5283-90	170
1221	Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. 2004 , 64, 6616-25	150
1220	Endothelial progenitor cells for postnatal vasculogenesis. 2004 , 287, C572-9	409
1219	Transduction of soluble Flt-1 gene to peritoneal mesothelial cells can effectively suppress peritoneal metastasis of gastric cancer. 2004 , 64, 3624-8	52
1218	Physiology of the endothelium. 2004 , 93, 105-13	377
1217	Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. 2004 , 10, 33-42	36
1216	The powerful microbubble: from bench to bedside, from intravascular indicator to therapeutic delivery system, and beyond. 2004 , 287, H450-7	165
1215	Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. 2004 , 71, 1-9	103
1214	Cancer therapeutics: understanding the mechanism of action. 2004 , 32 Suppl 1, 116-21	18
1213	Tumor angiogenesis and outcome in osteosarcoma. 2004 , 21, 611-9	38
1212	The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis. 2004 , 101, 2345-50	64
1211	Angiopoietin-3 is tethered on the cell surface via heparan sulfate proteoglycans. 2004 , 279, 41179-88	28
1210	Angiogenesis and tumor proliferation/metastasis of human colorectal cancer cell line SW620 transfected with endocrine glands-derived-vascular endothelial growth factor, as a new angiogenic factor. 2004 , 64, 1906-10	39
1209	Thalidomid: current role in the treatment of non-plasma cell malignancies. 2004 , 22, 2477-88	78
1208	Modulating angiogenesis: more vs less. 2004 , 292, 972-7	75

1207	Cyclooxygenase-2 in lung carcinogenesis and chemoprevention: Roger S. Mitchell lecture. 2004 , 125, 134S-40S	7
1206	Effects of modulation of the NO/cGMP pathway in tumor cell lines derived from the upper airway tract. 2004 , 72, 167-76	2
1205	Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: Correlation with long-term patient outcome. 2004 , 24, 1197	1
1204	Therapeutic angiogenesis: a biologic bypass. 2004 , 101, 131-43	45
1203	Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: Tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer. 2004 , 25, 1397	
1202	Maintenance of G1 Checkpoint Controls in Telomerase-Immortalized Endothelial Cells. 2004 , 3, 809-814	21
1201	New treatments for colon cancer. 2004 , 329, 124-6	5
1200	Treatment of inoperable coronary disease and refractory angina: spinal stimulators, epidurals, gene therapy, transmyocardial laser, and counterpulsation. 2004 , 8, 43-58	17
1199	Essential role of PDGFRalpha-p70S6K signaling in mesenchymal cells during therapeutic and tumor angiogenesis in vivo: role of PDGFRalpha during angiogenesis. 2004 , 94, 1186-94	58
1198	Neuroblastoma angiogenesis is inhibited with a folded synthetic molecule corresponding to the epidermal growth factor-like module of the follistatin domain of SPARC. 2004 , 64, 7420-5	46
1197	Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. 2005 , 26, 271-9	113
1196	Role of insulin receptor substrates and protein kinase C-zeta in vascular permeability factor/vascular endothelial growth factor expression in pancreatic cancer cells. 2004 , 279, 3941-8	46
1195	Role of inflammation in mouse lung tumorigenesis: a review. 2005 , 31, 57-82	56
1194	Copper deficiency as an anti-cancer strategy. 2004 , 11, 255-63	114
1193	Tumour angiogenesis, vascular biology and enhanced drug delivery. 2004 , 12, 245-55	9
1192	Human T-cell lymphotropic virus type I-infected cells extravasate through the endothelial barrier by a local angiogenesis-like mechanism. 2004 , 64, 2039-46	45
1191	Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. 2004 , 22, 499-506	77
1190	Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. 2004 ,	7

1189	Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity. 2004 , 95, 85-90	54
1188	Antitumor activity of pyrvinium pamoate, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methyl-quinolinium pamoate salt, showing preferential cytotoxicity during glucose starvation. 2004 , 95, 685-90	105
1187	Enhanced angiogenesis following allogeneic blood transfusion. 2004 , 26, 129-35	24
1186	Angiogenesis [Recent developments in molecular pathogenesis, morphological markers, and therapeutic applications. 2004 , 112, 399-401	
1185	Angiogenesis: now and then. 2004 , 112, 402-12	49
1184	Molecular regulation of the VEGF family -- inducers of angiogenesis and lymphangiogenesis. 2004 , 112, 463-80	111
1183	Endogenous angiogenesis inhibitors. 2004 , 112, 496-507	282
1182	The discovery of receptor tyrosine kinases: targets for cancer therapy. 2004 , 4, 361-70	932
1181	Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. 2004 , 3, 391-400	1872
1180	Bevacizumab. 2004 , 3, 995-6	44
1179	Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. 2004 , 23, 1745-53	63
1178	Prospective strategies to enforce selectively cell death in cancer cells. 2004 , 23, 2967-75	78
1177	Microenvironmental adaptation of experimental tumours to chronic vs acute hypoxia. 2004 , 91, 1181-9	25
1176	Chromosome 12, frequently deleted in human pancreatic cancer, may encode a tumor-suppressor gene that suppresses angiogenesis. 2004 , 84, 1339-51	16
1175	A requirement for copper in angiogenesis. 2004 , 62, 60-4	107
1174	SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours. 2004 , 97, 219-30	155
1173	A novel method for isolation of endothelial cells and macrophages from murine tumors based on Ac-LDL uptake and CD16 expression. 2004 , 295, 183-93	9
1172	Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand". 2004 , 14, 93-104	58

1171	UVA-mediated activation of signaling pathways involved in skin tumor promotion and progression. 2004 , 14, 131-8	206
1170	Antiangiogenic cancer therapy. 2004 , 14, 139-45	82
1169	Expression of vascular endothelial growth factor and prognosis of oral squamous cell carcinoma. 2004 , 40, 321-5	54
1168	Antiangiogenic therapy and tumor progression. 2004 , 5, 13-7	220
1167	Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. 2004 , 31, 2-11	276
1166	Future directions in the use of antiangiogenic agents in patients with colorectal cancer. 2004 , 31, 17-21	37
1165	Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer. 2004 , 93, 215-22	50
1164	The activity of thymidine phosphorylase as a new ovarian tumor marker. 2004 , 94, 86-92	9
1163	Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment. 2004 , 54, 285-94	33
1162	Tumour metabolites regulate tissue kallikrein in human umbilical vein endothelial cells. 2004 , 1691, 117-27	2
1161	Molecular targeting of angiogenesis. 2004 , 1654, 39-49	28
1160	Genetic dissection of tumor angiogenesis: are PlGF and VEGFR-1 novel anti-cancer targets?. 2004 , 1654, 79-94	32
1159	Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. 2004 , 6, 485-95	450
1158	Perfusion-weighted magnetic resonance imaging of the brain: techniques and application in children. 2004 , 14, 59-72	57
1157	VEGF-DT385 toxin conjugate inhibits mammary adenocarcinoma development in a transgenic mouse model of spontaneous tumorigenesis. 2004 , 85, 161-71	11
1156	The significance of angiogenesis in malignant pheochromocytomas. 2004 , 15, 39-45	14
1155	Serum semicarbazide-sensitive amine oxidase (SSAO) activity correlates with VEGF in non-small-cell lung cancer patients. 2004 , 21, 241-50	14
1154	Squamous cell carcinoma related oncogene regulates angiogenesis through vascular endothelial growth factor-A. 2004 , 11, 530-4	21

1153	Immunotherapy of tumor by targeting angiogenesis. 2004 , 47, 545-52	
1152	Vascular endothelial growth factor and other signaling pathways in developmental and pathologic angiogenesis. 2004 , 80, 7-20	26
1151	Angiogenic and antiangiogenic balance regulates concomitant antitumoral resistance. 2004 , 21, 177-83	13
1150	Complexity in the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF)-receptors signaling. 2004 , 264, 51-61	23
1149	Therapeutic myocardial angiogenesis with vascular endothelial growth factors. 2004 , 264, 63-74	44
1148	Angiogenic strategy for human ischemic heart disease: brief overview. 2004 , 264, 143-9	25
1147	High-level synthesis of recombinant murine endostatin in Chinese hamster ovary cells. 2004 , 35, 11-6	7
1146	Therapeutic angiogenesis and vasculogenesis for ischemic disease: part II: cell-based therapies. 2004 , 109, 2692-7	326
1145	Molecular imaging of tumor angiogenesis. 2004 , 1014, 67-75	51
1144	Time course of angiogenesis in solid pineal autografts. 2004 , 315, 349-59	1
1143	Role of cyclooxygenase-2 in the angiogenesis of colorectal cancer. 2004 , 19, 1-11	28
1142	Class-specific pro-apoptotic effect of statins on human vascular endothelial cells. 2004 , 93, 398-402	30
1141	Inhibition of the arachidonic acid metabolism blocks endothelial cell migration and induces apoptosis. 2004 , 146, 483-94	21
1140	A highly efficient electroporation method for the transfection of endothelial cells. 2004 , 7, 235-41	15
1139	Synthesis and cytotoxicity of 2,5-dihydroxychalcones and related compounds. 2004 , 27, 581-8	11
1138	A mathematical model of tumour angiogenesis, regulated by vascular endothelial growth factor and the angiopoietins. 2004 , 229, 435-54	57
1137	Molecular targeting of angiogenesis for imaging and therapy. 2004 , 31, 1327-41	29
1136	Antimalarial dihydroartemisinin also inhibits angiogenesis. 2004 , 53, 423-32	109

1135	Mathematical modeling of tumor-induced angiogenesis. 2004 , 49, 111-87	231
1134	Novel therapies for pancreatic adenocarcinoma. 2004 , 6, 119-25	14
1133	Vascular targeting agents. 2004 , 6, 103-10	7
1132	Novel therapies for pancreatic adenocarcinoma. 2004 , 6, 199-206	18
1131	Prognostic value of VEGF expression in primary esophageal squamous cell carcinoma. 2004 , 16, 85-89	4
1130	Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study. 2004 , 30, 118-25	68
1129	Antiangiogenic strategies, compounds, and early clinical results in breast cancer. 2004 , 49, 91-107	33
1128	Are tumours angiogenesis-dependent?. 2004 , 202, 5-13	103
1127	Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: a malignant transformation. 2004 , 3, 1	92
1126	Angiogenesis and neoplastic transformation of Barrett's epithelium. 2004 , 91, 941-2	4
1125	Hepatic expression of ANG2 RNA in metastatic colorectal cancer. 2004 , 39, 528-39	44
1124	Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. 2004 , 39, 1517-24	94
1123	Antiangiogenic property of pigment epithelium-derived factor in hepatocellular carcinoma. 2004 , 40, 252-9	97
1122	Increased expression of collagen XVIII and its prognostic value in nonsmall cell lung carcinoma. 2004 , 100, 1665-72	19
1121	The role of angiogenesis, vascular maturation, regression and stroma infiltration in dormancy and growth of implanted MLS ovarian carcinoma spheroids. 2004 , 108, 524-31	55
1120	Inhibition of human vascular endothelial cells proliferation by terbinafine. 2004 , 111, 51-9	33
1119	Study of puupehenone and related compounds as inhibitors of angiogenesis. 2004 , 110, 31-8	51
1118	Inhibition of solid tumor growth by gene transfer of VEGF receptor-1 mutants. 2004 , 111, 348-57	42

1117	An anticopper antiangiogenic approach for advanced cancer in spontaneously occurring tumors using tetrathiomolybdate: A pilot study in a canine animal model. 2004 , 17, 9-20	18
1116	Angiogenesis in hepatocellular nodules: correlation of MR imaging and vascular endothelial growth factor. 2004 , 20, 426-34	15
1115	Intravoxel distribution of DWI decay rates reveals C6 glioma invasion in rat brain. 2004 , 52, 994-1004	51
1114	Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-beta-cyclodextrin. 2004 , 272, 79-89	23
1113	Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells. 2004 , 60, 1220-32	55
1112	In vitro anti-proliferative activities of ellagic acid. 2004 , 15, 672-8	211
1111	Role of copper in tumour angiogenesis--clinical implications. 2004 , 18, 1-8	117
1110	Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases. 2004 , 8, 432-41	39
1109	Lattice and non-lattice models of tumour angiogenesis. 2004 , 66, 1785-819	102
1108	Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. 2004 , 1697, 17-27	110
1107	Parvovirus vectors for cancer gene therapy. 2004 , 4, 53-64	10
1106	Validation of molecular docking calculations involving FGF-1 and FGF-2. 2004 , 47, 1683-93	21
1105	In vitro inhibition of the activation of Pro-matrix Metalloproteinase 1 (Pro-MMP-1) and Pro-matrix metalloproteinase 9 (Pro-MMP-9) by rice and soybean Bowman-Birk inhibitors. 2004 , 52, 4730-6	22
1104	Capsaicin inhibits in vitro and in vivo angiogenesis. 2004 , 64, 644-51	170
1103	Evaluation of ⁶⁴ Cu- and ¹²⁵ I-radiolabeled bitistatin as potential agents for targeting alpha v beta 3 integrins in tumor angiogenesis. 2004 , 15, 988-96	33
1102	Vascular endothelial growth factor as a target for anticancer therapy. 2004 , 9 Suppl 1, 2-10	462
1101	Novel treatments in non-small cell lung cancer. 2004 , 18, 245-67	10
1100	Significado pronóstico de la densidad microvascular en el cáncer de ovario: estudio de una serie de 74 casos. 2004 , 47, 20-26	

1099	Shark cartilage, cancer and the growing threat of pseudoscience. 2004 , 64, 8485-91	74
1098	Antiangiogenic therapy for primary and metastatic brain tumors. 2004 , 18, 1161-81, x	18
1097	The vascular endothelial growth factor family and its receptors. 2004 , 18, 951-71, vii	45
1096	Isolated hepatic perfusion: experimental evidence and clinical utility. 2004 , 84, 627-41	11
1095	Pancreatic cancer: future outlook, promising trials, newer systemic agents, and strategies from the Gastrointestinal Intergroup Pancreatic Cancer Task Force. 2004 , 13, 751-60, xi	9
1094	Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer. 2004 , 18, 1121-41, ix	12
1093	Thalidomide: tragic past and promising future. 2004 , 79, 899-903	68
1092	[Hereditary retinal pathologies and AMD: new therapeutic perspectives]. 2004 , 27, 623-33	
1091	Inorganic selenium retards progression of experimental hormone refractory prostate cancer. 2004 , 171, 907-10	81
1090	Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways. 2004 , 18, 1039-57, viii	34
1089	Angiogenic factors in squamous cell carcinoma of the oral cavity: do they have prognostic relevance?. 2004 , 32, 176-81	34
1088	Vascular endothelial growth factor: basic science and clinical progress. 2004 , 25, 581-611	2749
1087	Stimulation of collateral artery growth: a potential treatment for peripheral artery disease. 2004 , 2, 581-8	13
1086	Molecular targeting in radiotherapy of lung cancer. 2004 , 45 Suppl 2, S187-97	22
1085	Targeting of the vascular system of solid tumours by photodynamic therapy (PDT). 2004 , 3, 765-71	106
1084	The role of the angiopoietins in tumour angiogenesis. 2004 , 22, 1-11	26
1083	Thalidomide and analogues: current proposed mechanisms and therapeutic usage. 2004 , 3, 54-61	18
1082	Newer therapies in advanced prostate cancer. 2004 , 3, 150-6	25

1081	Angiogenesis-targeted therapies in prostate cancer. 2004 , 3, 165-73		25
1080	Antiangiogenic gene therapy of cancer: recent developments. 2004 , 2, 22		79
1079	Pegaptanib for neovascular age-related macular degeneration. <i>New England Journal of Medicine</i> , 2004 , 351, 2805-16	59.2	1885
1078	A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. 2004 , 64, 3365-70		339
1077	Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. 2003 , 519, 29-49		166
1076	Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis. 2004 , 6, 725-35		40
1075	Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis. 2004 , 18, 1143-59, ix-x		9
1074	Local radiological staging of rectal cancer. 2004 , 59, 215-26		37
1073	Endothelial cell effects of cytotoxics: balance between desired and unwanted effects. 2004 , 30, 495-513		41
1072	Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives. 2004 , 7, 125-38		62
1071	Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. 2004 , 7, 289-300		72
1070	Re-evaluating therapeutic neovascularization. 2004 , 36, 25-32		51
1069	Targeting the tumor vascular compartment to improve conventional cancer therapy. 2004 , 25, 536-42		48
1068	Ghrelin inhibits FGF-2-mediated angiogenesis in vitro and in vivo. 2004 , 25, 2179-85		61
1067	Effects of 2-methoxyestradiol on proliferation, apoptosis and PET-tracer uptake in human prostate cancer cell aggregates. 2004 , 31, 867-74		12
1066	Antiproliferative and antiangiogenic activities of genistein in human renal cell carcinoma. 2004 , 64, 389-93		39
1065	N-acetyl-cysteine promotes angiostatin production and vascular collapse in an orthotopic model of breast cancer. 2004 , 164, 1683-96		55
1064	Angiogenesis as an immunopharmacologic target in inflammation and cancer. 2004 , 4, 1537-47		42

1063	A murine model of ex vivo angiogenesis using aortic disks grown in fibrin clot. 2004 , 68, 179-87	29
1062	Therapeutic angiogenesis: cellular approach from bone marrow, cord blood and peripheral blood. 2004 , 1262, 332-338	1
1061	Aryl hydrocarbon receptor-mediated inhibition of LNCaP prostate cancer cell growth and hormone-induced transactivation. 2004 , 88, 27-36	65
1060	Dual flagellar systems enable motility under different circumstances. 2004 , 7, 18-29	202
1059	Tumor/Normal Counterpart Microvessel Density Ratio has a Better Correlation with Clinicopathologic Parameters in Endometrial Carcinoma than Tumor Microvessel Density Alone. 2004 , 43, 199-205	
1058	The comparative study of tumor angiogenesis and CT enhancement in pancreatic carcinoma. 2004 , 49, 274-80	7
1057	Epidermal growth factor receptor in tumor angiogenesis. 2004 , 18, 1007-21, viii	130
1056	Therapeutic angiogenesis: the next frontier for interventional radiology. 2004 , 7, 40-8	9
1055	3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (pravastatin) inhibits endothelial cell proliferation dependent on G1 cell cycle arrest. 2004 , 15, 625-32	31
1054	Effect of thalidomide on growth and metastasis of canine osteosarcoma cells after xenotransplantation in athymic mice. 2004 , 65, 659-64	13
1053	Open Discussion. 2004 , 52, 518	
1052	Endostatin inhibits ischemia-induced neovascularization and increases ischemic tissue loss. 2004 , 52, 512-8; discussion 518	12
1051	The Importance of Tumor Angiogenesis. 2004 , 122, 675-677	27
1050	The biological "scrabble" of pulmonary arteriovenous malformations: considerations in the setting of cavopulmonary surgery. 2004 , 14, 417-37	14
1049	Pancreatic carcinogenesis: apoptosis and angiogenesis. 2004 , 28, 317-9	13
1048	Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring. 2004 , 27, 161-75	25
1047	Gene therapy in heart and lung disease. 2004 , 17, 13-20	2
1046	Phase II study of thalidomide in patients with metastatic malignant melanoma. 2004 , 14, 527-31	34

1045	Enhanced tumorigenesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma. 2004 , 104, 3305-11	46
1044	Human endothelial cells derived from circulating progenitors display specific functional properties compared with mature vessel wall endothelial cells. 2004 , 103, 2577-84	223
1043	Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity. 2004 , 103, 3131-7	45
1042	Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. 2004 , 104, 1159-65	123
1041	Do antiangiogenic protein fragments have amyloid properties?. 2004 , 104, 1601-5	23
1040	Inhibition of tumor angiogenesis in vivo by a monoclonal antibody targeted to domain 5 of high molecular weight kininogen. 2004 , 104, 2065-72	26
1039	Protease inhibitors potentiate chemotherapy-induced neutropenia. 2004 , 104, 2943-6	95
1038	Angiogenesis and Blood Supply. 2004 , 333-367	
1037	Antiangiogenic therapy. 2004 , 10, 27-37	12
1036	Diagnostic and therapeutic applications of recombinant antibodies: targeting the extra-domain B of fibronectin, a marker of tumor angiogenesis. 2004 , 10, 1537-49	40
1035	The pharmacological actions of nicotine on the gastrointestinal tract. 2004 , 94, 348-58	50
1034	Chemical Approaches to Angiogenesis. 2004 , 475-487	8
1033	Vascular endothelial growth factor (VEGF) in human tooth germ center. 2005 , 18, 587-94	8
1032	Protein Kinase Inhibitors Drug Discovery. 2005 , 1191-1257	4
1031	Novel Imaging Agents for Molecular MR Imaging of Cancer. 2005 , 1309-1341	
1030	Targets and Approaches for Cancer Drug Discovery. 2005 , 1343-1373	
1029	Angiogenesis in lymphoproliferative disorders: a therapeutic target?. 2005 , 12, 279-83	5
1028	Metronomic therapy: it makes sense and is patient friendly. 2005 , 27, 571-2	8

1027	Angiogenesis, choroidal neovascularization, and the coagulation system. 2005 , 25, 19-25	2
1026	Invited Commentary. 2005 , 25, S97-S98	1
1025	Magnetic resonance imaging and expression of vascular endothelial growth factor in hepatocellular nodules in cirrhosis and hepatocellular carcinomas. 2005 , 16, 67-75	11
1024	A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. 2005 , 27, 573-81	163
1023	Immunotherapy and cancer vaccines in the management of breast cancer. 2005 , 11, 3475-83	12
1022	Bone marrow-derived endothelial progenitor cells for neovascular formation. 2005 , 147-54	3
1021	Physiological mechanisms of tumor-cell invasion and migration. 2005 , 20, 194-200	103
1020	Synergistic anti-tumor effect of recombinant human endostatin adenovirus combined with gemcitabine. 2005 , 16, 551-7	25
1019	Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. 2005 , 105, 420-5	227
1018	Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. 2005 , 106, 125-34	116
1017	Noninvasive monitoring of cellular movements: the utility of MRI and magnetically labeled cells. 2005 , 105, 7-8	
1016	Long live T cells. 2005 , 105, 8-9	3
1015	Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. 2005 , 106, 4303-7	72
1014	Only a specific subset of human peripheral-blood monocytes has endothelial-like functional capacity. 2005 , 106, 2347-55	101
1013	On the role of endothelial progenitor cells in tumor neovascularization. 2005 , 235, 338-49	20
1012	Modeling and simulation of multicellular tumor growth using a nonlinear matter wave equation. 2005 , 41, 1299-1306	4
1011	Mathematical modelling of flow in 2D and 3D vascular networks: Applications to anti-angiogenic and chemotherapeutic drug strategies. 2005 , 41, 1137-1156	124
1010	Applicability of anti-neovascular therapy to drug-resistant tumor: suppression of drug-resistant P388 tumor growth with neovessel-targeted liposomal adriamycin. 2005 , 296, 133-41	23

1009	Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity. 2005 , 13, 5475-91	47
1008	Molecular mechanisms of tumor vascularization. 2005 , 54, 53-61	90
1007	Evolving molecular-based targeted therapy for cancer: an exciting field. 2005 , 31, 299-305	
1006	The role of cystatin C and the angiogenic cytokines VEGF and bFGF in patients with esophageal carcinoma. 2005 , 22, 29-38	13
1005	Endothelial progenitor cells. 2005 , 56, 79-101	315
1004	Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. 2005 , 23, 1011-27	2248
1003	Comprehensive model for simultaneous MRI determination of perfusion and permeability using a blood-pool agent in rats rhabdomyosarcoma. 2005 , 15, 2497-505	42
1002	The evolution of cancer research and drug discovery at Lilly Research Laboratories. 2005 , 45, 229-55	25
1001	Angiogenesis inhibitors in the treatment of cancer. 2005 , 6, 1701-11	39
1000	Systemic therapy for colorectal cancer. <i>New England Journal of Medicine</i> , 2005 , 352, 476-87	59.2 925
999	Protein Therapeutic Delivery Using Encapsulated Cell Platform. 2005 , 197-209	3
998	Review article: angiogenesis soluble factors as liver disease markers. 2005 , 22, 23-30	23
997	alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma. 2005 , 22, 217-26	40
996	Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. 2005 , 130, 709-15	95
995	Timeline: Chemotherapy and the war on cancer. 2005 , 5, 65-72	1259
994	The contributions of Santiago Ramón y Cajal to cancer research - 100 years on. 2005 , 5, 904-9	10
993	A multiprong approach to cancer gene therapy by coencapsulated cells. 2005 , 12, 369-80	15
992	Antiangiogenic treatment with endostatin inhibits progression of AML in vivo. 2005 , 19, 1312-7	45

991	SP100 inhibits ETS1 activity in primary endothelial cells. 2005 , 24, 916-31	33
990	Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathway. 2005 , 24, 5510-20	51
989	Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin. 2005 , 24, 6785-95	54
988	VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms. 2005 , 85, 608-23	60
987	Combination treatment significantly enhances the efficacy of antitumor therapy by preferentially targeting angiogenesis. 2005 , 85, 756-67	50
986	Angiogenesis as a therapeutic target. 2005 , 438, 967-74	2127
985	Various immunostaining patterns of CD31, CD34 and endoglin and their relationship with lymph node metastasis in oral squamous cell carcinomas. 2005 , 34, 70-6	49
984	Topical vascular endothelial growth factor reverses delayed wound healing secondary to angiogenesis inhibitor administration. 2005 , 13, 506-12	50
983	Therapeutic targeting of the tumor microenvironment. 2005 , 7, 513-20	440
982	A mechanistic study of colon cancer growth promoted by cigarette smoke extract. 2005 , 519, 52-7	46
981	In silico analysis of angiogenesis associated gene expression identifies angiogenic stage related profiles. 2005 , 1755, 121-34	14
980	The role of pH dynamics and the Na ⁺ /H ⁺ antiporter in the etiopathogenesis and treatment of cancer. Two faces of the same coin--one single nature. 2005 , 1756, 1-24	103
979	Invasion and metastasis markers in cancers. 2005 , 58, 466-74	25
978	Role of human papillomavirus in the carcinogenesis of squamous cell carcinoma and adenocarcinoma of the cervix. 2005 , 19, 469-83	65
977	Anticopper therapy against cancer and diseases of inflammation and fibrosis. 2005 , 10, 1103-9	101
976	Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. 2005 , 32, 61-8	33
975	Current management of advanced non-small cell lung cancer: targeted therapy. 2005 , 32, 315-28	39
974	The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors. 2005 , 32, S23-9	20

973	A novel model for post-transplant obliterative airway disease reveals angiogenesis from the pulmonary circulation. 2005 , 5, 248-54	33
972	Angiogenesis inhibitors found within the haemostasis pathway. 2005 , 9, 286-302	23
971	Angiogenesis, l'enfant terrible of vascular biology is coming of age. 2005 , 9, 775-6	6
970	Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). 2005 , 9, 777-94	528
969	Anti-angiogenic effects and regression of localized murine AML produced by anti-VEGF and anti-Flk-1 antibodies. 2005 , 75, 41-6	7
968	Decrease in circulating anti-angiogenic factors (angiostatin and endostatin) after surgical removal of primary colorectal carcinoma coincides with increased metabolic activity of liver metastases. 2005 , 137, 246-9	47
967	Gene expression perturbation in vitro--a growing case for three-dimensional (3D) culture systems. 2005 , 15, 405-12	416
966	Antiangiogenesis: a possible treatment option for prostate cancer?. 2005 , 4, 197-202	8
965	Angiostatin's molecular mechanism: aspects of specificity and regulation elucidated. 2005 , 96, 242-61	106
964	Combined endostatin/sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC. 2005 , 41, 879-86	44
963	Effective angiostatic treatment in a murine metastatic and orthotopic hepatoma model. 2005 , 41, 1233-40	31
962	Combination therapy with tumor-lysate pulsed dendritic cells and antiangiogenic drug TNP-470 for mouse pancreatic cancer. 2005 , 117, 499-505	17
961	Ethanol stimulates tumor progression and expression of vascular endothelial growth factor in chick embryos. 2005 , 103, 422-31	42
960	Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy. 2005 , 103, 1561-70	35
959	A long view of fashions in cancer research. 2005 , 27, 833-8	67
958	Molecular recognition of basic fibroblast growth factor by polyoxometalates. 2005 , 44, 4048-52	40
957	Molecular Recognition of Basic Fibroblast Growth Factor by Polyoxometalates. 2005 , 117, 4116-4120	20
956	Overexpression of cyclooxygenase-2 in multiple myeloma: association with reduced survival. 2005 , 80, 169-73	26

955	Nitric oxide modulation of low-density mononuclear cell transendothelial migration. 2005 , 25, 452-6	6
954	PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy. 2005 , 6, 550-7	50
953	A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck. 2005 , 55, 295-300	39
952	Antiangiogenic and antitumoral properties of a polysaccharide isolated from the seaweed <i>Sargassum stenophyllum</i> . 2005 , 56, 436-46	70
951	[Which role do new therapeutic options play in palliative care of colorectal cancer?]. 2005 , 46, 1339-46	1
950	The antivasular action of physiotherapy ultrasound on murine tumors. 2005 , 31, 1403-10	57
949	Vascular development in endometriosis. 2005 , 8, 147-56	153
948	Use of human VEGF(165) gene for therapeutic angiogenesis in coronary patients: first results. 2005 , 140, 106-12	4
947	A high peripheral microvessel density count correlates with a poor prognosis in pancreatic cancer. 2005 , 40, 402-8	37
946	Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. 2005 , 131, 31-40	98
945	VEGF significance in peritoneal recurrence from gastric cancer. 2005 , 8, 155-63	40
944	Antiangiogenic, antimicrobial, and cytotoxic potential of sponge-associated bacteria. 2005 , 7, 245-52	50
943	Second-line therapy for advanced colorectal carcinoma. 2005 , 7, 173-80	3
942	Angiogenesis and prostate cancer: important laboratory and clinical findings. 2005 , 7, 215-9	14
941	Correlation between expression of matrix metalloproteinase-2, matrix metalloproteinase-9 and angiogenesis in gastric cancer. 2005 , 17, 283-287	7
940	Ectopic localization of mitochondrial ATP synthase: a target for anti-angiogenesis intervention?. 2005 , 37, 461-5	28
939	The role of copper in tumour angiogenesis. 2005 , 10, 299-310	120
938	VEGF-targeting therapy for breast cancer. 2005 , 10, 319-23	19

937	Carcinogenic effect of nickel compounds. 2005 , 279, 45-67	160
936	Low-dose methotrexate inhibits lung metastasis and lengthens survival in rat osteosarcoma. 2005 , 22, 559-64	25
935	Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancer. 2005 , 3, 26-32	37
934	Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective. 2005 , 10, 1415-39	50
933	Angiogenesis as an indicator of metastatic potential in papillary thyroid carcinoma. 2005 , 60, 233-40	19
932	Senescence and its bypass in the vascular endothelium. 2005 , 10, 940-50	13
931	Physiological and psychological factors may be involved in remarkable recovery. 2005 , 20, 634-6, 638, 644-9	1
930	Bevacizumab in combination chemotherapy for colorectal and other cancers. 2005 , 62, 1021-32	42
929	Bone morphogenetic proteins and vascular differentiation: BMPing up vasculogenesis. 2005 , 94, 713-8	44
928	Prognostic values of tumor endothelial markers in patients with colorectal cancer. 2005 , 11, 1283-6	56
927	Neurosurgical Applications for Polymeric Drug Delivery Systems. 2005 , 18, 458-498	
926	Angiogenesis. 2005 ,	
925	Integrins, cancer and snake toxins (mini-review). 2005 , 11, 217	8
924	Resistance to Apoptosis in Cancer Therapy. 2005 , 43-64	1
923	Bone marrow stem cells and their role in angiogenesis. 2005 , 4, 366-370	2
922	Use of Animal Models to Evaluate Signal Transduction Inhibitors As Modulators of Cytotoxic Therapy. 2005 , 231-275	
921	Targeting Established Tumor Vasculature: A Novel Approach to Cancer Treatment. 2005 , 1, 1-9	34
920	Chemoradiotherapy for colorectal cancer. 2005 , 54, 1194-202	66

919	Copper lowering therapy with tetrathiomolybdate as an antiangiogenic strategy in cancer. 2005 , 5, 195-202	53
918	Bevacizumab. 2005 , Suppl, S8-9	64
917	3,3'-Diindolylmethane inhibits angiogenesis and the growth of transplantable human breast carcinoma in athymic mice. 2005 , 26, 771-8	122
916	Nonviral vectors for cancer gene therapy: prospects for integrating vectors and combination therapies. 2005 , 5, 629-41	36
915	Control of copper status for cancer therapy. 2005 , 5, 543-9	50
914	Penta-O-galloyl-beta-D-glucose suppresses tumor growth via inhibition of angiogenesis and stimulation of apoptosis: roles of cyclooxygenase-2 and mitogen-activated protein kinase pathways. 2005 , 26, 1436-45	92
913	Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. 2005 , 65, 8896-904	275
912	Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. 2005 , 23, 3502-8	543
911	Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. 2005 , 11, 7851-60	129
910	Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. 2005 , 65, 8690-7	288
909	MR angiography of tumor-related vasculature: from the clinic to the micro-environment. 2005 , 25 Suppl 1, S85-97; discussion S97-8	25
908	Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. 2005 , 11, 7749-56	251
907	Targeting coagulation to the tumor microvasculature: perspectives and therapeutic implications from preclinical studies. 2005 , 97, 705-7	13
906	A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases. 2005 , 18, 417-24	49
905	Cartilage dysplasia and tissue mineralization in the rat following administration of a FGF receptor tyrosine kinase inhibitor. 2005 , 33, 449-55	43
904	Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. 2005 , 11, 3514-22	138
903	AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. 2005 , 65, 4389-400	632
902	Does vasculogenic mimicry exist in astrocytoma?. 2005 , 53, 997-1002	120

8901	Neoangiogenesis and sinusoidal capillarization in hepatocellular carcinoma: correlation between dynamic CT and density of tumor microvessels. 2005 , 237, 529-34	50
8900	Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model. 2005 , 237, 151-8	106
899	Antiangiogenic gene therapy: disruption of neovascular networks mediated by inducible caspase-9 delivered with a transcriptionally targeted adenoviral vector. 2005 , 12, 320-9	20
898	The role of blood-brain barrier permeability in brain tumor imaging and therapeutics. 2005 , 185, 763-7	71
897	Expression of vascular endothelial growth factor in hepatocellular carcinoma and the surrounding liver and correlation with MRI findings. 2005 , 184, 832-41	19
896	Tumor Vasculature as a Target for Cancer Therapy. 2005 , 415-428	
895	Quantitative assessment of colorectal cancer perfusion using MDCT: inter- and intraobserver agreement. 2005 , 185, 225-31	62
894	Angiogenic pathways in diabetic retinopathy. <i>New England Journal of Medicine</i> , 2005 , 353, 839-41	59.2 145
893	Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. 2005 , 46, 885-91	51
892	Inhibition of angiogenesis in cancer patients. 2005 , 10, 403-12	16
891	How Cancer Could be Cured by 2015. 2005 , 4, 268-277	35
890	Paclitaxel for AIDS-associated Kaposi's sarcoma. 2005 , 5, 215-9	18
889	Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors. 2005 , 235, 509-16	25
888	Antiangiogenic agents: studies on fumagillin and curcumin analogs. 2005 , 11, 357-73	35
887	4 Angiogenesis, Metastasis, and Epigenetics in Cancer. 2005 , 4, 45-57	
886	Contortrostatin, a snake venom disintegrin with anti-angiogenic and anti-tumor activity. 2005 , 34, 169-76	41
885	Correlation between melanoma angiogenesis and the mesenchymal stem cells and endothelial progenitor cells derived from bone marrow. 2005 , 14, 292-8	65
884	Cryptotanshinone but not tanshinone IIA inhibits angiogenesis in vitro. 2005 , 37, 133-7	63

883	713. Growth Suppression of Hepatocellular Carcinoma by AAV-Mediated Angiogenic Inhibitors. 2005 , 11, S276-S277	
882	716. Transducing Efficiency Screening for rAAV2, rAAV1, and rAAV5 in 56 Human Tumor Cell Lines. 2005 , 11, S277-S278	
881	Angiogenin in Gastric Cancer and Its Roles in Malignancy. 2005 , 4, 195-203	
880	Development of an angiogenesis-focused cDNA chip and validation of its functionality. 2005 , 37, 365-70	3
879	715. Noninvasive Bioluminescence Imaging of Gene Expression Following Intracerebral Gene Delivery of AAV and Adenovirus into the Mouse Brain. 2005 , 11, S277	
878	714. Adenoassociate Virus Mediated Long Term Expression of Human TERTC27 Polypeptide Inhibited Glioblastoma Carcinogenesis by Multiple Mechanisms. 2005 , 11, S277	
877	2-Methoxyestradiol-induced apoptosis in prostate cancer cells requires Smad7. 2005 , 280, 14773-9	27
876	Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas. 2005 , 65, 7241-8	81
875	What tumors need. 2005 , 201, 1024-1024	1
874	Oxygen distribution in murine tumors: characterization using oxygen-dependent quenching of phosphorescence. 2005 , 98, 1503-10	75
873	Stable suppression of tumorigenicity by Pin1-targeted RNA interference in prostate cancer. 2005 , 11, 7523-31	98
872	Delivery of antiangiogenic agents for cancer gene therapy. 2005 , 4, 331-41	3
871	Plexin D1 expression is induced on tumor vasculature and tumor cells: a novel target for diagnosis and therapy?. 2005 , 65, 8317-23	55
870	Antibody against junctional adhesion molecule-C inhibits angiogenesis and tumor growth. 2005 , 65, 5703-10	89
869	Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kappaB and CXC chemokines. 2005 , 65, 5063-9	91
868	Endogenous inhibitors of angiogenesis. 2005 , 65, 3967-79	445
867	Bendrofluazide fails to reduce elevated blood pressure levels in the immediate post-stroke period. 2005 , 19, 253-9	25
866	Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. 2005 , 16, 1695-701	48

865	Integration/Interaction of Oncologic Growth. 2005,	3
864	In vivo generation of angiostatin isoforms by administration of a plasminogen activator and a free sulfhydryl donor: a phase I study of an angiostatic cocktail of tissue plasminogen activator and mesna. 2005, 11, 6218-25	24
863	Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model. 2005, 11, 2337-44	21
862	The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide. 2005, 11, 4610-9	64
861	Tumour proliferation, angiogenesis, and ploidy status in human colon cancer. 2005, 58, 1170-4	17
860	Endothelial progenitor cells for vasculogenesis. 2005, 20, 36-42	107
859	Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. 2005, 5, 579-94	144
858	Managing patients treated with bevacizumab combination therapy. 2005, 69 Suppl 3, 25-33	232
857	Cell binding isoforms of vascular endothelial growth factor-A (VEGF189) contribute to blood flow-distant metastasis of pulmonary adenocarcinoma. 2005, 26, 1517-24	13
856	Anti-angiogenic strategies for cancer therapy (Review). 2005, 27, 563	2
855	Modulation of growth factor action in the cardiovascular system. 2005, 65, 547-9	4
854	How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy. 2005, 4, 1307-10	66
853	Hypoxia inducible factor pathways as targets for functional foods. 2005, 53, 3751-68	23
852	Angiogenesis, Thrombospondin-1 and Cervical Carcinogenesis. 2005, 44, 128-138	
851	Tumor angiogenesis and therapy. 2005, 59 Suppl 2, S340-3	65
850	CDK2 translational down-regulation during endothelial senescence. 2005, 307, 118-30	40
849	Perfusion Bioreactors for Cardiovascular Tissue Engineering. 2005, 285-307	
848	Current imaging paradigms in radiation oncology. 2005, 163, 1-25	51

847	Facilitation of a structural transition in the polypurine/polypyrimidine tract within the proximal promoter region of the human VEGF gene by the presence of potassium and G-quadruplex-interactive agents. 2005 , 33, 6070-80	319
846	Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. 2005 , 40, 352-68	190
845	Imaging hypoxia and angiogenesis in tumors. 2005 , 43, 169-87	120
844	Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1). 2005 , 12, 347-57	101
843	Enhanced antitumor effect of the combination of tumstatin gene therapy and gemcitabine in murine models. 2005 , 16, 1075-86	18
842	Mechanisms of Angiogenesis. 2005 ,	5
841	Endothelial precursors and mature endothelial cells are increased in the peripheral blood of myelodysplastic syndromes. 2005 , 46, 1345-51	36
840	Angiogenesis and lung cancer: prognostic and therapeutic implications. 2005 , 23, 3243-56	207
839	Novel therapeutics in adult malignant brain gliomas. 2005 , 14, 643-58	4
838	Anti-angiogenic treatment of gastrointestinal malignancies. 2005 , 23, 712-26	18
837	Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. 2005 , 9, 1217-33	118
836	COX-2: a molecular target for colorectal cancer prevention. 2005 , 23, 2840-55	443
835	Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression. 2005 , 65, 8359-65	39
834	Diffusion-Weighted, Perfusion-Weighted, and Functional MR Imaging. 2005 , 1073-1114	1
833	Engineering myocardial tissue. 2005 , 97, 1220-31	216
832	Bevacizumab in the treatment of colorectal cancer. 2005 , 5, 997-1005	47
831	Copoly(styrene-maleic acid)-pirarubicin micelles: high tumor-targeting efficiency with little toxicity. 2005 , 16, 230-6	85
830	Angiogenesis: a curse or cure?. 2005 , 81, 236-42	58

829	Angiogenesis of breast cancer. 2005 , 23, 1782-90	244
828	Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. 2005 , 68, 382-90	21
827	6-substituted 5-fluorouracil derivatives as transition state analogue inhibitors of thymidine phosphorylase. 2005 , 24, 367-73	13
826	Angiogenesis and chronic inflammation; the potential for novel therapeutic approaches in chronic liver disease. 2005 , 42, 7-11	41
825	Silibinin inhibits angiogenesis via Flt-1, but not KDR, receptor up-regulation. 2005 , 128, 140-6	42
824	Alpha-actinin-2, a cytoskeletal protein, binds to angiogenin. 2005 , 329, 661-7	24
823	Antiangiogenic activity of 4-O-methylgallic acid from <i>Canavalia gladiata</i> , a dietary legume. 2005 , 330, 1268-74	48
822	Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. 2005 , 333, 292-8	92
821	Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. 2005 , 333, 328-35	723
820	Angioarrestin: a unique angiopoietin-related protein with anti-angiogenic properties. 2005 , 333, 308-15	20
819	Angiogenesis inhibitors: from laboratory to clinical application. 2005 , 333, 289-91	17
818	[6]-Gingerol, a pungent ingredient of ginger, inhibits angiogenesis in vitro and in vivo. 2005 , 335, 300-8	199
817	Butyrate-induced proapoptotic and antiangiogenic pathways in EAT cells require activation of CAD and downregulation of VEGF. 2005 , 335, 993-1001	18
816	[Angiogenesis and breast neoplasms. The pathologist's point of view]. 2005 , 33, 140-6	4
815	Bladder transitional cell carcinoma: correlation of contrast enhancement on computed tomography with histological grade and tumour angiogenesis. 2005 , 60, 215-23	13
814	Antiangiogenic strategies in neuroblastoma. 2005 , 31, 27-34	38
813	Endostatin: the logic of antiangiogenic therapy. 2005 , 8, 59-74	91
812	Does surgery unfavourably perturb the "natural history" of early breast cancer by accelerating the appearance of distant metastases?. 2005 , 41, 508-15	150

811	Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. 2005 , 41, 1291-9	152
810	Growth factors and their relationship to neoplastic and paraneoplastic disease. 2005 , 16, 83-94	3
809	Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models. 2005 , 31, 1042-50	27
808	Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. 2005 , 218, 1-14	108
807	Rho, Rac, Pak and angiogenesis: old roles and newly identified responsibilities in endothelial cells. 2005 , 229, 13-23	77
806	A cultural renaissance: in vitro cell biology embraces three-dimensional context. 2005 , 192, 1-6	67
805	Heterogeneity of Tie2 expression in tumor microcirculation: influence of cancer type, implantation site, and response to therapy. 2005 , 167, 1753-62	33
804	Mechanisms of nitric oxide interplay with Rho GTPase family members in modulation of actin membrane dynamics in pericytes and fibroblasts. 2005 , 166, 1861-70	70
803	Effect of terazosin on tissue vascularity and apoptosis in transitional cell carcinoma of bladder. 2005 , 65, 1019-23	11
802	New treatments for age-related macular degeneration. 2005 , 112, 531-2	28
801	A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. 2005 , 112, 1747-57	515
800	[Thalidomide: mechanisms of action and new insights in hematology]. 2005 , 26, 119-27	7
799	VEGF as a key mediator of angiogenesis in cancer. 2005 , 69 Suppl 3, 4-10	1006
798	Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial. 2005 , 5, 24-6	30
797	Thalidomide in patients with malignant pleural mesothelioma. 2005 , 48, 291-6	85
796	Antineovascular therapy, a novel antiangiogenic approach. 2005 , 9, 63-76	17
795	The marine bromotyrosine derivatives. 2005 , 61, 59-262	48
794	Breast cancer detection based on incremental biochemical and physiological properties of breast cancers: a six-year, two-site study. 2005 , 12, 925-33	156

- 793 [Anti-angiogenic agents in cancerology: myth or reality?]. **2005**, 63, 25-7
- 792 [Search for new anti-angiogenic agents with structural analogy with thalidomide]. **2005**, 63, 85-9
- 791 Reactive oxygen species as signaling molecules in cardiovascular differentiation of embryonic stem cells and tumor-induced angiogenesis. **2005**, 7, 1423-34 109
- 790 Local delivery of antineoplastic agents by controlled-release polymers for the treatment of malignant brain tumours. **2005**, 5, 477-94 37
- 789 Death Receptors in Cancer Therapy. **2005**, 3
- 788 Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts. **2006**, 8, 534-42 29
- 787 Principles of Targeted and Biological Therapies. **2006**, 73-90
- 786 Cancer Drug Resistance. **2006**, 17
- 785 Hyperthermia in Cancer Treatment: A Primer. **2006**, 40
- 784 Metronomic dosing of chemotherapy: applications in pediatric oncology. **2006**, 24, 432-43 28
- 783 Applications in the Clinic: The Anti-VEGF Aptamer. **2006**, 443-460 1
- 782 A multitargeted receptor tyrosine kinase inhibitor, SU6668, does not affect the healing of cutaneous full-thickness incisional wounds in SKH-1 mice. **2006**, 19, 245-54 7
- 781 The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies. **2006**, 11, 665-83 1
- 780 A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy. **2006**, 168, 2074-84 69
- 779 Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. **2006**, 169, 1739-52 131
- 778 YM-201627: an orally active antitumor agent with selective inhibition of vascular endothelial cell proliferation. **2006**, 238, 119-27 37
- 777 CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. **2006**, 203, 941-51 262
- 776 Endostatin and Vascular Endothelial Growth Factor Concentrations in Healthy Dogs, Dogs with Selected Neoplasia, and Dogs with Nonneoplastic Diseases. **2006**, 20, 144-150 19

775	The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. 2006 , 103, 19478-83	168
774	Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. 2006 , 29, 308-13	39
773	The role of angiopoietins during angiogenesis in gliomas. 2005 , 15, 311-7	86
772	Correlaci3n entre la densidad vascular y la expresi3n inmunohistoqu3mica de factores pron3sticos en el carcinoma ductal infiltrante de mama. 2006 , 39, 167-170	
771	Piper longum inhibits VEGF and proinflammatory cytokines and tumor-induced angiogenesis in C57BL/6 mice. 2006 , 6, 733-41	28
770	Future innovations in treating advanced prostate cancer. 2006 , 33, 247-72, viii	3
769	Laser applications in laryngology: past, present, and future. 2006 , 39, 159-72	47
768	Recent advances in the basic science of chondrosarcoma. 2006 , 37, 9-14	21
767	Molecular biology of oral cavity squamous cell carcinoma. 2006 , 39, 229-47	18
766	Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. 2006 , 130, 2060-73	308
765	Mathematical modeling of cancer progression and response to chemotherapy. 2006 , 6, 1361-76	84
764	Mathematical modeling of tumor-induced angiogenesis. 2006 , 8, 233-57	200
763	Contrast ultrasound imaging of the carotid artery vasa vasorum and atherosclerotic plaque neovascularization. 2006 , 48, 236-43	209
762	Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. 2006 , 51, 143-58	277
761	Vascular endothelial growth factor signaling pathways: therapeutic perspective. 2006 , 12, 5018-22	446
760	The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts. 2006 , 60, 576-81	68
759	Angiogenesis: health and disease. 2006 , 17 Suppl 10, x65-70	24
758	Synthesis and evaluation of multisubstrate bicyclic pyrimidine nucleoside inhibitors of human thymidine phosphorylase. 2006 , 49, 7807-15	21

757	Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. 2006 , 76, 217-57	191
756	Histomorphological and immunohistochemical studies of angiogenesis and angiogenic growth factors in normal ovaries of the mare. 2006 , 94, 199-203	
755	A novel model of image acquisition and processing for holistic quantification of angiogenesis disrupted by application of mainstream and sidestream cigarette smoke solutions. 2006 , 21, 22-33	2
754	Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials. 2006 , 83, 1005-16	72
753	Identification of derlin-1 as a novel growth factor-responsive endothelial antigen by suppression subtractive hybridization. 2006 , 348, 1272-8	7
752	Anti-angiogenesis and anti-tumor activity of recombinant anginex. 2006 , 349, 1073-8	26
751	Regulators of angiogenesis and strategies for their therapeutic manipulation. 2006 , 38, 333-57	123
750	Antiangiogenic and proapoptotic activity of a novel glycoprotein from <i>U. indica</i> is mediated by NF-kappaB and Caspase activated DNase in ascites tumor model. 2006 , 88, 297-307	31
749	Current status of angiogenesis inhibitors combined with radiation therapy. 2006 , 32, 348-64	97
748	Angiogenesis and anti-angiogenesis in hepatocellular carcinoma. 2006 , 32, 437-44	64
747	Chemically modified tetracyclines inhibit VEGF secretion by breast cancer cell lines. 2006 , 35, 115-25	5
746	Microtubule-targeting agents in angiogenesis: where do we stand?. 2006 , 9, 74-86	70
745	Thalidomide and lenalidomide in the treatment of multiple myeloma. 2006 , 42, 1612-22	97
744	Pulmonary nodule characterization: a comparison of conventional with quantitative and visual semi-quantitative analyses using contrast enhancement maps. 2006 , 59, 244-52	38
743	Macromolecular MRI contrast agents for imaging tumor angiogenesis. 2006 , 60, 353-66	130
742	Vaccines targeting tumour angiogenesis--a novel strategy for cancer immunotherapy. 2006 , 32, 363-70	36
741	<i>Ganoderma lucidum</i> polysaccharides peptide inhibits the growth of vascular endothelial cell and the induction of VEGF in human lung cancer cell. 2006 , 78, 1457-63	102
740	Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy 926 cells. 2006 , 78, 2558-63	48

739	Is cancer stem cell a cell, or a multicellular unit capable of inducing angiogenesis?. 2006 , 66, 601-4	31
738	Blockage of HGF/c-Met system by gene therapy (adenovirus-mediated NK4 gene) suppresses hepatocellular carcinoma in mice. 2006 , 45, 688-95	28
737	Does cancer growth depend on surface extension?. 2006 , 67, 1338-41	14
736	PEDF: a potential molecular therapeutic target with multiple anti-cancer activities. 2006 , 12, 497-502	96
735	Vascular-specific quantification in an in vivo Matrigel chamber angiogenesis assay. 2006 , 71, 69-75	18
734	Angiogenesis and Ewing sarcoma--relationship to pulmonary metastasis and survival. 2006 , 41, 524-9	8
733	Lysophosphatidic acid (LPA)-induced vascular endothelial growth factor (VEGF) by mesothelial cells and quantification of host-derived VEGF in malignant ascites. 2006 , 130, 94-101	20
732	Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression. 2006 , 135, 282-90	49
731	Angiogenesis. 2006 , 57, 1-18	1059
730	The role of vascular endothelial growth factor and its receptor Flk-1/KDR in promoting tumour angiogenesis in feline and canine mammary carcinomas: a preliminary study of autocrine and paracrine loops. 2006 , 81, 350-7	44
729	Cloning, purification, and characterization of a non-collagenous anti-angiogenic protein domain from human alpha1 type IV collagen expressed in Sf9 cells. 2006 , 49, 211-8	22
728	Expression of the non-glycosylated kringle domain of tissue type plasminogen activator in Pichia and its anti-endothelial cell activity. 2006 , 50, 1-8	3
727	Synthesis and evaluation of 4-[(18)F]fluorothalidomide for the in vivo studies of angiogenesis. 2006 , 33, 255-62	9
726	Radioimmunotherapy targeting the extra domain B of fibronectin in C6 rat gliomas: a preliminary study about the therapeutic efficacy of iodine-131-labeled SIP(L19). 2006 , 33, 661-6	25
725	Epithelioid hemangioendothelioma of tongue: A case report with immunohistochemical studies. 2006 , 42, 101-104	10
724	Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. 2006 , 113, 1695.e1-1533	33
723	Angiogenesis: from plants to blood vessels. 2006 , 27, 297-309	178
722	Antibodies and antibody-fusion proteins as anti-angiogenic, anti-tumor agents. 2006 , 1, 159-173	4

721	Angiogenesis inhibitors in clinical oncology. 2006 , 1, 429-434	2
720	The use of thalidomide in androgen-independent prostate cancer. 2006 , 24, 246-9	12
719	Current status of anti-angiogenesis therapy for prostate cancer. 2006 , 24, 260-8	16
718	Anti-angiogenic and cytotoxic targeted systemic therapy for high-risk prostate cancer. 2006 , 24, 243-245	
717	Short interfering RNA-mediated gene silencing of vascular endothelial growth factor: effects on cellular proliferation in colon cancer cells. 2006 , 141, 367-74; discussion 374	25
716	Cancer gene therapy targeting angiogenesis: an updated review. 2006 , 12, 6941-8	27
715	Tumour angiogenesis: the relevance to surgeons. 2006 , 88, 525-9	7
714	Angiogenic Molecules in Hodgkin's Disease: Results from Sequential Serum Analysis. 2006 , 19, 205873920601909	
713	The war on cancer: a report from the front lines. 2006 , 19, 323-34	1
712	Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. 2006 , 47, 4569-78	135
711	Dynamic MR imaging as a predictor of prognosis in breast cancer. 2006 , 20, 19-28	
710	. 2006 ,	106
709	. 2006 ,	1
708	. 2006 ,	22
707	Positively-Charged Liposomes for Targeting Tumor Vasculature. 2006 , 613-627	1
706	Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: Differences in growth rate and therapeutic response between tumors growing at different sites. 2006 , 29, 1087	3
705	Enhanced Permeability and Retention (EPR) Effect and Tumor-Selective Delivery of Anticancer Drugs. 2006 , 37-52	7
704	Can angiogenesis be exploited to improve stroke outcome? Mechanisms and therapeutic potential. 2006 , 111, 171-83	111

- 703 Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. **2006**, 107, 2705-12 202
- 702 Molecular and cellular approaches to patient management in oncology. **2006**, 3, 299-310
- 701 Gene Therapy for Angiogenesis. **2006**, 171-205
- 700 Neuroendocrine cell differentiation of poorly differentiated colorectal adenocarcinoma correlates with liver metastasis. **2006**, 29, 357 4
- 699 Experimental models of arteriogenesis: differences and implications. **2006**, 35, 36-44 10
- 698 Tumor Angiogenesis. 1087-1106 0
- 697 Vascular Endothelial Growth Factor (VEGF) Pathway. **2006**, 1, 768-770 26
- 696 Quantitative Assessment of the Effect of Nitric Oxide Synthase Inhibition on Tumor Vascular Activity Using Dynamic Contrast-Enhanced Computed Tomography. **2016**, 06, 42-52
- 695 Molecular Targeted Therapies in Head and Neck Cancer. **2016**, 349-372
- 694 BAYESIAN ACCELERATED FAILURE TIME AND ITS APPLICATION IN CHEMOTHERAPY DRUG TREATMENT TRIAL. **2016**, 17, 671-690
- 693 New Treatments and New Therapies. **2016**, 681-710
- 692 Antiangiogenic Therapy for Glioblastoma. **2016**, 143-149 1
- 691 p27kip1 and p57Kip2 (CDKN1B and CDKN1C). **2016**, 221-228
- 690 A Correlative Study between CT Perfusion Parameters and Angiogenesis in Rabbit VX2 Liver Tumors. **2016**, 06, 72-79
- 689 Discoveries Interview: Professor Harold F. Dvorak on the discovery of Vascular Endothelial Growth Factor (VEGF). **2016**, 4, e62
- 688 Use Case III: Imaging Biomarkers in Breast Tumours. Development and Clinical Integration. **2017**, 195-251
- 687 Melanoma. **2017**, 81-94
- 686 Peptide-Based Cancer Vaccines and Therapeutics for Solid Tumors Overexpressing HER-1, HER-2, HER-3, VEGF and IGF-1R. **2017**, 1-31

- 685 Angiogenesis model with Erlang distributed delays. **2017**, 14, 1-15 1
- 684 The Effects of All-Trans Retinoic Acid on Vasculogenic Mimicry Formation Ability in CD133+ Glioma Stem Cells and Its Mechanisms. **2017**, 05, 42-54
- 683 Angiogenesis and Prostate Cancer: Friends or Foes. **2017**, 241-256
- 682 Cytotoxics and Anti-Angiogenics: Metronomic Therapies. **2017**, 1-22
- 681 Multiparametric Imaging: Cutting-Edge Sequences and Techniques Including Diffusion-Weighted Imaging, Magnetic Resonance Spectroscopy, and PET/CT or PET/MRI. **2017**, 283-320
- 680 The Tumor Microenvironment in Cutaneous Melanoma: Friend or Foe. **2017**, 481-506
- 679 Sales for anti-angiogenic drugs. **2017**, 8, 38080-38081 2
- 678 Extracting Intercellular Signaling Network of Cancer Tissues using Ligand-Receptor Expression Patterns from Whole-tumor and Singlecell Transcriptomes. 0
- 677 The Complex Ecosystem in Non Small Cell Lung Cancer Invasion.
- 676 Whole-exome sequencing of plasma cell-free DNA portrays the somatic mutation landscape of refractory metastatic colorectal cancer and enables the discovery of mutatedKDR/VEGFR2 receptors as modulators of anti-angiogenic therapies.
- 675 Efficacy of anti-VEGF agents in the treatment of elderly hepatocellular carcinoma: a systematic review. **2017**, 8, 93179-93185 1
- 674 The role of telomere shortening in carcinogenesis: A hybrid stochastic-deterministic approach.
- 673 Functional and Molecular Photoacoustic Tomography of Small-Animal Brains. **2017**, 351-362
- 672 Clinical significance of CD34 in endometrioid carcinoma of the uterine body. **2018**, 34, 1579-1586
- 671 Pathology of Tumor Angiogenesis. **2018**, 1-22
- 670 OBSOLETE: Angiogenesis. **2018**,
- 669 Mechanism of Tumour Dissemination in Hepatobiliary and Pancreatic Tumours. **2018**, 1-12
- 668 Stochastic Models of Tumor Induced Angiogenesis. **2018**, 97-116

667 M2-polarized macrophages contribute to neovascuogenesis, leading to recurrence of oral cancer after radiation. **2018**, 64, 307-320

666 Modern aspects of antiangiogenic therapy in ovarian cancer. **2018**, 17-21

665 Magnetic resonance imaging for predicting personalized antitumor nanomedicine efficacy. **2019**, 21-24

664 VEGF dynamical changes in laboratory rodents with transplanted experimental tumors of various histological types. **2018**, 9, 49-56

663  **2019**, 22-26

662 Pathology of Tumor Angiogenesis. **2019**, 253-274

661 Combination of Anti-angiogenics and Other Targeted Therapies. **2019**, 359-376

660 Cytotoxics and Anti-angiogenics: Metronomic Therapies. **2019**, 327-347

659 Why is a new journal dedicated to vascular biology required?. **2019**, 1, E1-E2

658 Tumors of the Nervous System: General Considerations. **2019**, 1263-1331

657 Mechanisms of resistance to anti-angiogenic treatments.. **2019**, 2, 595-607

656 Tumor Blood Vessels as Targets for Cancer Therapy. **2019**, 41-56

655 Targeting Angiogenesis in Malignant Pleural Mesothelioma. **2019**, 235-242

654 Biomarkers for Anti-angiogenic Therapy. **2019**, 293-310

653 Vascular-Mediated Mechanisms and SRS/SBRT. **2019**, 3-13

652 Notch signaling and taxis mechanisms regulate early stage angiogenesis: A mathematical and computational model.

651 Perfusion Imaging: Physical Principles and Applications in the Brain. **2019**, 273-308

650 IL-1RA controls the development of esophageal cancer by inhibition of VEGF via PI3K/NF- κ B signaling pathway.

- 649 Continuous Endoglin (CD105) Overexpression Disrupts Angiogenesis and Facilitates Tumor Cell Metastasis.
- 648 Virtual screening, docking and molecular dynamics simulation of selected phytochemical compounds bound to receptor tyrosine kinases: A correlative anti angiogenic study. **2019**, 15, 613-620
- 647 PTTG has a Dual Role of Promotion-Inhibition in the Development of Pituitary Adenomas. **2019**, 26, 800-818
- 646 The tale of lenalidomide clinical superiority over thalidomide and regulatory and cost-effectiveness issues. **2019**, 24, 3783-3792 0
- 645 Editorial foreword: Angiogenesis: Cells, tissues and organs. **2020**, 49, 583-584
- 644 Investigating the Angiogenic Modulating Properties of *Spirostachys africana* in MCF-7 Breast Cancer Cell Line. **2019**, 15, 970-977 1
- 643 The role of tumor-derived exosomes in tumor angiogenesis and tumor progression. **2019**, 32, 193-202 5
- 642 Endostar Given at Different Times Combined with Radiotherapy to the Effect of Gastric Cancer Transplanted in Mice and Its Possible Mechanism. **2020**, 10, 399-405
- 641 Plasma HGF concentration in patients with brain tumors. **2020**, 7, 107-119
- 640 Metabolic pathway alterations in microvascular endothelial cells in response to hypoxia.
- 639 What Are the New Challenges of the Current Cancer Biomarkers?.
- 638 Anti-angiogenesis and apoptogenic potential of the brown marine alga, *Chnoospora minima*. **2020**, 6, 1
- 637 The effect of methenamine on vascular development: Experimental investigation using in vivo and insilico methods. **2020**, 18, 579-590
- 636 Regulation of opticin on bioactivity of retinal vascular endothelial cells cultured in collagen. **2020**, 13, 1202-1209 2
- 635 In vitro modeling of tumor spheroid interactions to perfused blood vessels. 1
- 634 The Dual Effect of the BMP9-ALK1 Pathway in Blood Vessels: An Opportunity for Cancer Therapy Improvement?. **2021**, 13, 1
- 633 Recent Advances in the Mechanism Research and Clinical Treatment of Anti-Angiogenesis in Biliary Tract Cancer. **2021**, 11, 777617 0
- 632 Isopimpinellin extends antiangiogenic effect through overexpression of miR-15b-5p and downregulating angiogenic stimulators. **2021**, 1 1

- 631 Effect and mechanism of circRNAs in tumor angiogenesis and clinical application. **2021**, 1
- 630 Local and systemic endothelial cell response to cancer: RKIP-mimetic therapy and endothelial safety. **2020**, 227-255 0
- 629 Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical Results and Outlook. **2020**, 125-153
- 628 Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers. **2021**, 21, 162-186 0
- 627 Nanoparticles as a Therapeutic Approach for Tumor Angiogenesis. **2022**, 52-113
- 626 Tumor perivascular cell-derived extracellular vesicles promote angiogenesis via the Gas6/Axl pathway. **2022**, 524, 131-143 2
- 625 Search for new anticancer drugs among new carbohydrate derivatives urea. **2019**, 18, 31-38
- 624 ROS and Oxidative Stress in Cancer: Recent Advances. **2020**, 109-138 2
- 623 Antiangiogenic Activity of Flavonols in Chorioallantoic Membrane (CAM) Assay. **2020**, 26, 891-896
- 622 4D Point Cloud Registration for Tumor Vascular Networks Monitoring from Ultrasensitive Doppler Images. **2020**, 437-456
- 621 Target Delivery of Iron Oxide Magnetic Nanoparticles for Imaging and Treatment. **2020**, 267-285
- 620 Anti-Vascular Endothelial Growth Molecules. **2020**, 331-341
- 619 Tumour-associated Angiogenesis and Intermediate Blood Vessels in Renal Cell Carcinoma.. **2021**, 1, 231-234
- 618 Identification of differentially expressed genes and biological pathways in para-carcinoma tissues of HCC with different metastatic potentials. **2020**, 19, 3799-3814
- 617 Emerging Functions and Clinical Applications of Exosomal ncRNAs in Ovarian Cancer. **2021**, 11, 765458 4
- 616 LRG1 destabilizes tumor vessels and restricts immunotherapeutic potency.. **2021**, 2, 1231-1252.e10 4
- 615 Chimaphila umbellata extract exerts anti-proliferative effect on human breast cancer cells via RIP1K/RIP3K-mediated necroptosis. **2021**, 100159 0
- 614 Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study. **2021**, 14, 7625-7637 2

- 613 Angiogenesis Inhibition in Anti-Neoplastic Therapy. **2005**, 233-237
- 612 Combinations of Cytotoxic Drugs, Ionizing Radiation, and Angiogenesis Inhibitors. **2006**, 103-114
- 611 Tumor models for preclinical development of targeted agents. **2005**, 63, 43-66
- 610 Novel Therapeutic Strategies For Posterior Segment Neovascularization. **2008**, 445-526
- 609 Clinical Angioblast Therapy. **2007**, 245-258
- 608 Targeted Therapy For Breast Cancer. **2008**, 309-342
- 607 Molecular Targeting of Colorectal Cancer. **2008**, 133-163
- 606 Targeted Drug Therapy in Pancreatic Cancer. **2008**, 271-287
- 605 Drug Development in Cancer Medicine: Challenges for Targeted Approaches. **2008**, 383-410
- 604 Angiogenèse tumorale. **2008**, 9-13
- 603 Traitements antiangiogéniques dans le cancer du poumon. **2008**, 93-103
- 602 Numerical simulation and graphical analysis of in vitro benign tumor growth: application of single-particle state bosonic matter equation with length scaling. 641-648
- 601 Anti-angiogenic Therapy Models. **2021**, 111-122
- 600 Regulation of Angiogenesis Using Nanomaterial Based Formulations: An Emerging Therapeutic Strategy to Manage Multiple Pathological Conditions.
- 599 Fluorescence guided intraluminal endoscopy in the gastrointestinal tract: A systematic review. **2020**, 12, 388-400 0
- 598 Comparing the Role of the p53 Gene and Telomerase Enzyme in 'Accelerated Aging Due to Cancer': A Literature Review. **2020**, 12, e10794
- 597 A Meta-Analysis of the Association Between the Gene Polymorphism and Digestive System Cancer Susceptibility. **2020**, 24, 732-744 2
- 596 Macrophages orchestrate the expansion of a pro-angiogenic perivascular niche during cancer progression. 1

595	Weichang'an Formula Inhibits Tumor Growth in Combination with Bevacizumab in a Murine Model of Colon Cancer-Making up for the Deficiency of Bevacizumab by inhibiting VEGFR-1. 2020 , 11, 512598	5
594	The role of angiogenesis in multiple myeloma treatment. 2020 , 56, 1-6	
593	Regional Uveal Response to Increased Nutritional Needs in the Retinal Zone of the Developing Eye Demonstrated in an Eye With Retinoblastoma. 1989 , 26, 120-123	
592	Matters of the heart transcriptome: a brief history of cardiovascular genomics. 2002 , 29, 81-91	1
591	Rubeosis iridis in retinoblastoma and pseudoglioma. 1978 , 76, 584-609	11
590	Lonidamine: basic science and rationale for treatment of prostatic proliferative disorders. 2005 , 7 Suppl 7, S21-6	13
589	A review of recent experimental work on the dental cyst. 1974 , 67, 1259-63	2
588	Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. 1997 , 151, 1417-23	214
587	Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype. 1997 , 151, 1215-24	26
586	Mouse model of angiogenesis. 1998 , 152, 1667-79	522
585	Intratumor microvessel density as a prognostic factor in cancer. 1995 , 147, 9-19	606
584	Angiogenesis in human coronary atherosclerotic plaques. 1994 , 145, 883-94	181
583	Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. 1994 , 144, 1188-94	135
582	The resistance of certain tissues to invasion: penetrability of explanted tissues by vascularized mesenchyme. 1973 , 73, 765-74	98
581	The vascular endothelium-pathobiologic significance. 1978 , 93, 803-48	112
580	Angiogenesis inhibitors generated by tumors. 1995 , 1, 120-2	43
579	Angiogenesis and vasculogenesis in treatment of cardiovascular disease. 1998 , 4, 429-40	15
578	Establishing a link between oncogenes and tumor angiogenesis. 1998 , 4, 286-95	28

577	Suppression of breast cancer metastasis through the inhibition of VEGF-mediated tumor angiogenesis. 2007 , 5, 273-286	20
576	Odontogenic cyst growth and prostaglandin-induced bone resorption. 1978 , 60, 85-91	30
575	Tumour angiogenesis. 1985 , 67, 295-8	4
574	Angiogenesis in cancer: the role of endothelin-1. 1999 , 81, 306-10	22
573	Rationale for combining biotherapy in the treatment of advanced colon cancer. 2008 , 2, 145-51	3
572	Antiangiogenic agents in first-line and second-line therapy for advanced colorectal cancer. 2007 , 1, S22-8	
571	Global tumor RNA expression in early establishment of experimental tumor growth and related angiogenesis following COX-inhibition evaluated by microarray analysis. 2007 , 3, 125-39	1
570	Chemoradiotherapy for esophageal cancer. 2009 , 3, 57-65	11
569	Intravitreal bevacizumab: an analysis of the evidence. 2007 , 1, 273-84	7
568	Coregistration of ultrasonography and magnetic resonance imaging with a preliminary investigation of the spatial colocalization of vascular endothelial growth factor receptor 2 expression and tumor perfusion in a murine tumor model. 2009 , 8, 187-98	6
567	Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers. 2009 , 3, 429-41	3
566	Targeted therapies in the management of colorectal carcinoma: role of bevacizumab. 2009 , 2, 1-15	8
565	Decreased risk of bladder cancer in men treated with quinazoline-based α -adrenoceptor antagonists. 2008 , 12, 253-258	9
564	Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents. 2011 , 4, 15-21	36
563	Preclinical molecular imaging of tumor angiogenesis. 2010 , 54, 291-308	27
562	Circulating vascular endothelial growth factor (VEGF) levels in advanced stage cancer patients compared to normal controls and diabetes mellitus patients with critical ischemia. 2007 , 2, 105-9	
561	Positron Emission Tomography and Near-Infrared Fluorescence Imaging of Vascular Endothelial Growth Factor with Dual-Labeled Bevacizumab. 2012 , 2, 1-13	54
560	(⁶⁸ Ga)-Labeling of RGD peptides and biodistribution. 2012 , 5, 165-72	17

559	New approaches for cancer treatment: antitumor drugs based on gene-targeted nucleic acids. 2009 , 1, 44-60	2
558	Peptoid-based PET imaging of vascular endothelial growth factor receptor (VEGFR) expression. 2011 , 1, 65-75	18
557	Hematopoietic stem cell derived carcinoma-associated fibroblasts: a novel origin. 2012 , 5, 863-73	30
556	Anti-angiogenic agents in Non-Small-Cell Lung Cancer (NSCLC): a perspective on the MONET1 (Motesanib NSCLC Efficacy and Tolerability) study. 2012 , 4, 558-61	5
555	Recent progress in therapeutic angiogenesis. 2007 , 3, 153-8	1
554	Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy. 2013 , 5, 393-403	20
553	Continuum of care with anti-angiogenic therapies in metastatic colorectal cancer. 2013 , 4, 299-307	5
552	Targeted Cancer Therapy with Tumor Necrosis Factor-Alpha. 2008 , 2008, 15-21	13
551	Cloning and expression of soluble vascular endothelial growth factors receptor-1 (sFlt-1) fragments in CHO-K1. 2013 , 6, 773-8	2
550	The effects of selected Australian snake venoms on tumour-associated microvascular endothelial cells (TAMECs) in vitro. 2013 , 4, 21-30	3
549	Ewing's sarcoma: overcoming the therapeutic plateau. 2012 , 13, 405-15	16
548	Neovascularization in Glioblastoma: Current Pitfall in Anti-angiogenic therapy. 2013 , 1, 16-19	6
547	Mechanism of kidney injury caused by bevacizumab in rats. 2014 , 7, 8675-83	5
546	Evaluation and Comparison of Vascular Endothelial Growth Factor Expression between Ameloblastoma and Keratocystic Odontogenic Tumor. 2015 , 7, 48-52	4
545	Establishment of a malignant pleural effusion mouse model with lewis lung carcinoma cell lines expressing enhanced green fluorescent protein. 2012 , 1, 170-8	1
544	Resistance to anti-angiogenic agents: a brief review of mechanisms and consequences. 2013 , 2, 304-7	7
543	Angiogenesis, multitarget kinase inhibitors and non-small cell lung cancer: a lesson from MONET1 trial. 2013 , 2, E13-6	
542	Clinical use of Bevacizumab in treating refractory glaucoma. 2015 , 8, 8-12	5

541	Parameters of prostate cancer at contrast-enhanced ultrasound: correlation with prostate cancer risk. 2015 , 8, 2562-9	6
540	Fibroblast ER β promotes bladder cancer invasion via increasing the CCL1 and IL-6 signals in the tumor microenvironment. 2015 , 5, 1146-57	22
539	Prognostic significance of placenta growth factor expression in patients with multiple cancers: a meta-analysis. 2015 , 8, 12726-35	2
538	Prognostic value of circulating endothelial cells in non-small cell lung cancer patients: a systematic review and meta-analysis. 2015 , 4, 610-8	8
537	Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors. 2015 , 7, 1675-98	40
536	HRP-3 protects the hepatoma cells from glucose deprivation-induced apoptosis. 2015 , 8, 14383-91	3
535	Anti-vascular endothelial growth factor therapies at the crossroads: linifanib for non-small cell lung cancer. 2016 , 5, 78-81	5
534	In vitro and in vivo antiangiogenic activity of desacetylvinblastine monohydrazone through inhibition of VEGFR2 and Axl pathways. 2016 , 6, 843-58	12
533	Drug Development Against Metastatic Cancers. 2017 , 90, 119-123	4
532	Revisiting the hallmarks of cancer. 2017 , 7, 1016-1036	267
531	Poly-L-Lysine Inhibits Tumor Angiogenesis and Induces Apoptosis in Ehrlich Ascites Carcinoma and in Sarcoma S-180 Tumor. 2017 , 18, 2255-2268	9
530	Long non-coding RNA HOTAIR enhances angiogenesis by induction of VEGFA expression in glioma cells and transmission to endothelial cells via glioma cell derived-extracellular vesicles. 2017 , 9, 5012-5021	56
529	Preparation and evaluation of a Ga-labeled RGD-containing octapeptide for noninvasive imaging of angiogenesis: biodistribution in non-human primate. 2018 , 8, 15-31	3
528	[Recombinant Human Endostatin in the Treatment of Advanced Lung Squamous Cell Carcinoma]. 2016 , 19, 670-674	2
527	[Application of Bevacizumab in Non-small Cell Lung Cancer]. 2017 , 20, 272-277	
526	[Establishment of a malignant pleural effusion mouse model with Lewis lung carcinoma cell lines expressing enhanced green fluorescent protein]. 2012 , 15, 317-23	3
525	[Combining bevacizumab with endostatin gets better antitumor efficacy in vivo in lung cancer animal model]. 2013 , 16, 61-6	
524	[Effects of rh-endostar in combination with radiotherapy on rats with lung cancer]. 2010 , 13, 386-90	2

523	[Advances of VEGR gene polymorphism and its clinical values in lung cancer]. 2013 , 16, 433-7	1
522	[Adverse events related to bevacizumab and the management principles in non-small cell lung cancer]. 2010 , 13, 563-7	0
521	The chick chorioallantoic membrane (CAM) as a versatile patient-derived xenograft (PDX) platform for precision medicine and preclinical research. 2018 , 8, 1642-1660	32
520	Bevacizumab Inhibits Angiogenic Cytokines in Head and Neck Squamous Cell Carcinoma: From Gene to the Protein. 2018 , 12, 136-141	6
519	Immunohistochemically Detection of Angiogenesis in Oral Pre-Cancerous Lesions Compared with Oral Invasive Carcinomas. 2018 , 19, 1805-1808	1
518	Assessment of Micro-vessel Density in Brain Gliomaby CD105 Expression. 2018 , 13, 205-211	
517	Relationship Between PIK3CA Amplification and P110 α and CD34 Tissue Expression as Angiogenesis Markers in Iranian Women with Sporadic Breast Cancer. 2018 , 13, 447-453	1
516	High-level expression of periostin is significantly correlated with tumor angiogenesis in prostate cancer. 2018 , 11, 1569-1574	2
515	PPAR γ mediates sunitinib resistance via NF- κ B activation in clear cell renal cell carcinoma. 2018 , 11, 2389-2400	3
514	Roundabout1 distribution in neoplastic and non-neoplastic diseases with a focus on neoangiogenesis. 2018 , 11, 5755-5764	3
513	Induction of humoral immune responses and inhibition of metastasis in mice by a VEGF peptide-based vaccine. 2020 , 23, 507-514	2
512	[Inhibitory effect of von Willebrand factor-cleaving protease on angiogenesis]. 2015 , 36, 602-6	
511	Recurrent inverted papilloma: diagnosis with pharmacokinetic dynamic gadolinium-enhanced MR imaging. 1999 , 20, 1445-51	14
510	Why we do what we do. A brief analysis of cancer therapies. 2020 , 19, 1401-1413	
509	Angiotensin receptor blocker Losartan inhibits tumor growth of colorectal cancer. 2021 , 20, 506-521	2
508	[Research Progress of Anti-angiogenic Agents Combined with Immunotherapy ?in Patients with Advanced Non-small Cell Lung Cancer]. 2021 , 24, 196-203	
507	Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy. 2000 , 21, 471-8	37
506	The emerging roles of exosomal miRNAs in nasopharyngeal carcinoma. 2021 , 11, 2508-2520	2

487	[Prospects and Challenges of Anti-VEGF Drug Treatment for Pathological Angiogenesis of the Retina]. 2021 , 141, 1307-1317	1
486	Mechanism of Gallic Acid Anticancer Activity Through Copper Mediated Cell Death. 2021 , 1-12	
485	Tolerance and Pharmacokinetics of Recombinant Human Endostatin Administered as Single-Dose or Multiple-Dose Infusions in Patients With Advanced Solid Tumors: A Phase I Clinical Trial.. 2021 , 20, 15330338211064434	0
484	Clinical Research Progress of Apatinib in the Treatment of Hepatocellular Carcinoma. 2021 , 11, 6195-6200	
483	A narrative review of systemic treatment options for hepatocellular carcinoma: state of the art review.. 2022 , 13, 426-437	0
482	Reactive Species and ER-Mitochondrial Performance for Glioblastoma Multiforme Treatment Strategy. 2021 , 1-19	
481	Gambogic amide inhibits angiogenesis by suppressing VEGF/VEGFR2 in endothelial cells in a TrkA-independent manner. 2021 , 59, 1566-1575	
480	Antiangiogenesis: Vessel Regression, Vessel Normalization, or Both?. 2022 , 82, 15-17	4
479	Immunotherapy in skin cancers - A narrative review. 1-8	
478	Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity.. 2022 , 24, 577-584	0
477	Gene expression profiles of some prognostic markers in a human breast cell line (MCF7) exposed to Curcumin nanoparticles and nanocapsules.	
476	RhoJ facilitates angiogenesis in glioblastoma via JNK/VEGFR2 mediated activation of PAK and ERK signaling pathways.. 2022 , 18, 942-955	1
475	Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management.. 2021 , 7, 100338	2
474	Anticancer effects of acteoside: Mechanistic insights and therapeutic status.. 2021 , 916, 174699	4
473	Synthesis, structure analysis, DFT calculations and energy frameworks of new coumarin appended oxadiazoles, to regress ascites malignancy by targeting VEGF mediated angiogenesis. 2022 , 1252, 132173	0
472	Lactose-binding lectin from Vatairea macrocarpa seeds induces in vivo angiogenesis via VEGF and TNF- α expression and modulates in vitro doxorubicin-induced genotoxicity.. 2021 , 194, 55-55	0
471	Antiangiogenese-Ansätze in der Tumorthherapie. 2000 , 32, 251-254	1
470	Study of expression of endoglin (CD105) in oral squamous cell carcinoma.. 2021 , 25, 552	0

- 469 Periodic solutions for a model of tumor volume with anti-angiogenic periodic treatment. **2021**, 55, 13-20
- 468 Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects.. **2022**, 11, 4
- 467 Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study.. **2022**, 10, 100 1
- 466 Association of Angiogenesis Gene Expression With Cancer Prognosis and Immunotherapy Efficacy.. **2022**, 10, 805507 0
- 465 Therapeutic angiogenesis in Buerger's disease: reviewing the treatment landscape. **2022**, 3, 263300402110702
- 464 Nanobiomaterials for drug delivery and theranostics. **2022**, 25-56
- 463 The Good, the Bad, and the Ugly: Neutrophils, Angiogenesis, and Cancer.. **2022**, 14, 2
- 462 Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies.. **2021**, 11, 789330 0
- 461 Application of Nanoemulsion in Cancer Treatment. **2022**, 237-258
- 460 Identification and Validation of Angiogenesis-Related Gene Expression for Predicting Prognosis in Patients With Ovarian Cancer.. **2021**, 11, 783666 0
- 459 Perfusion measurement in brain gliomas using velocity-selective arterial spin labeling: comparison with pseudo-continuous arterial spin labeling and dynamic susceptibility contrast MRI.. **2022**, 1 0
- 458 Investigation of the Effectiveness of Microvascular Doppler Ultrasound and Q-Pack in the Discrimination of Malign Thyroid Nodules From Benign.. **2022**, 1
- 457 Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study.. **2022**, 1
- 456 Drug-Specific Orofacial Complications of Novel Anti-cancer Therapies. **2022**, 153-169
- 455 Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment.. **2022**, 14, 1
- 454 Mechanism of Gallic Acid Anticancer Activity Through Copper-Mediated Cell Death. **2022**, 2559-2570
- 453 Variable roles of interleukin-17F in different cancers.. **2022**, 22, 54 0
- 452 The role of leucine-rich alpha-2-glycoprotein-1 in proliferation, migration, and invasion of tumors.. **2022**, 148, 283 1

451	Exosome-Encased Nucleic Acid Scaffold Chemotherapeutic Agents for Superior Anti-Tumor and Anti-Angiogenesis Activity.. 2022 , 2, 140-149	1
450	Single-Cell RNA Sequencing in Lung Cancer: Revealing Phenotype Shaping of Stromal Cells in the Microenvironment.. 2021 , 12, 802080	1
449	Exosome-derived noncoding RNAs: Function, mechanism, and application in tumor angiogenesis.. 2022 , 27, 983-997	1
448	Reactive Species and ER-Mitochondrial Performance for Glioblastoma Multiforme Treatment Strategy. 2022 , 3-21	
447	Chapter 1. Introduction and Historical Overview of Drug Repurposing Opportunities. 2022 , 1-13	2
446	4-Acetylanthroquinonol B Suppresses Prostate Cancer Growth and Angiogenesis via a VEGF/PI3K/ERK/mTOR-Dependent Signaling Pathway in Subcutaneous Xenograft and In Vivo Angiogenesis Models.. 2022 , 23,	1
445	Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review.. 2022 , 11, 276-287	2
444	Resistance to antiangiogenic treatments: A review. 2022 , 147-197	
443	Introduction. 2022 , 1-28	
442	Mast Cell-Tumor Interactions: Molecular Mechanisms of Recruitment, Intratumoral Communication and Potential Therapeutic Targets for Tumor Growth.. 2022 , 11,	2
441	Role of Exosomes in Immune Microenvironment of Hepatocellular Carcinoma.. 2022 , 2022, 2521025	0
440	Angioprevention of Urologic Cancers by Plant-Derived Foods.. 2022 , 14,	0
439	Signaling Mechanisms and Pharmacological Modulators Governing Diverse Aquaporin Functions in Human Health and Disease.. 2022 , 23,	7
438	Inhibition of Walker-256 Tumor Growth by Combining Microbubble-Enhanced Ultrasound and Endostar.. 2022 ,	0
437	Clinical and Biological Interpretation of Survival Curves of Cancer Patients, Exemplified With Stage IV Non-Small Cell Lung Cancers With Long Follow-up.. 2022 , 12, 837419	0
436	Targeted delivery of exosomal miR-484 reprograms tumor vasculature for chemotherapy sensitization.. 2022 , 530, 45-45	6
435	A novel numerical and artificial intelligence based approach to study anti-angiogenic drugs: Endostatin. 2022 , 105, 258-283	1
434	The potential of advanced MR techniques for precision radiotherapy of glioblastoma.. 2022 , 35, 127	

- 433 A Reassessment of the Barrier Effect of the Physis against Metaphyseal Osteosarcoma: A Comprehensive Pathological Study with Its Radiological and Clinical Follow-Up Correlations.. **2022**, 12, 1
- 432 Angiogenesis as Therapeutic Target in Metastatic Prostate Cancer - Narrowing the Gap Between Bench and Bedside.. **2022**, 13, 842038 0
- 431 Combretastatin A4-loaded poly(lactic-co-glycolic acid)/soybean lecithin nanoparticles with enhanced drug dissolution rate and antiproliferation activity.. **2022**, 1
- 430 The 3D in vivo chorioallantoic membrane model and its role in breast cancer research.. **2022**, 1 0
- 429 Membrane progesterone receptor 4 (mPR4) enhances hypoxia-induced vascular endothelial growth factor secretion and angiogenesis in lung adenocarcinoma through STAT3 signaling.. **2022**, 20, 72 1
- 428 Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment.. **2022**, 22, 73 0
- 427 New developments in the biology of fibroblast growth factors.. **2022**, e1549 1
- 426 Multi-Omics Prognostic Signatures Based on Lipid Metabolism for Colorectal Cancer.. **2021**, 9, 811957 0
- 425 Modulating Angiogenesis by Proteomimetics of Vascular Endothelial Growth Factor.. **2021**, 5
- 424 A New Antitumor Direction: Tumor-Specific Endothelial Cells.. **2021**, 11, 756334 1
- 423 Green synthesis of zinc oxide nanoparticles and evaluation of anti-angiogenesis, anti-inflammatory and cytotoxicity properties. **2019**, 44, 5
- 422 Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update.. **2022**, 34, 28-39 0
- 421 Serum vascular endothelial growth factor in dogs with various proliferative diseases.. **2022**, 1
- 420 Newcastle disease virus suppresses angiogenesis in mammary adenocarcinoma models. **2022**, 25, 33-45 0
- 419 New Progress in Drug Treatment of Recurrent and Metastatic Cervical Cancer. **2022**, 12, 1-6 0
- 418 Recent progress of carbon dots in targeted bioimaging and cancer therapy.. **2022**, 12, 2860-2893 7
- 417 Biology and pathophysiology of central nervous system metastases. **2022**, 55-78
- 416 The effect of docetaxel on retinal pigment epithelial cells.. **2022**, 9, 670-678

415	A radiologist's guide to novel anticancer therapies in the era of precision medicine.. 2022 , 9, 100406	0
414	The Impact of Obesity, Adipose Tissue, and Tumor Microenvironment on Macrophage Polarization and Metastasis.. 2022 , 11,	1
413	Glioblastoma Vasculature: From its Critical Role in Tumor Survival to Relevant in Vitro Modelling. 2022 , 2,	0
412	Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches.. 2022 , 13, 838133	6
411	DECIPHERING ENDOTHELIAL HETEROGENEITY IN HEALTH AND DISEASE AT SINGLE CELL RESOLUTION: PROGRESS AND PERSPECTIVES.. 2022 ,	1
410	Cardiovascular toxicity associated with the multitargeted tyrosine kinase inhibitor anlotinib.. 2022 , 300891622108436	
409	Thrombospondin-2 holds prognostic value and is associated with metastasis and the mismatch repair process in gastric cancer.. 2022 , 22, 250	2
408	Role of the Endothelium in Neonatal Diseases. 2022 , 1, 44-57	
407	Periprostatic adipose tissue displays a chronic hypoxic state that limits its expandability.. 2022 ,	1
406	The Prognostic Role and Significance of DLL4 and Toll-like Receptors in Cancer Development.. 2022 , 14,	0
405	The role of long non-coding RNAs in angiogenesis and anti-angiogenic therapy resistance in cancer.. 2022 , 28, 397-407	1
404	The Fibrillin-1/VEGFR2/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells.. 2022 ,	4
403	Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening.. 2022 , 12, 755053	2
402	The function and regulation network mechanism of circRNA in liver diseases.. 2022 , 22, 141	0
401	Cardio-Oncology: A Myriad of Relationships Between Cardiovascular Disease and Cancer.. 2022 , 9, 727487	3
400	Exosomes derived from stem cells of human deciduous exfoliated teeth inhibit angiogenesis in vivo and in vitro via the transfer of miR-100-5p and miR-1246.. 2022 , 13, 89	2
399	Expression of Dickkopf-1 and Twist2 in Cervical Squamous Cell Carcinoma and Their Correlation with Vasculogenic Mimicry.. 2022 , 2022, 9288476	0
398	Targeting circDGKD Intercepts TKI's Effects on Up-Regulation of Estrogen Receptor and Vasculogenic Mimicry in Renal Cell Carcinoma.. 2022 , 14,	0

- 397 A novel personalised treatment approach for psoriasis: anti-VEGF-A therapy. **2021**, 0
- 396 p73 controls cell junction dynamics during sprouting angiogenesis and acts via Angiotonin.
- 395 Tumor-Derived Exosomes Modulate Primary Site Tumor Metastasis.. **2022**, 10, 752818 0
- 394 Association Between Vascular Index Measured Superb Microvascular Imaging and Molecular Subtype of Breast Cancer.. **2022**, 12, 861151 0
- 393 PHF20L1 mediates PAX2 expression to promote angiogenesis and liver metastasis in colorectal cancer through regulating HIC1.. **2022**,
- 392 Signal enhancement ratio of CE-MRI: a potential biomarker of survival after hepatic arterial infusion chemotherapy in biliary tract cancers.. **2022**, 13, 46 0
- 391 The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors.. **2022**, 13, 711704 0
- 390 Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors.. **2022**, 12, 837952 2
- 389 The Roles of Tumor Endothelial Cells in Cancer Metastasis. 0
- 388 Hippo Signaling in the Endometrium.. **2022**, 23, 0
- 387 Current status of cancer starvation therapy.. **2021**, 50, 1-11
- 386 Association of KMT2C Genetic Variants with the Clinicopathologic Development of Oral Cancer.. **2022**, 19,
- 385 A comprehensive systematic review and network meta-analysis: the role of anti-angiogenic agents in advanced epithelial ovarian cancer.. **2022**, 12, 3803 3
- 384 Efficacy and safety of angiogenesis inhibitors in melanoma: a meta-analysis of seven randomized controlled trials.. **2022**,
- 383 Editorial: Tumor Vessels as Directors of the Tumor Microenvironment: New Findings, Current Challenges & Perspectives.. **2022**, 10, 885670 0
- 382 Association of Elevated Expression Levels of in Stromal Cells with an Immunosuppressive Tumor Microenvironment in Low-Grade Glioma, Pancreatic Adenocarcinoma, Skin Cutaneous Melanoma, and Stomach Adenocarcinoma.. **2022**, 12, 1
- 381 Cancer combination therapies by angiogenesis inhibitors; a comprehensive review.. **2022**, 20, 49 6
- 380 Association of colorectal cancer with genetic and epigenetic variation in PEAR1-A population-based cohort study.. **2022**, 17, e0266481

- 379 Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial.. **2022**, 20, 107 1
- 378 Endometriosis-Associated Angiogenesis and Anti-angiogenic Therapy for Endometriosis.. **2022**, 3, 856316 0
- 377 Notch signaling regulates vessel structure and function via Hspg2.. **2022**, 826, 146439
- 376 Tumour generated exosomal miRNAs: A major player in tumour angiogenesis.. **2022**, 166383 0
- 375 Synthesis and Biological Evaluation of Marine Natural Product, Cryptoechinuline D Derivatives as Novel Antiangiogenic Agents.. **2022**, 128717
- 374 Sulfated galactoglucan impedes xenografted lung cancer cell growth by blocking angiogenesis via binding BMPRs.. **2022**, 289, 119412
- 373 Computational Simulation of Breast Tissue with Lesion Characterized by a Thermal Gradient Oriented to Anomalies Smaller than 1 cm of Diameter. **2021**, 2021, 4366-4369
- 372 Identification and Development of Subtypes with Poor Prognosis in Gastric Cancer Based on Both Hypoxia and Immune Cell Infiltration.. **2021**, 14, 9379-9399 1
- 371 New Thiazole-Bearing Oxadiazole Derivatives: Synthesis, Thymidine Phosphorylase Inhibitory Potential, and Molecular Docking Study. **2021**, 57, 1993-2001 0
- 370 An Immune-Related Prognostic Signature for Predicting Clinical Outcomes and Immune Landscape in IDH-Mutant Lower-Grade Gliomas.. **2021**, 2021, 3766685 0
- 369 KLK3 in the Regulation of Angiogenesis-Tumorigenic or Not?. **2021**, 22, 0
- 368 Vascular Microenvironment, Tumor Immunity and Immunotherapy.. **2021**, 12, 811485 6
- 367 Frontiers in Anti-Cancer Drug Discovery: Challenges and Perspectives of Metformin as Anti-Angiogenic Add-On Therapy in Glioblastoma.. **2021**, 14, 2
- 366 A multidisciplinary perspective on the complex interactions between sleep, circadian, and metabolic disruption in cancer patients.. **2021**, 40, 1055 3
- 365 Association of pigment epithelium derived factor expression with cancer progression and prognosis: a meta-analysis study.. **2021**, 12, 61
- 364 MiRNAs as Anti-Angiogenic Adjuvant Therapy in Cancer: Synopsis and Potential.. **2021**, 11, 705634 1
- 363 A review of the mechanisms of anti-cancer activities of some medicinal plants-biochemical perspectives.. **2021**,
- 362 The role of vascular endothelial growth factor as a prognostic and clinicopathological marker in osteosarcoma: a systematic review and meta-analysis.. **2021**, 16, 738 2

- 361 Canagliflozin Modulates Hypoxia-Induced Metastasis, Angiogenesis and Glycolysis by Decreasing HIF-1 β Protein Synthesis via AKT/mTOR Pathway.. **2021**, 22, 3
- 360 Anti-Cancer Role and Therapeutic Potential of Extracellular Vesicles.. **2021**, 13, 1
- 359 Implication of Polymorphism on the Prognosis of Anlotinib Monotherapy for Patients With Treatment-Refractory Advanced NSCLC: An Exploratory Study.. **2022**, 21, 15330338221080993
- 358 FBXW7 and the Hallmarks of Cancer: Underlying Mechanisms and Prospective Strategies.. **2022**, 12, 880077 0
- 357 Endothelial Cell Metabolism in Vascular Functions.. **2022**, 14, 1
- 356 pH-Responsive Liposomes Loaded with Targeting Procoagulant Proteins as Potential Embolic Agents for Solid Tumor-Targeted Therapy.. **2022**, 1
- 355 Cervical cancer therapies: current challenges and future perspectives.. **2022**, 200238 4
- 354 Hepatocellular carcinoma organoid co-cultures mimic angiocrine crosstalk to generate inflammatory tumor microenvironment.. **2022**, 284, 121527 3
- 353 Targeting Angiogenic Factors for the Treatment of Medulloblastoma.. **2022**, 23, 864
- 352 Table_1.DOCX. **2020**,
- 351 Table_2.DOCX. **2020**,
- 350 Table_1.docx. **2020**,
- 349 Table_2.xlsx. **2020**,
- 348 Image_1.TIF. **2019**,
- 347 Data_Sheet_1.PDF. **2020**,
- 346 Table_1.xlsx. **2019**,
- 345 Table_2.xlsx. **2019**,
- 344 Table_3.xlsx. **2019**,

343 Video_1.MP4. 2019,

342 Image1.JPEG. 2018,

341 Image10.JPEG. 2018,

340 Image11.JPEG. 2018,

339 Image12.JPEG. 2018,

338 Image13.JPEG. 2018,

337 Image2.JPEG. 2018,

336 Image3.JPEG. 2018,

335 Image4.JPEG. 2018,

334 Image5.JPEG. 2018,

333 Image6.JPEG. 2018,

332 Image7.JPEG. 2018,

331 Image8.JPEG. 2018,

330 Image9.JPEG. 2018,

329 Table1.DOCX. 2018,

328 Table2.PDF. 2018,

327 datasheet1.docx. 2020,

326 Image_1.tif. 2020,

325 Image_2.tif. **2020**,

324 Image_1.tiff. **2020**,

323 Image_2.tiff. **2020**,

322 Table_1.pdf. **2020**,

321 Table_2.pdf. **2020**,

320 Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer.. **2022**, 45, 263 1

319 SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors.. **2022**, 0

318 A Handheld Imaging Probe for Acoustic Angiography with an Ultra-Wideband Capacitive Micromachined Ultrasonic Transducer (CMUT) Array.. **2022**, PP, 0

317 Pharmacotherapy of Age-Related Macular Degeneration. **2022**, 3619-3644

316 Quantitative Study of Angiogenesis in Three-Dimensional Matrigel Barrier Using Electric Impedance Measurement Technique.

315 Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study.. **2022**, 15, 4453-4464 0

314 A two-dimensional mathematical model of tumor angiogenesis with CD147.. **2022**, 9544119221093845

313 Intrinsic Differences in Spatiotemporal Organization and Stromal Cell Interactions Between Isogenic Lung Cancer Cells of Epithelial and Mesenchymal Phenotypes Revealed by High-Dimensional Single-Cell Analysis of Heterotypic 3D Spheroid Models.. **2022**, 12, 818437 0

312 Design and Implementation of Anatomically Inspired Mesenteric and Intestinal Vascular Patterns for Personalized 3D Bioprinting. **2022**, 12, 4430

311 Modulators of Tumor Angiogenesis: Insights into the Role of Galectin-3 and IL-17 Signaling.

310 The Cellular Tumor Immune Microenvironment of Childhood Solid Cancers: Informing More Effective Immunotherapies.. **2022**, 14,

309 STAT6 Upregulates NRP1 Expression in Endothelial Cells and Promotes Angiogenesis. **2022**, 12,

308 Ligustilide Inhibits Tumor Angiogenesis by Downregulating VEGFA Secretion from Cancer-Associated Fibroblasts in Prostate Cancer via TLR4. **2022**, 14, 2406 1

307	Tyrosine Phosphorylation Profiling Revealed the Signaling Network Characteristics of CAMKK2 in Gastric Adenocarcinoma. 2022 , 13,	1
306	Advances in Drug Treatments for Mesothelioma.. 2022 ,	0
305	Targeting SMYD2 inhibits angiogenesis and increases the efficiency of apatinib by suppressing EGFL7 in colorectal cancer.. 2022 , 1	
304	Michael acceptor-dependent pro-oxidative intervention against angiogenesis by [6]-dehydroshogaol, a pungent constituent of ginger.. 2022 , 174990	
303	Transforming Cold Tumors into Hot Ones via tumor-microenvironment-responsive siRNA micelleplexes for enhanced immunotherapy. 2022 ,	10
302	Intra-tumoral angiogenesis correlates with immune features and prognosis in glioma.. 2022 , 14,	
301	Platelets and (Lymph)angiogenesis.. 2022 ,	0
300	Cancer Biology of Molecular Imaging. 2022 , 1-37	
299	Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy. 2022 , 13,	2
298	Metronomic Chemotherapy in Prostate Cancer. 2022 , 11, 2853	1
297	IGF2BP3-stabilized SIX4 promotes the proliferation, migration, invasion and tube formation of ovarian cancer cells. 2022 , 26,	0
296	Cytokine chemokine network in tumor microenvironment: Impact on CSC properties and therapeutic applications. 2022 , 156, 155916	0
295	Cancer-Induced Metabolic Rewiring of Tumor Endothelial Cells. 2022 , 14, 2735	1
294	Resistance Mechanisms of the Metastatic Tumor Microenvironment to Anti-Angiogenic Therapy. 12,	0
293	Hypoxia orchestrates the lymphovascular-immune ensemble in cancer. 2022 ,	1
292	Knockdown of the stem cell marker Musashi-1 inhibits endometrial cancer growth and sensitizes cells to radiation. 2022 , 13,	0
291	Tumour Angiogenesis in Breast Cancer.	
290	Hyaluronan network: a driving force in cancer progression.	2

- 289 Synthetic 18F-FDG PET Image Generation Using a Combination of Biomathematical Modeling and Machine Learning. **2022**, 14, 2786 5
- 288 Pigment epithelium-derived factor and its role in microvascular-related diseases. **2022**, 1
- 287 Cancer therapeutic drug guide. **2023**, 451-506
- 286 ??????????????????. **2022**, 0
- 285 Biological aspects in controlling angiogenesis: current progress. **2022**, 79, 0
- 284 Vascular differences between glioblastoma IDH-wildtype and astrocytoma IDH-mutant grade 4 at imaging and transcriptomic level.
- 283 Daily administration of low-dose daunorubicin or doxorubicin inhibits hypoxia-inducible factor 1 and tumor vascularization.
- 282 Novel Drugs with High Efficacy against Tumor Angiogenesis. **2022**, 23, 6934 1
- 281 Identification of FABP7 as a Potential Biomarker for Predicting Prognosis and Antiangiogenic Drug Efficacy of Glioma. **2022**, 2022, 1-16
- 280 Involvement of Ceramide Signalling in Radiation-Induced Tumour Vascular Effects and Vascular-Targeted Therapy. **2022**, 23, 6671 0
- 279 Flow goes forward and cells step backward: endothelial migration. 0
- 278 FOLFIRI plus BEvacizumab or aFLibercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): an AGEO multicenter study. 0
- 277 Use of Circular RNAs in Diagnosis, Prognosis and Therapeutics of Renal Cell Carcinoma. 10, 0
- 276 Intra-tumor heterogeneity and its impact on cytotoxic therapy in a two-dimensional vascular tumor growth model. **2022**, 259, 117792
- 275 Vascular Co-option in the Brain Tumor Microenvironment. **2022**, 537-547
- 274 Therapeutic Potential of Cannabinoids on Tumor Microenvironment: A Molecular Switch in Neoplasia Transformation. **2022**, 21, 153473542210967 0
- 273 The Role of Inflammatory Cells in Tumor Angiogenesis. **2022**, 375-397
- 272 The Role of <i>KiSS1</i> Gene on the Tumor Growth and Migration of Prostate Cancer and the Underlying Molecular Mechanisms.

- 271 Vasculogenic Mimicry An Overview. **2022**, 3-13
- 270 The Role of the Microenvironment in Endometriosis: Parallels and Distinctions to Cancer. **2022**, 483-496
- 269 Tissue-Based Biomarkers of Tumor-Vascular Interactions. **2022**, 17-30
- 268 Molecular Imaging of Tumor Progression and Angiogenesis by Dual Bioluminescence. **2022**, 457-469
- 267 Molecular Phenotypes of Endothelial Cells in Malignant Tumors. **2022**, 31-52 0
- 266 Cancer Biology of Molecular Imaging. **2022**, 1-37
- 265 Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. **2022**, 15, 2
- 264 The dynamic roles of the bladder tumour microenvironment. 0
- 263 Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients. **2022**, 15, 796 0
- 262 A Delayed Dynamical Model Describing the Effect of Tumor-Induced Vascular Endothelial Growth Factor on Angiogenesis: Backward Bifurcations and Global Dynamics. **2022**, 32,
- 261 Transcriptomic and Functional Evidence for Differential Effects of MCF-7 Breast Cancer Cell-Secretome on Vascular and Lymphatic Endothelial Cell Growth. **2022**, 23, 7192 1
- 260 Atractylenolide III Attenuates Angiogenesis in Gastric Precancerous Lesions Through the Downregulation of Delta-Like Ligand 4. 13, 0
- 259 Fluorescent Carbon Quantum Dots Functionalized by Poly L-Lysine: Efficient Material for Antibacterial, Bioimaging and Antiangiogenesis Applications. 0
- 258 Design, synthesis and evaluation of novel tetrahydropyridothienopyrimidin-ureas as cytotoxic and anti-angiogenic agents. **2022**, 12,
- 257 Sanguinarine Regulates Tumor-Associated Macrophages to Prevent Lung Cancer Angiogenesis Through the WNT/ β Catenin Pathway. 12, 0
- 256 Improved Delivery Performance of n-Butylidene-phthalide-Polyethylene Glycol-Gold Nanoparticles Efficient for Enhanced Anti-Cancer Activity in Brain Tumor. **2022**, 11, 2172
- 255 A pharmacological exploration of targeted drug therapy in non-small cell lung cancer. **2022**, 39, 1
- 254 Population Pharmacokinetic Modeling of Lucitanib in Patients with Advanced Cancer. 0

253	Impact of Anti-Angiogenic Treatment on Bone Vascularization in a Murine Model of Breast Cancer Bone Metastasis Using Synchrotron Radiation Micro-CT. 2022 , 14, 3443	0
252	3D Models as a Tool to Assess the Anti-Tumor Efficacy of Therapeutic Antibodies: Advantages and Limitations. 2022 , 11, 46	0
251	The Treatment Combining Antiangiogenesis with Chemoradiotherapy Impinges on the Peripheral Circulation Vascular Endothelial Cells and Therapeutic Effect in the Patients with Locally Advanced Nasopharyngeal Carcinoma. 2022 , 2022, 1-7	
250	Research progress in targeted therapy and immunotherapy for gastric cancer. Publish Ahead of Print,	1
249	The role of tumor neogenesis pipelines in tumor progression and their therapeutic potential.	0
248	Hypophysial angiogenesis decodes annual time and underlies physiological adaptation to seasonal changes in the environment.	1
247	The Role of Citrate Homeostasis in Merkel Cell Carcinoma Pathogenesis. 2022 , 14, 3425	1
246	Mechanisms of action of immunomodulatory drugs ¶From teratogenicity to treatment of multiple myeloma. 2022 , 67, 240-260	0
245	PAX8 in the Junction between Development and Tumorigenesis. 2022 , 23, 7410	0
244	The Angiogenic Balance and Its Implications in Cancer and Cardiovascular Diseases: An Overview. 2022 , 58, 903	0
243	Targeting Angiogenesis via Resolution of Inflammation. a041172	0
242	CD93 orchestrates the tumor microenvironment and predicts the molecular subtype and therapy response of bladder cancer. 2022 , 147, 105727	1
241	New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects. 2022 , 64, 100849	0
240	Normalization of tumor vasculature: A potential strategy to increase the efficiency of immune checkpoint blockades in cancers. 2022 , 110, 108968	1
239	Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. 2004 , 3, 1301-1310	44
238	KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth. 2004 , 3, 1639-1649	23
237	Targeting Angiogenesis for Mammary Cancer Prevention: Factors to Consider in Experimental Design and Analysis. 2004 , 13, 1173-1184	4
236	SMITH: Spatially Constrained Stochastic Model for Simulation of Intra-Tumour Heterogeneity.	

235	Novel artemisinin derivative FO8643 with anti-angiogenic activity inhibits growth and migration of cancer cells via VEGFR2 signaling. 2022 , 175158	1
234	Pharmacodynamic Analysis of Target Inhibition and Endothelial Cell Death in Tumors Treated with the Vascular Endothelial Growth Factor Receptor Antagonists SU5416 or SU6668. 2005 , 11, 678-689	10
233	Carotenoids and Carcinogenesis: Exploring the Antioxidant and Cell Signalling Roles of Carotenoids in the Prevention of Cancer. 2022 ,	
232	The Hepatic Pre-Metastatic Niche. 2022 , 14, 3731	
231	Sanguinarine Inhibition of TNF- α -Induced CCL2, IKK β /NF- κ B/ERK1/2 Signaling Pathway, and Cell Migration in Human Triple-Negative Breast Cancer Cells. 2022 , 23, 8329	0
230	Recent advances in smart nanoplatfoms for tumor non-interventional embolization therapy. 2022 , 20,	1
229	New Insights into Bile Acids Related Signaling Pathways in the Onset of Colorectal Cancer. 2022 , 14, 2964	1
228	Exosomal Non-Coding RNAs: New Insights into the Biology of Hepatocellular Carcinoma. 2022 , 29, 5383-5406	1
227	Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers. 9,	1
226	Fight the Cancer, Hit the CAF!. 2022 , 14, 3570	1
225	?????????????. 2022 ,	0
224	Deep Learning-Based Image Analysis for the Quantification of Tumor-Induced Angiogenesis in the 3D In Vivo Tumor Model Establishment and Addition to Laser Speckle Contrast Imaging (LSCI). 2022 , 11, 2321	1
223	Alpinumisoflavone against cancer pro-angiogenic targets: In silico, In vitro, and In ovo evaluation.	
222	Recombinant Human Arresten and Canstatin Inhibit Angiogenic Behaviors of HUVECs via Inhibiting the PI3K/Akt Signaling Pathway. 2022 , 23, 8995	1
221	Radiation therapy and antiangiogenic therapy: Opportunities and challenges. 2022 ,	0
220	PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?. 2022 , 14, 4039	3
219	Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy. 13,	2
218	Comparison of the Behavior of Perivascular Cells (Pericytes and CD34+ Stromal Cell/Telocytes) in Sprouting and Intussusceptive Angiogenesis. 2022 , 23, 9010	1

- 217 Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy. 1
- 216 Angiogenesis in gastrointestinal stromal tumors: From bench to bedside. **2022**, 14, 1469-1477 1
- 215 Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications. 12, 0
- 214 Understanding Breast Cancers through Spatial and High-Resolution Visualization Using Imaging Technologies. **2022**, 14, 4080
- 213 Development of siRNA Delivery System by Lipid Nanoparticles Modified with Functional Materials for Cancer Treatment. **2022**, 45, 972-977 0
- 212 Research Advances in Nanomedicine Applied to the Systemic Treatment of Colorectal Cancer. 0
- 211 Mechanical regulation of signal transduction in angiogenesis. 10, 1
- 210 Immune Modulatory Effects of Molecularly Targeted Therapy and Its Repurposed Usage in Cancer Immunotherapy. **2022**, 14, 1768 1
- 209 *Annona cherimola* Mill. Leaf Extracts Affect Melanoma Cells Growth and Progression. **2022**, 11, 2420
- 208 Automated in vivo compound screening with zebrafish and the discovery and validation of PD 81,723 as a novel angiogenesis inhibitor. **2022**, 12, 0
- 207 Cancer-associated Fibroblasts: Origin, Function, Imaging, and Therapeutic Targeting. **2022**, 114504 0
- 206 Is extremely low frequency pulsed electromagnetic fields applicable to gliomas? A literature review of the underlying mechanisms and application of extremely low frequency pulsed electromagnetic fields. 0
- 205 Artemisinin derivative FO-ARS-123 as a novel VEGFR2 inhibitor suppresses angiogenesis, cell migration, and invasion. **2022**, 365, 110062
- 204 Quantitative study of tumor angiogenesis in three-dimensional matrigel barrier using electric impedance measurement technique. **2022**, 370, 132458 0
- 203 Application of Laser Speckle Contrast Imaging (LSCI) for the Angiogenesis Measurement of Tumors in the Chorioallantoic Membrane (CAM) Model. **2023**, 141-153 1
- 202 A concise review of VEGF, PDGF, FGF, Notch, angiopoietin, and HGF signalling in tumor angiogenesis with a focus on alternative approaches and future directions. **2022**, 221, 1428-1438 2
- 201 Inducing vascular normalization: A promising strategy for immunotherapy. **2022**, 112, 109167 0
- 200 IVIM and Non-Gaussian DWI of the Breast. **2023**, 116-143 0

199	Neuroinflammation. 2023 , 87-106	0
198	Cancer Biology of Molecular Imaging. 2022 , 3-39	0
197	Diagnostic Hysteroscopy. 2022 , 73-181	0
196	Rosa hybrida Petal Extract Exhibits Antitumor Effects by Abrogating Tumor Progression and Angiogenesis in Bladder Cancer Both In Vivo and In Vitro. 2022 , 21, 153473542211143	1
195	Angiogenesis and the Tumor Microenvironment. 2022 , 1-17	0
194	The extracellular matrix in breast cancer. 2022 , 195-220	1
193	Introduction: Cancer a Global Challenge and Role of Angiogenesis in Cancer. 2022 , 1-9	0
192	Targeting tumor microenvironment for breast cancer treatment. 2022 , 249-277	1
191	Emerging nanomedicines strategies focused on tumor microenvironment against cancer recurrence and metastasis. 2023 , 452, 139506	1
190	Computer Techniques for Detection of Breast Cancer and Follow Up Neoadjuvant Treatment. 2022 , 457-493	0
189	Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2). 2022 , 20,	0
188	Melanoma Tumour Vascularization and Tissue-Resident Endothelial Progenitor Cells. 2022 , 14, 4216	0
187	Heterocycles in Breast Cancer Treatment: The use of Pyrazole Derivatives. 2022 , 29,	0
186	An integrative analysis of DNA methylation and gene expression to predict lung adenocarcinoma prognosis. 13,	0
185	RNA Demethylase ALKBH5 Promotes Progression and Angiogenesis of Lung Cancer via Regulating the Stability of LncRNA PVT1.	0
184	Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab. 13,	0
183	A novel hKDR mouse model depicts the anti-angiogenesis and apoptosis-promoting effects of neutralizing antibodies targeting VEGFR2.	0
182	Non-small cell lung cancer in China.	3

- 181 Exploration of Site-Specific Drug Targeting: A Review on EPR-, Stimuli-, Chemical-, and Receptor-Based Approaches as Potential Drug Targeting Methods in Cancer Treatment. **2022**, 2022, 1-26 0
- 180 Blood Perfusion Characteristics of Renal Cell Carcinoma in the Process of Tumor Growth: Monitored With Multiple Sonographic Modalities. Publish Ahead of Print, 0
- 179 Classical Angiogenic Signaling Pathways and Novel Anti-Angiogenic Strategies for Colorectal Cancer. **2022**, 44, 4447-4471 0
- 178 Low- dose Apatinib promotes vascular normalization and hypoxia reduction and sensitizes radiotherapy in lung cancer. 0
- 177 Methyl Gallate Suppresses Tumor Development by Increasing Activation of Caspase3 and Disrupting Tumor Angiogenesis in Melanoma. **2022**, 2022, 1-13 0
- 176 Expression and clinical significance of CD31, CD34, and CD105 in pulmonary ground glass nodules with different vascular manifestations on CT. 12, 0
- 175 Design and implementation of an adaptive fuzzy sliding mode controller for drug delivery in treatment of vascular cancer tumours and its optimisation using genetic algorithm tool. 1
- 174 Metabolic Reprogramming in Tumor Endothelial Cells. **2022**, 23, 11052 3
- 173 Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma. 12, 1
- 172 Characterization of circulating immune cells and correlation with Tie2/Angiopoietins level in well differentiated neuroendocrine gastroenteropancreatic tumors: a cross-sectional analysis. 0
- 171 The complementary role of lymphovascular invasion and perineural invasion in the TNM staging process of rectal cancer. **2022**, 101, e30687 0
- 170 A Bloody Conspiracy: Blood Vessels and Immune Cells in the Tumor Microenvironment. **2022**, 14, 4581 1
- 169 Discovery and Development of Tumor Angiogenesis Assays. **2023**, 1-37 0
- 168 Usnic Acid Isolated from *Usnea antarctica* (Du Rietz) Reduced In Vitro Angiogenesis in VEGF- and bFGF-Stimulated HUVECs and Ex Ovo in Quail Chorioallantoic Membrane (CAM) Assay. **2022**, 12, 1444 1
- 167 The role of KiSS1 gene on the growth and migration of prostate cancer and the underlying molecular mechanisms. **2022**, 121009 0
- 166 PLXDC1 Can Be a Biomarker for Poor Prognosis and Immune Evasion in Gastric Cancer. Volume 15, 5439-5455 0
- 165 Counter regulation of tumor angiogenesis by vascular endothelial growth factor and thrombospondin-1. **2022**, 86, 126-135 0
- 164 *Neonauclea formicaria* (Rubiaceae) Leaf Extract Inhibits Vascularization in the Chorioallantoic Membrane of Duck Embryos. 83, 22-31 0

163	Animal Models for Angiogenesis on Cancer Research. 2022 , 1-23	0
162	Improved Long-Term Survival of Patients with Recurrent Medulloblastoma Treated with a MEMMAT-like Metronomic Antiangiogenic Approach. 2022 , 14, 5128	1
161	The Biological Relevance of Papaverine in Cancer Cells. 2022 , 11, 3385	1
160	VEGFR2-MICA fusion antibodies enhance immunotherapy effect and synergize with PD-1 blockade.	0
159	Endostatin induces normalization of blood vessels in colorectal cancer and promotes infiltration of CD8+ T cells to improve anti-PD-L1 immunotherapy. 13,	1
158	Squalamines in Blockade of Tumor-Associated Angiogenesis and Cancer Progression. 2022 , 14, 5154	0
157	Pelargonidin inhibits vascularization and metastasis of brain gliomas by blocking the PI3K/AKT/mTOR pathway. 2022 , 47,	1
156	Targeted Nano Sized Drug Delivery to Heterogeneous Solid Tumor Microvasculatures: Implications for Immunoliposomes Exhibiting Bystander Killing Effect.	0
155	Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy. 2022 , 23, 13050	1
154	Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021. 9,	0
153	Matrix stiffness in regulation of tumor angiogenesis. 2022 , 30, 871-878	0
152	A homogalacturonan from <i>Lonicera japonica</i> Thunb. disrupts angiogenesis via epidermal growth factor receptor and Delta-like 4 associated signaling.	0
151	Landscape of the clinical development of China innovative anti-lung cancer drugs. 2022 ,	0
150	Synergy of Polydopamine Nanovaccine and Endostar Alginate Hydrogel for Improving Antitumor Immune Responses Against Colon Tumor. Volume 17, 4791-4805	0
149	Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers. 12,	0
148	Molecular mechanism of VEGF and its role in pathological angiogenesis.	0
147	Alkaloid Derivative (Z)-3-Ethylamino-Pregn-17(20)-en Inhibits Triple-Negative Breast Cancer Metastasis and Angiogenesis by Targeting HSP90. 2022 , 27, 7132	0
146	SOD3 Expression in Tumor Stroma Provides the Tumor Vessel Maturity in Oral Squamous Cell Carcinoma. 2022 , 10, 2729	0

145	Biological and Therapeutic Implications of the Tumor Microenvironment in Pituitary Adenomas.	0
144	Tumor Angiogenesis. 1-30	0
143	The impact of aging and physical training on angiogenesis in the musculoskeletal system. 10, e14228	0
142	Artemisinin suppressed tumour growth and induced vascular normalisation in oral squamous cell carcinoma via inhibition of MIF.	0
141	Targeting the tumor stroma for cancer therapy. 2022 , 21,	3
140	Multi-scale model of lumen formation via inverse membrane blebbing mechanism during sprouting angiogenesis process. 2023 , 556, 111312	0
139	The malignant phenotype. 2006 , 116,	0
138	MECHANIZMY PROWADZĄCE DO ANGIOGENEZY W NOWOTWORACH. 2019 , 17, 60-65	0
137	Overcoming the therapeutic resistance of hepatomas by targeting the tumor microenvironment. 12,	1
136	Effective treatment of intractable diseases using nanoparticles to interfere with vascular supply and angiogenic process. 2022 , 27,	1
135	Role of extracellular vesicles in cancer-specific interactions between tumour cells and the vasculature. 2022 ,	1
134	TGF- β promotes human breast cancer angiogenesis and malignant behavior by regulating endothelial-mesenchymal transition. 12,	0
133	The RNA demethylase ALKBH5 promotes the progression and angiogenesis of lung cancer by regulating the stability of the LncRNA PVT1. 2022 , 22,	0
132	Gold nanoparticles as antiangiogenic and antimetastatic agents. 2022 , 103438	0
131	The past, present, and future of chemotherapy with a focus on individualization of drug dosing. 2022 , 352, 840-860	2
130	Vessel size as a marker of survival in estrogen receptor positive breast cancer.	0
129	Principles of Drug Metabolism and Interactions in Cardio-Oncology. 2022 , 967-992	0
128	Metronomická terapie v léčbě rakoviny onkologické 2022 , 71, 91-97	0

- 127 Nanosized zingerone-triggered anti-angiogenesis contributes to tumor suppression in human hepatocellular carcinoma. **2023**, 658, 130697 ○
- 126 Chapter 2. Introduction to the Tumor Microenvironment. **2022**, 11-29 ○
- 125 Performance Assessment of Ultra-Wideband and Dual-Mode 1D CMUT Arrays for Acoustic Angiography. **2022**, ○
- 124 Progression of hepatocellular carcinoma after radiofrequency ablation: Current status of research. 12, ○
- 123 The efficacy and safety of Apatinib in the treatment of advanced non-small cell lung cancer: A retrospective trial. 12, ○
- 122 Biological implications and clinical potential of invasion and migration related miRNAs in glioma. 16, ○
- 121 Supplement of iron abrogates SARS-CoV-2 pseudovirus infection in a 3D model of vascularized organoids. **2022**, ○
- 120 Hypoxia-Induced miR-210 Promotes Endothelial Cell Permeability and Angiogenesis via Exosomes in Pancreatic Ductal Adenocarcinoma. **2022**, 2022, 1-13 ○
- 119 Tumor-on-a-chip: Perfusable vascular incorporation brings new approach to tumor metastasis research and drug development. 10, ○
- 118 Research progress on the circRNA-mediated regulation of tumor angiogenesis through ceRNA mechanisms (Review). **2022**, 49, ○
- 117 Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients. 12, ○
- 116 Chemotherapeutic Potential of Saikosaponin D: Experimental Evidence. **2022**, 12, 378-405 ○
- 115 Genome Editing of Pik3cd Impedes Abnormal Retinal Angiogenesis. ○
- 114 Optoacoustic Imaging With Decision Support for Differentiation of Benign and Malignant Breast Masses: A 15-Reader Retrospective Study. 1
- 113 Nobiletin is capable of regulating certain anti-cancer pathways in a colon cancer cell line. ○
- 112 Synthesis, Structural Investigations, and In Vitro/In Silico Bioactivities of Flavonoid Substituted Biguanide: A Novel Schiff Base and Its Diorganotin (IV) Complexes. **2022**, 27, 8874 ○
- 111 PARP inhibition promotes endothelial-like traits in melanoma cells and modulates pericyte coverage dynamics during vasculogenic mimicry. ○
- 110 Characterization of circulating immune cells and correlation with Tie2/Angiopoietins level in well differentiated neuroendocrine gastroenteropancreatic tumors: a cross-sectional analysis. 1

109	Role of hypoxia-inducible proteins in ameloblastoma: A review. 2022 ,	0
108	Fibronectin Fibrillogenesis During Angiogenesis. 2023 , 1-27	0
107	Interventional effect of processing temperature on anti-angiogenesis of <i>Coptis chinensis</i> and screening of active components by UPLC-MS/MS on quail chick chorioallantoic membrane model. 2022 , 116014	0
106	INVESTIGATION OF THE EFFECT OF COMPOUND B-47/2 CONTAINING AZOMETHINE GROUP ON ANGIOGENESIS.	0
105	Comprehensive analysis prediction prognosis and immune therapy value of angiogenesis-associated genes in kidney renal clear cell carcinoma.	0
104	Bovine Lactoferrin Suppresses Tumor Angiogenesis through NF- κ B Pathway Inhibition by Binding to TRAF6. 2023 , 15, 165	1
103	Newly Emerging Concepts in Blood Vessel Growth: Recent Discovery of Endothelial Progenitor Cells and Their Function in Tissue Regeneration. 2003 , 51, 353-359	3
102	C�ncer renal. Descripci�n poblacional en una instituci�n acad�mica. 2016 , 21,	0
101	Investigation of the evolution of tumor-induced microvascular network under the inhibitory effect of anti-angiogenic factor, angiostatin: A mathematical study. 2023 , 20, 5448-5480	0
100	Using a zebrafish xenograft tumor model to compare the efficacy and safety of VEGFR-TKIs.	0
99	Integrated design and fabrication strategies based on bioprinting for skeletal muscle regeneration: Current status and future perspectives. 2023 , 225, 111591	0
98	Targeted nano-sized drug delivery to heterogeneous solid tumor microvasculatures: Implications for immunoliposomes exhibiting bystander killing effect. 2023 , 35, 011905	1
97	The role of Andrographolide in the prevention and treatment of liver diseases. 2023 , 109, 154537	0
96	Non-operable glioblastoma: proposition of patient-specific forecasting by image-informed poromechanical model.	0
95	Remarkable anti-breast cancer activity and molecular docking studies of ferrocene tethered pyrimidobenzothiazoles and pyrimidobenzimidazoles. 2023 , 5, 100758	0
94	Progress in Clinical Gene Therapy for Cardiac Disorders.	0
93	Role of myeloid-derived suppressor cells in tumor recurrence.	1
92	Involvement of angiogenesis in cancer-associated acinar-to-ductal metaplasia lesion of pancreatic cancer invasive front.	0

91	Purinergic signaling: Diverse effects and therapeutic potential in cancer. 13,	o
90	68Ga-DOTAGA-IAC PET/CT for Imaging Metastatic and Recurrent Adrenocortical Carcinoma. 2023, 48, e95-e98	o
89	Heterogeneity of cGMP signalling in tumour cells and the tumour microenvironment: Challenges and chances for cancer pharmacology and therapeutics. 2023, 242, 108337	o
88	The influence of discoidin domain receptor 1 expression on angiogenic factors: VEGF-A and FGF-2 in non-small cell lung cancer. 2023, 30, 101734	o
87	Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer. 2022, 18, 755-767	o
86	Stroma-targeting strategies in pancreatic cancer: a double-edged sword.	1
85	Relationship between Tumor Infiltrating Immune Cells and Tumor Metastasis and Its Prognostic Value in Cancer. 2023, 12, 64	o
84	Design, synthesis, and antitumor evaluation of trimethoxyflavonoid with arylurea structure against hepatocellular carcinoma.	o
83	Hypoxia signaling in cancer: Implications for therapeutic interventions. 2023, 4,	1
82	Therapeutic potentials of medicinal plants and significance of computational tools in anti-cancer drug discovery. 2023, 393-455	o
81	Placental Galectins in Cancer: Why We Should Pay More Attention. 2023, 12, 437	o
80	Treatment of neurofibromatosis type II with anlotinib: a case report and literature review. Publish Ahead of Print,	o
79	Vascular and Neuronal Network Formation Regulated by Growth Factors and Guidance Cues. 2023, 13, 283	o
78	Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas. 2023, 15, 700	o
77	Mathematical Modeling of the Effect of Angiostatin on the Density of the Circular Tumor-Induced Microvascular Network. 2022,	o
76	Molecular Imaging in Oncology. 2023, 303-373	o
75	Clinical Observation of Immunotherapy Combined with Antiangiogenic Targeted Drugs in the Treatment of 20 Cases Advanced Hepatocellular Carcinoma. 2023, 13, 2575-2580	o
74	Mechanotransduction in tumor dynamics modeling. 2023, 44, 279-301	o

- 73 Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma. 14, ○
- 72 Nanomaterial-Based Antivascular Therapy in the Multimodal Treatment of Cancer. **2023**, 15, 1207 ○
- 71 Vagus innervation in the gastrointestinal tumor: Current understanding and challenges. **2023**, 1878, 188884 ○
- 70 Towards dual function of autophagy in breast cancer: A potent regulator of tumor progression and therapy response. **2023**, 161, 114546 ○
- 69 Tregs are involved in VEGFA/ VASH1-related angiogenesis pathway in ovarian cancer. **2023**, 32, 101665 ○
- 68 Predictive value of CT-based extracellular volume fraction in the preoperative pathologic grading of rectal adenocarcinoma: A preliminary study. **2023**, 163, 110811 ○
- 67 A dynamical model of the immune system interaction in a melanoma. **2023**, 122, 107248 ○
- 66 The Regulation Pathway of VEGF Gene Expression Is Different between 2D Cells and 3D Spheroids in Human Lung Cancer Cells. **2023**, 46, 608-613 ○
- 65 Cancer Angiogenesis and Its Master Regulator Perlecan. **2022**, 399-419 ○
- 64 Animal Models for Angiogenesis on Cancer Research. **2023**, 397-419 ○
- 63 Comparison of integrin $\alpha_5\beta_1$ expression with ^{68}Ga -NODAGA-RGD PET/CT and glucose metabolism with ^{18}F -FDG PET/CT in esophageal or gastroesophageal junction cancers. **2023**, 7, ○
- 62 Single-cell spatial landscapes of the lung tumour immune microenvironment. **2023**, 614, 548-554 ○
- 61 Cannabidiol as a potential novel treatment for endometriosis by its anti-inflammatory, antioxidative and antiangiogenic effects in an experimental rat model. **2023**, ○
- 60 Research Progress in the Treatment of Malignant Pleural Effusion with Intrathoracic Perfusion of Antiangiogenic Drugs. **2023**, 13, 123-1237 ○
- 59 Potential of Copper and Copper Compounds for Anticancer Applications. **2023**, 16, 234 1
- 58 The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies. **2023**, 24, 3226 ○
- 57 VEGF (Vascular Endothelial Growth Factor) Inhibition and Hypertension: Does Microvascular Rarefaction Play a Role?. **2023**, 80, 901-911 ○
- 56 The Role of Silver Nanoparticles in the Diagnosis and Treatment of Cancer: Are There Any Perspectives for the Future?. **2023**, 13, 466 1

55	Inhibition of MMPs supports amoeboid angiogenesis hampering VEGF-targeted therapies via MLC and ERK 1/2 signaling. 2023 , 21,	0
54	Advances in Molecular Regulation of Prostate Cancer Cells by Top Natural Products of Malaysia. 2023 , 45, 1536-1567	1
53	Targeting Breast Cancer: An Overlook on Current Strategies. 2023 , 24, 3643	0
52	Scandium-44 Radiolabeled Peptide and Peptidomimetic Conjugates Targeting Neuropilin-1 Co-Receptor as Potential Tools for Cancer Diagnosis and Anti-Angiogenic Therapy. 2023 , 11, 564	1
51	Cancer: A Pragmatic Switch to Combat Metabolic Syndrome?. 17,	0
50	Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines. 2023 , 15, 661	0
49	Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. 2023 , 8,	1
48	Exosomal circTUBGCP4 promotes vascular endothelial cell tipping and colorectal cancer metastasis by activating Akt signaling pathway. 2023 , 42,	1
47	Association of Ang/Tie2 pathway mediators with endothelial barrier integrity and disease severity in COVID-19. 14,	0
46	Identification of angiogenesis-related subtypes, the development of prognostic models, and the landscape of tumor microenvironment infiltration in colorectal cancer. 14,	0
45	Inhibiting Angiogenesis by Anti-Cancer Saponins: From Phytochemistry to Cellular Signaling Pathways. 2023 , 13, 323	0
44	What is hemoglobin, albumin, lymphocyte, platelet (HALP) score? A comprehensive literature review of HALP prognostic ability in different cancer types. 2023 , 14, 153-172	0
43	JAG1 is correlated to suppressive immune microenvironment and predicts immunotherapy resistance in lung adenocarcinoma. 13,	0
42	Successful multidisciplinary therapy for a patient with liver metastasis from ascending colon adenocarcinoma: A case report and review of literature. 11, 1498-1505	0
41	Gene Therapy for Regenerative Medicine. 2023 , 15, 856	0
40	Low-dose metronomic gemcitabine pretreatments overcome the resistance of breast cancer to immune checkpoint therapy. 2023 , 15, 429-442	0
39	Temporal phosphoproteomic analysis of VEGF-A signaling in HUVECs: an insight into early signaling events associated with angiogenesis.	0
38	The Role of Long Noncoding RNAs in Glioblastoma: What the Neurosurgeon Should Know. 2023 , Publish Ahead of Print,	0

- 37 Zbtb46coordinates angiogenesis and immunity to control tumor outcome. ○
- 36 The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. **2023**, 175586 ○
- 35 Analysis of Efficacy-To-Safety Ratio of Angiogenesis-Inhibitors Based Therapies in Ovarian Cancer: A Systematic Review and Meta-Analysis. **2023**, 13, 1040 ○
- 34 Angiogenesis Inhibitors in the Treatment of Cancer. **2023**, 1-33 ○
- 33 The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. **2023**, 41, 374-403 ○
- 32 Menthol: An underestimated anticancer agent. 14, ○
- 31 The role of physics in multiomics and cancer evolution. 13, ○
- 30 Modulation of Nrf2/HO-1 by Natural Compounds in Lung Cancer. **2023**, 12, 735 ○
- 29 Mesoporous nanodrug delivery system: a powerful tool for a new paradigm of remodeling of the tumor microenvironment. **2023**, 21, ○
- 28 Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications. **2023**, 16, ○
- 27 The evaluation of tumor microenvironment infiltration and the identification of angiogenesis-related subgroups in skin cutaneous melanoma. ○
- 26 Sequential-delivery nanocomplex for combined anti-angiogenesis and gene therapy against colorectal cancer. **2023**, 637, 122850 ○
- 25 Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody. **2023**, 11, e006680 ○
- 24 Immunostaining for VEGF and Decorin Predicts Poor Survival and Recurrence in Canine Soft Tissue Sarcoma. **2023**, 10, 256 ○
- 23 Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy. **2023**, 12, ○
- 22 Tumor Microenvironment in Sporadic Vestibular Schwannoma: A Systematic, Narrative Review. **2023**, 24, 6522 ○
- 21 Non-operable glioblastoma: Proposition of patient-specific forecasting by image-informed poromechanical model. **2023**, 4, 100067 ○
- 20 The clinical value of DCE-MRI for differentiating secondary laryngeal cartilage lesions. **2023**, 102, e33352 ○

- 19 Regenerative medicine: current research and perspective in pediatric surgery. **2023**, 39,
- 18 Turning Cold into Hot: New Insights in Cancer Immunotherapy. **2022**, 1-13
- 17 Nanoformulations-Based Metronomic Chemotherapy: Mechanism, Challenges, Recent Advances, and Future Perspectives. **2023**, 15, 1192
- 16 Hallmarks of an Aging and Malignant Tumor Microenvironment and the Rise of Resilient Cell Subpopulations. **2023**, 113-137
- 15 The neural addiction of cancer.
- 14 Targeting angiogenesis in oncology, ophthalmology and beyond.
- 13 Molecular Ultrasound Imaging Depicts the Modulation of Tumor Angiogenesis by Acetylsalicylic Acid. **2023**, 24, 7060
- 12 A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer. 13,
- 11 Role of Hypoxia and Reactive Oxygen Species in Cancer Biology. **2023**, 41-63
- 10 Morphometric analysis of tumor microvessels for detection of hepatocellular carcinoma using contrast-free ultrasound imaging: A feasibility study. 13,
- 9 Pathological angiogenesis: mechanisms and therapeutic strategies.
- 8 New Treatment Options in Metastatic Pancreatic Cancer. **2023**, 15, 2327
- 7 Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities. **2023**, 15, 2354
- 6 Combining Multikinase Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor and Cluster of Differentiation 47 Signaling Pathways Is Predicted to Increase the Efficacy of Antiangiogenic Combination Therapies.
- 5 A novel VEGFR inhibitor ZLF-095 with potent antitumor activity and low toxicity. **2023**, e15152
- 4 Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies; a rapidly evolving strategy. **2023**, 154473
- 3 Fluid Mechanics in Circulating Tumour Cells: Role in Metastasis and Treatment Strategies. **2023**, 100158
- 2 Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L. **2023**, 14,

- 1 Discovery of novel antibody-drug conjugates bearing tissue protease specific linker with both anti-angiogenic and strong cytotoxic effects. **2023**, 137, 106575

o